




Synthesis and Optimization of Group B Streptococcus 





to obtain the academic degree 
Doctor rerum naturalium (Dr. rer. nat.) 
 
submitted to the Department of Biology, Chemistry, Pharmacy 













This work was performed between June 2016 and June 2019 in GlycoUniverse 
GmbH & Co KGaA and in the Department of Biomolecular Systems of Max Planck 
Institute of Colloids and Interfaces under the guidance of Prof. Dr. Peter H. 
Seeberger. 
 
1st Reviewer: Prof. Dr. Peter H. Seeberger 













I would like to acknowledge Professor Dr. Peter H. Seeberger for giving me the 
opportunity to work in his group, for providing an environment at the forefront of 
innovation and technology, and for making this PhD thesis possible. 
I acknowledge Dr. Mario Salwiczek for scientific guidance and for his support 
throughout the period of my PhD. 
I am grateful to Mr. Sascha Meyer for his support in the early stages of my PhD. 
I sincerely thank Prof. Dr. Christoph Tzschucke for agreeing to review this 
thesis. 
I am deeply thankful to Tanistha Gupta for the close collaboration and 
assistance in designing and executing the majority of the experiments conducted for 
this thesis and for her support throughout the whole time of my PhD, since the very 
first day of work in Arnimallee 22 untill the submission of this thesis. The continuous 
sharing of thoughts, ideas, tasks, responsibilities, joys, and sorrows, was a major 
help in overcoming the challenges of these past three and a half years. 
I am grateful to Dr. Roberto Adamo for taking interest in my project, for the 
productive collaboration, for giving constructive feedback and support. I am also 
grateful to my fellow PhD student Linda Delbino for fruitful discussions and 
collaborations. 
I am thankful to Prof. Sabine Flitsch for hosting me at the Manchester Institute 
of Biotechnology in Manchester and guiding my studies in enzymatic sialylation. I 
am also thankful to Dr. Peter Both and to my fellow PhD student Andrea Marchesi 
for their valuable participation in this collaboration. 
I am very grateful to Dr. Maria Bräutigam for her prompt availability to assist 
me in writing the Zusammenfassung as well as for scientific discussions and sharing 
of ideas during my PhD. 
 vi 
I am thankful to all the colleagues at the Department of Biomolecular Systems 
of MPIKG for their professionalism, assistance and support. 
I would like to thank all my fellow PhD students from GLYCOVAX network for 
sharing their experiences and engaging in creating a truly collaborative and friendly 
group. I am also grateful to all the PIs involved in the GLYCOVAX consortium as well 
as ALTA, the logistics partner, providing the means for this network to flourish. 
I acknowledge the funding received from the European Union's Framework 
Programme for Research and Innovation Horizon 2020 (2014-2020) under the 
Marie Sklodowska-Curie Grant Agreement No. 675671. 
Last but certainly not the least, I am deeply thankful to my friends and my 
family who supported me from the very first moment and encouraged me to pursue 
my dreams with the most unconditional support. From them I learn the most 






J. Louçano, P. Both, A. Marchesi, L. del Bino, R. Adamo, S. Flitsch, M. Salwiczek, 
P. Seeberger. Automated glycan assembly of Streptococcus pneumoniae type 14 
capsular polysaccharide fragments. (submitted to RSC Advances) 
 
Scientific Conferences and Symposia 
Synthesis of Group B Streptococcus type III capsular polysaccharide related 
glycans. (Oral) “A. Corbella” International Summer School on Organic Synthesis, 
Gargnano, Italy, June 2019. 
Optimization of Automated Glycosylation Cycles in the Glyconeer Automated 
Synthesizer. (Poster) International Carbohydrate Symposium, Lisbon, July 2018. 
Towards Automated Synthesis of Type IV Group B Streptococcus 





   
ix 
Abstract 
Group B Streptococcus (GBS) is a major neonatal pathogen and a leading cause 
of infant mortality worldwide. Management of GBS infection relies on the 
prophylactic and therapeutic use of antibiotics. This approach has limited efficiency 
and increases antibiotic resistance. Carbohydrate conjugate vaccines are 
consensually regarded as the best possible alternative and several formulations 
have been and are now in clinical trials. 
In general, carbohydrate vaccine development suffers from shortfalls 
associated with the availability oligosaccharide libraries. Chemically pure glycans 
enable the prosecution of structure-immunogenicity studies that elucidate minimal 
epitopes and the intermolecular interactions responsible for recognition and 
immunity. One of the most promising methodologys to produce libraries of glycans 
is Automated Glycan Assembly (AGA). In this work, glycans from GBS are produced 
by AGA using the commercial synthesizer Glyconeer. The entire process is optimized 
since the production of building blocks to the automated oligosaccharide synthesis 
process. 
Ready-to-use building blocks (BBs) are required in bulk to do automated 
experiments continuously.  The synthesis of BBs can be achieved with a variety of 
different methods and the choice is usually based on the chemist preference and 
experience. This work optimizes and streamlines the strategies for the synthesis of 
building blocks for AGA bearing a thiolate aglycon as a leaving group.  The synthetic 
schemes are completed and upscaled with minimal column purifications.  
This thesis goes on to describing the optimization of elongation cycles that 
introduce each BB in the growing oligosaccharide chain during AGA. The first target 
is GBS type IV capsular polysaccharide. In the synthesis of GBS type IV, the major 
bottleneck was the assemble of the Glc-α-1,4-Gal cis linkage. A trisaccharide 
containing this linkage was successfully synthesized. However, the low yields 
obtained rendered the elongation of the chain unsuccessful. 
 
 x 
The other target structures were related with GBS type III. With only three 
different BBs, four different GBS type III fragments were assembled. A sialic acid 
moiety present in the native polysaccharide was introduced enzymatically, proving 
that the combination of enzymatic sialylation with AGA is an expeditious approach 
to the preparation of complex glycans for vaccine development. 
Overall, the work in this thesis is a contribution to the standardization of the 
chemical work involved in AGA and a steppingstone for the fast and cheap 





Die zur Lancefield-Gruppe B gehörenden Streptokokken (GBS)  sind ein 
neonatales Pathogen und eine Hauptursache für die weltweite Kindersterblichkeit. 
Die Behandlung von GBS-Infektionen beruht auf prophylaktischem und 
therapeutischem Einsatz von Antibiotika. Die Effizienz dieses Ansatzes ist begrenzt 
und führt zu einem Anstieg von Resistenzen. Polysaccharid-Konjugat-Impfstoffe 
werden als beste Alternative zum Einsatz von Antibiotika gesehen und mehrere 
GBS-Impfstoff-Formulierungen werden derzeit in klinischen Studien evaluiert. 
Ein generelles Problem bei der Entwicklung von Polysaccharid-Impfstoffen ist 
die begrenzte Zugänglichkeit zu Oligosaccharid-Bibliotheken. Chemisch reine 
Glykane erlauben die Durchführung von Struktur-Immunogenitäts-Studien, die das 
minimale Epitop und die intermolekularen Interaktionen, die für Erkennung und 
Immunität verantwortlich sind, aufklären. Eine der vielversprechendsten 
Methoden, um Glykan-Bibliotheken aufzubauen, ist die automatisierte 
Festphasensynthese von Glykanen (Automated Glycan Assembly, AGA). In dieser 
Arbeit werden GBS-Glykane durch den Einsatz von AGA hergestellt und der gesamte 
Prozess, von der Synthese der Monosaccharid-Bausteine bis zum automatisierten 
Prozess der Oligosaccharid-Synthese, optimiert.  
Gebrauchsfertige Monosacharid-Bausteine werden in großem Maßstab für die 
kontinuierliche Ausführung automatisierter Experimente  benötigt. Für die 
Synthese der Bausteine steht eine Vielzahl an Methoden zur Verfügung und die 
Entscheidung, eine Methode zu nutzen, basiert in vielen Fällen auf der Präferenz und 
Erfahrung des einzelnen Chemikers. In dieser Arbeit werden Synthesestrategien für 
Bausteine, die im AGA eingesetzt werden und eine Thiol-Abgangsgruppe haben, 
optimiert und rationalisiert. Die Syntheseschemata werden vervollständigt und in 
großem Maßstab mit wenigen säulenchromatographischen Aufreinigungsschritten 
durchgeführt.  
Darüber hinaus wird in dieser Arbeit die Optimierung der Elongations-Zyklen, 
die die einzelnen Bausteine während des AGA in die wachsende Oligosaccharidkette 
einführen, beschrieben. Das erste Zielmolekül ist das GBS Typ IV kapsuläre 
Polysaccharid. Die Herausforderung bei der Synthese dieses Polysaccharids ist die 
 xii 
Glc-α-1,4-Gal-cis-Verknüpfung. Ein Trisaccharid, das diese Verknüpfung enthält, 
wurde erfolgreich synthetisiert. Jedoch zeigen die geringen Ausbeuten, dass die 
Elongation der Zuckerkette nicht erfolgreich war. 
Die weiteren Zielmoleküle in dieser Arbeit gehören zu der GBS Typ III. Mit nur 
drei unterschiedlichen Bausteinen, wurden drei GBS Typ III-Fragmente dargestellt. 
Ein Sialinsäure-Rest, der im natürlichen Polysaccharid vorkommt, wurde 
enzymatisch eingeführt. Dies zeigt, dass die Kombination aus enzymatischer 
Sialylierung mit AGA einen schnellen Zugang zu komplexen Glykanen für die 
Impfstoffentwicklung darstellt.  
Zusammenfassend ist die vorgelegte Arbeit ein Beitrag zur Standardisierung 
der chemischen Schritte, die Teil des AGA sind und ein Sprungbrett für die schnelle 
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1.1. Group B Streptococcus 
1.1.1. Epidemiology and Management 
Streptococcus agalactiae or Group B Streptococcus (GBS) is a Gram-positive 
bacterium that is often part of the normal human gastrointestinal and vaginal flora. 
Since the 1970s, GBS has emerged as a major neonatal pathogen and today it is 
responsible for at least 409 000 maternal/fetal/infant infection cases (Figure 1.1) 
and 147 000 stillbirths and infant deaths globally.1 GBS invasive disease in infants 
is classified in early-onset disease (EOD), when it develops on days 0-6 after birth, 
and late-onset disease (LOD), when it develops between the 7th and the 89th day of 
life. The most common manifestations of EOD are pneumonia and sepsis. Newborns 
with EOD frequently develop respiratory failure and septic shock. LOD is more likely 
associated with meningitis, which can lead to chronic neurological sequelae or even 
death. GBS is also responsible for infections in pregnant women and is increasingly 
associated with infections in elderly and immunocompromised populations.2  
 
 
Figure 1.1 Estimated number GBS disease cases in pregnant/postpartum women, fetuses 
and infants in 2015.1 
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Maternal colonization is the main transmission pathway in EOD, with vertical 
transmission occurring at or just before birth. The most widely used strategy for 
prevention of GBS disease is the use of intrapartum antibiotic prophylaxis (IAP) 
based on GBS colonization status. Pregnant women are subjected to a 
microbiological screening with a rectovaginal swab at 35-37 weeks´ gestation. If 
they test positive for GBS or if they present relevant clinical risk factors (such as 
previous infant with GBS disease, preterm labour, maternal pyrexia) they are given 
benzylpenicillin or ampicillin intrapartum.  The implementation of IAP significantly 
decreased the number of EOD events. However, no impact was observed in cases of 
LOD, and GBS persists as the leading cause of mortality and morbidity in neonates. 
Furthermore, the microbiological screening policies and the coverage of IAP is 
substantially heterogeneous worldwide. In the UK, IAP is given based on risk factors 
and no universal screening is recommended. On the other hand, many low- and 
middle-income countries have no IAP policy or report a low coverage for its 
implementation. The major obstacles are in countries that lack healthcare 
professionals and infrastructure or where most births occur at home. 
An important drawback of the IAP is the increase in antibiotic resistance. In 
case of GBS, only a small number of isolates resistant to β-lactam antibiotics 
(penicillin and analogues) have been reported. However, there is an increasing 
resistance to erythromycin and clindamycin, which are the alternative options for 
penicillin-allergic women.  In this context, a vaccine against GBS may provide an 
ideal solution, with a higher chance for global coverage and a possibility of higher 
efficacy against EOD and LOD.3 
 
1.1.2. Capsular Polysaccharides 
Capsular polysaccharides are the most promising vaccine targets in GBS and 
therefore it is important to understand their structure and role. The capsule 
constitutes a powerful virulence factor in GBS. It helps evading the immune system 
of the host by preventing the binding of complement proteins, decreasing the 
phagocytic activity of neutrophils, and promoting intracellular survival inside 
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dendritic cells.2 Chemically, the capsule is made of a capsular polysaccharide (CPS) 
that mimics the host epitopes. GBS has been classified in serotypes according to the 
structure and immunogenicity of the CPS. To date, ten different serotypes are 
known: Ia, Ib, and II–IX. All serotypes are associated with colonization in pregnant 
women with serotype distribution subjected to variation according to the 
geographical region. The global estimated prevalence of maternal colonization is 
18%, with lower prevalence in Eastern and Southern Asia (around 11%).4 The 
global incidence of invasive GBS disease in infants is 0.49 per 1000 live births and is 
higher in Africa and lower in Asia. Serotype III alone accounts for over half of the 
cases of invasive disease by GBS (62%), followed by serotypes Ia, Ib, V and II. 
Together, these 5 serotypes account for 97% of the disease-causing isolates. 
Serotype Ia and V are dominant invasive isolates in non-pregnant cases. The 
prevalence of serotype IV is rising in invasive cases both in neonates and adults.2,5  
 
1.1.3. Structure of GBS Capsular Polysaccharides 
The chemical structures of GBS CPSs is described for all the serotypes and 
represented in Figure 1.2.6,7 Except for type VIII, which bears a rhamnose unit, all 
the repeating units are built with four monosaccharides (i.e. Glcp, Galp, GlcpNAc, and 
NeupNAc) and the glycosidic linkage pattern is unique to each serotype. The 
repeating units accommodate one or two side chains and the NeupNAc-α-2,3-Gal 




Figure 1.2 Repeating unit of the CPS of all the GBS serotypes. 
 
1.1.4. Progress on GBS Vaccine Development 
The research in CPS based GBS vaccines has been going on for decades. In 
1976, Baker and Kasper showed that low levels of maternal antibodies against type 
III CPS were strongly correlated with neonatal susceptibility to GBS EOD or LOD.8 
This finding provided the proof of concept that maternal vaccination could be a 
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suitable effective strategy to prevent GBS infection in newborns, supporting the 
rationale for the development of a vaccine against GBS using CPS as antigen. After 
this, several vaccines have been in clinical trials. In the first generation, unmodified 
type-specific polysaccharides were used. Purified native type Ia, II or III 
polysaccharides were injected in healthy adult volunteers, including pregnant 
women. Soon it was observed that unconjugated carbohydrate vaccines generate a 
heterogeneous response among the patients and are not capable of inducing B-cell 
memory response, particularly in infants. The immunogenicity of polysaccharides 
as human vaccines is enhanced by conjugation to protein carriers, and a second 
generation of vaccines conjugated to tetanus toxoid (TT) was tested. The third 
generation came with the pursuit of a broadly effective vaccine against the most 
common disease-causing strains: a multivalent conjugate formulation.9 
More recently, a trivalent formulation (Ia, Ib, III) was tested in phase I and II 
clinical trials and showed favourable safety and immunogenicity in non-pregnant 
and pregnant women.10 A hexavalent formulation (Ia, Ib, II, III and V) that covers 
97% of the invasive disease cases is currently undergoing phase I/II clinical trials in 
pregnant women (NCT03765073). 
The development of an anti-GBS vaccine suitable for immunization during 
pregnancy has been listed as a priority by the World Health Organization (WHO). An 
effective vaccine would induce the production of functionally active antibodies that 
could cross the placenta and provide protection to the infant. The most promising 
vaccine candidates able to confer protection and induce functionally active 
antibodies are represented by capsular polysaccharide (CPS) and surface proteins. 
 
1.1.5. Structure-Immunogenicity Studies 
Carbohydrate-based vaccines are typically obtained as heterogeneous and 
complex mixtures of poly- or oligosaccharides covalently linked to the immunogenic 
carrier protein through non-specific methods. Consequently, knowledge about 
correlation between structure and immunological properties is scarce. The most 
prevalent serotype within invasive GBS isolates is type III. Synthetic work has been done 
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to prepare libraries of fragments from the GBS type III polysaccharide (GBS PSIII) a 
substantial amount of studies about GBS PSIII minimum epitope has been conducted. 
With access to chemically pure GBS PSIII fragments, the protective epitope was 
elucidated by means of SPR, competitive ELISA, and STD-NMR experiments, and 
complemented with MD simulations. GBS PSIII forms a helical structure where the 
negatively charged sialic acid residue of the α-NeuNAc-(2→3)-β-D-Galp branch 
points outwards the trisaccharide backbone structure →4-β-D-Glcp-(1→6)-β-D-
GlcpNAc-(1→3)-β-D-Galp-(1→. A sialic acid-dependent functional epitope was 
found to be fully contained within four consecutive monosaccharide units deriving 
from the PSIII backbone and one branched disaccharide present in this sequence. 
The length dependent affinity to mAbs, once attributed to the existence of a 
conformational epitope, is now attributed to a multivalence effect.11 
These findings have critical implications in understanding the protective 
immunity against GBS type III and in the design of conjugate vaccines. Similar 
studies for other serotypes are scarce or non-existent. The structural complexity of 
carbohydrates, with α and β linkages, and with an array of possible branching sites, 
results in highly specific spatial motifs that are serologically distinct, even when few 
monosaccharides are at stake. For instance, each GBS serotype induces a type 
specific response, even when the structural similarity is high (e.g. types IV and VII).12 
The existence of helical conformational epitopes, which implies the need for longer 
oligosaccharides, has been considered a challenge for epitope-mapping studies.13 
The elucidation of functional epitopes requires elaborate synthetic efforts to 
procure chemically pure oligosaccharides. This has been a major bottleneck for the 
advancement of knowledge in this field. 
1.2. Production of Carbohydrates in the Context of Vaccine 
Development 
Carbohydrates play a pivotal role in recognition processes associated with 
adhesion, cell-cell interactions, infection and immunity14 and have been exploited 
for protective vaccination for decades. Currently, there are several vaccines in the 
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market based on carbohydrate antigens such as Haemophilus influenza type B (Hib), 
Streptococcus pneumoniae, and Neisseria meningitidis. 
Conventional carbohydrate vaccine development and manufacture relies on 
the cultivation of microorganisms and subsequent extraction of antigens through 
biochemical and microbiological methods. Cell cultures constitute an important 
source of carbohydrate antigens since they allow for large scale production and 
access to complex structures. However, antigen isolation and depolymerization is 
complex, costly, and results in a heterogeneous mixture of glycans. Moreover, the 
presence of contaminants may result in undesired effects on the immune response 
and introduces safety concerns.15 
Chemical synthesis provides access to chemically pure oligosaccharides that 
can be used to do epitope mapping and structure-immunogenicity relationship 
studies such as with GBS type III.11 The importance of synthetic carbohydrates was 
further highlighted with the approval of a chemically synthesized oligosaccharide 
Hib vaccine in Cuba in 2004.16 
 
1.2.1. Chemical Synthesis of Carbohydrates 
The key step in carbohydrate synthesis is the glycosylation reaction where a 
glycosyl donor (electrophile) reacts with a glycosyl acceptor (nucleophile). The 
formation of the glycosidic bond generates a stereogenic centre. Therefore, a tight 
control of regio- and stereoselectively is required. 
Mechanism of glycosylation 
The formation of the glycosidic bond happens upon displacement of a suitable 
leaving group. The reaction develops in four steps as depicted in Scheme 1.1. 17,18  
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Scheme 1.1 Simplified outline of glycosylation mechanism. E-X is the activator. CIP: 
contact ion pair. SSIP: solvent separated ion pair. 
In the first step, the donor is activated as a result of the interaction of the LG 
with the activator. Under particular conditions, the acceptor attacks the donor at 
this step in a SN2 fashion, leading to a stereospecific reaction with inversion of 
configuration. Most of the time, the reaction proceeds with the second step where 
the activated leaving group dissociates. This is a typically irreversible 
transformation and the rate-limiting step. It leads to the generation of a glycosyl 
cation that resonates into the oxocarbenium ion form. In turn, the oxocarbenium ion 
can interact with the counter ion to form contact ion pairs (CIP) or solvent separated 
ion pairs (SSIP) where either the alpha or beta are free to form a covalent bond 
giving rise to the alpha or beta anomers. In the third step, the nucleophilic attack 
determines the stereochemical outcome. The oxocarbenium ion, with its sp2-
hybridized anomeric carbon, allows the attack from both faces. The ion-pairs will 
favour one of the faces over the other and the covalent species will undergo a SN2-
type transformation with inversion of configuration. On the other hand, the acceptor 
electronic, steric and conformational properties translate into an inherent reactivity 
and stereochemical preference. As a balance between all these factors, the outcome 
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is often a mixture of anomers. In the fourth step, a proton transfer renders the 
glycosidic bond formation irreversible.17,19 
In order to gain control on the glycosylation product, both donor and acceptor 
are protected with selected protecting groups (PGs) and a leaving group that have a 
direct effect on the overall reactivity of the building block as well as on the stereo- 
and regioselectivity. 
 
The choice of the leaving group 
The classic Fischer glycosylation where a free sugar is activated by 
hydrochloric acid or the Koenigs-Knorr glycosylation where a glycoside halide is 
activated with silver carbonate have been supplanted by more efficient methods. 
Nowadays, a number of leaving groups has been developed and currently, imidates, 
phosphates, and thiolates are amongst the most popular ones. 
 
Scheme 1.2 Activation of imidate, phosphate and thiolate glycosyl donors. 
Glycosyl trichloroacetimidates can be readily prepared through the addition 
of the anomeric hydroxyl to trichloroacetonitrile in the presence of an inorganic 
(such as NaH, K2CO3 or CsCO3) or organic base (such as DBU). Imidates require a 
strong Lewis acid for activation such as TMSOTf, BF3·OEt2, Tf2O or AgOTf.20 
Trichloroacetimidates are more reactive than trifluoracetimidates.20 This difference 
in reactivity has been exploited to perform one-pot oligosaccharide synthesis where 
a trichloroacetimidate donor was activated with Yt(OTf)3 in the presence of a 
trifluoroacetimidate acceptor. The resulting disaccharide was activated by adding 
Bi(OTf)3 and a new monosaccharide donor to generate a trisaccharide. The same 
sequential transformation was achieved with Bi(OTf)3 as activator in both steps 
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where the temperature served as a switch to the selective activation (lower 
temperature activation of trichloroacetimidate and higher temperature activation 
of trifluoroacetimidate) .21  
Glycosyl phosphates are highly reactive donors that can be prepared by the 
epoxidation of a glycal with DMDO followed by opening of the epoxide with a 
dialkylphosphate.22 Alternatively, phosphates can be prepared from thioglycosides 
by activation in the presence of dialkylphosphate.23 Phosphate donors give high 
yielding couplings upon activation with stoichiometric amounts of TMSOTf. When 
such a strong acidic media poses a problem, phosphate donors can be activated 
under mild neutral conditions in concentrated solutions of lithium perchlorate in 
organic solvents, or with a silylated acceptor and a catalytic amount of TfOH.24 
Thioglycosides are versatile glycosyl donors. The anomeric thiolate is stable 
towards a variety of conditions used for protecting-group manipulations and is 
installed at the early stages of the building block synthetic scheme. Thiolates are 
easily prepared from the peracetylated sugar by reaction with the appropriate thiol 
in the presence of BF3·OEt. On the other hand, thioglycosides are easily activated 
with thiophilic species under mild conditions. The soft sulfur atom provides easy 
and selective reactivity with soft electrophiles. Activator systems for thioglycosides 
include NIS/TfOH, NBS/TfOH, and AgOTf.20 Thioglycoside reactivity can be tuned by 
manipulating the aglycon group. An ethyl thioglycoside was selectively activated in 
the presence of a toluyl thioglycoside acceptor, that was subsequently activated in a 
second glycosylation reaction.25 The sulphur substituent is also important to avoid 
aglycon transfer when a thioglycoside is used as an acceptor. Bulky substituents 
such as 2,6-demethylphenyl are able to prevent aglycon transfer.26  
 
Controlling the stereochemical outcome 
In a glycosylation reaction, both donor and acceptor possess inherent 
preferences for the formation of either the α or β anomer. Mannose has an inherent 
preference to form α-glycosides whereas glucose and galactose have an inherent 
preference to form β-glycosides.27 One of the big challenges of carbohydrate 
synthesis is to articulate environmental variables in order to create conditions that 
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enhance or override inherent preferences and lead to stereoselective glycosidic 
bond formation. 
The formation of 1,2-trans glycosidic linkages is made easy by installing a 
participating group at O2. By neighbouring group participation, an acyl group at O2 
stabilizes the oxocarbenium ion generating an acyloxonium ion that resolves upon 
attack of the nucleophile from the available trans-face. Donors with acyl protecting 
groups at O2 generally show high 1,2-trans stereoselectivity.17 The stereoselective 
outcome is also affected by remote substituents, particularly those with strong 
electron-withdrawing effect, steric hindrance or remote participation. Although 
remote participation can be weaker than for O2 substituents17, it has been 
successfully used previously. For instance, α-glucosides are successfully installed 
when the glucoside building block bears an acetyl group at O6. The α/β ratio rises 
from 8:1 to 11:1 when the O3 position is also acetylated. In the case of galactose 
building blocks, O4-acetylation leads to α-galactosides.28 
The solvent can play an important role in defining the stereochemical outcome 
of a glycosylation. Ethers such as diethyl ether, dioxane and tetrahydrofurane 
stabilize the oxocarbenium ion by generating an equatorial O-linked intermediate. 
The β face becomes sterically blocked and the α glycoside is preferentially formed. 
On the other hand, nitrile solvents such as acetonitrile form an axial glycosyl 
nitrilium cation and thus promote β-glycoside formation. 
Several other factors including temperature, amount, and type of activator 
used can influence the stereochemical outcome of glycosylations. Kinetically 
controlled reactions at low temperatures favour the formation of β linkages, 
particularly for glucose and galactose. However, opposite results have also been 
reported. 17,27 
 
Synthesis of oligosaccharides 
Oligosaccharide chains can be prepared following a linear or a convergent 
approach. In the linear stepwise approach, each monosaccharide is added 
sequentially. After glycosylation, additional synthetic steps may be required to 
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transform the resulting disaccharide into the donor or acceptor for the next step. 
The cycle repeats for as long as the target oligosaccharide chain. This approach is 
very straightforward but can lead to a drastic drop in yields as the sequence gets 
longer. In a convergent strategy, smaller oligosaccharides are pre-synthesized and 
linked together by a glycosylation reaction. The strategy provides time savings due 
to the use of oligomeric building blocks and can be particularly useful for the 
synthesis of sequences with two or more repeating units. 
To expedite oligosaccharide synthesis, efforts have been made to develop 
strategies that reduce or eliminate the manipulations in between glycosylation 
steps. These strategies explore the relative reactivity of the building blocks based on 
their leaving groups and protecting groups as well as the inherent reactivity of the 
hydroxyl groups of the acceptors.  
Chemoselective activation can be achieved using the armed-disarmed concept. 
Armed donors are equipped with electron donating groups (e.g. benzyl ether) and 
can be selectively activated in the presence of disarmed donors, which display 
electron withdrawing groups (e.g. acyl groups). The disarmed building block can be 
activated in a subsequent glycosylation reaction without the need for additional 
transformations. Another strategy is the use of different leaving groups that can be 
activated in a selective fashion. Thiocyanate glycosyl donor, for example, is activated 
over an S-thiazolinyl acceptor that can be activated in a subsequent glycosylation. 
Fluoro and S-phenyl orthogonal leaving groups can be used in sequential 
glycosylations by alternating the use of the thioglycoside donors, activated with 
NIS/AgOTf, with the use of fluoride donors, activated with Cp2Hf2Cl2/AgOTf.17  
One-pot glycosylations are interesting approaches to oligosaccharide 
synthesis. Knowledge of the relative reactivities of a library of glycosylating agents 
is the basis for the sequential one-pot combination of building blocks that can serve 
as glycosylating agents as well as nucleophiles. Despite conceptually attractive, the 
strategy requires many different building blocks. Moreover, each building block 
requires adjustments in reaction temperature and time which further complicates 
glycan syntheses.29  
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An important strategy to avoid lengthy chromatographic purifications in 
between glycosylation steps is the supported synthesis. A solid support allows for 
the use of excess building blocks and reagents that are easily washed away by 
filtration. At the same time, it reduces the oligosaccharide synthesis to a simplified 
iterative process setting the scene for an automated platform.  
 
1.3. Automated Glycan Assembly 
Automated Glycan Assembly (AGA) is based on a solid support equipped with 
a linker that is used to attach successively one building block after another with all 
synthetic manipulations being executed by automated instrumentation. Upon 
completion of AGA, the resulting oligosaccharide is cleaved from the solid support 
and purified by chromatography. The solid support can be equipped with either a 
nucleophile (acceptor-bound approach) or a glycosylation agent (donor-bound 
approach). The former approach proved to be more convenient as glycosyl donors 
are more prone to undergo side reactions and can be used in excess to ensure higher 
yields30. 
 
Solid phase and linker 
With stability towards a wide range of chemical conditions and with 
established efficiency in the peptide field, the Merrifield resin is widely used for 
solid-phase carbohydrate synthesis. The resin is functionalized with a linker that 
provides the first point of attachment for the growing oligosaccharide chain. At the 
same time, the linker bears a functionality that allows for cleavage of the glycan from 
the resin at the end of chain elongation. This functionality is key as it must be 
orthogonal to all the chemistry used during the oligosaccharide synthesis.  
Some of the most popular linkers are depicted in Scheme 1.3. The metathesis 
labile linker has been used in the synthesis of a wide range of structures, but it 
cannot be used with thioglycoside donors as they are activated in an electrophilic 
environment (NIS/TfOH) that reacts with the double bond. The pre-conjugated 
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base-labile and photolabile linkers generate oligosaccharides with a 
5-aminopentanyl chain that can be used as a handle for the preparation of 
microarrays or conjugation with proteins. The photolabile “reducible” linker 
provides glycans with free reducing ends. The big advantage of photolabile linkers 
is the exceptional orthogonality and the mild of cleaving conditions.30,31 
 
Scheme 1.3 Linkers for automated glycan assembly. Adapted from ref. 32.32 
 
Building blocks 
Thioglycosides, glycosyl phosphates and glycosyl imidates have been 
successfully used in AGA. Thioglycosides are activated with NIS/TfOH while 
phosphates and imidates are activated with TMSOTf in stoichiometric or catalytic 
amounts respectively. Thioglycosides are particularly interesting from the 
commercial point of view as they are stable for long periods of time and offer the 
possibility of large-scale production and storage. At the same time, thioglycosides 
react at higher temperatures than phosphates and imidates which reflects in time 
savings during cooling steps of the automated synthesis.30,33 
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To ensure stereoselectivity, the building blocks are equipped with 
participating protecting groups, generally benzoyl, trichloroacetamide or acetyl 
groups. The temporary protecting group of choice is 9-fluorenylmethyloxycarbonyl 
(Fmoc) as it is quantitatively cleaved with Et3N or piperidine in only five minutes. 
Other temporary protecting groups are used for branching building blocks such as 
levulinoyl esters (Lev), which are cleaved with hydrazine, and naphtyl ether (Nap), 
cleaved with DDQ30,33. 
 
1.4. The Glyconeer: The First Commercial Automated 
Glycan Synthesizer 
1.4.1. Description of the Hardware 
The Glyconeer (Figure 1.3) is a versatile automated platform designed to 
address the challenges of oligosaccharide solid-phase synthesis. The Glyconeer 
delivers solvents and reagents into a reaction vessel, incubates the reaction vessel 
contents at a controlled temperature, mixes the contents of the reaction vessel 
through gas bubbling, and drains the resulting solutions into the waste. 
Solvents and reagents are delivered in a fast and accurate manner through a 
pressure-driven system. Argon pushes solvents and reagents through valves and 
tubes that are inert to volatile and corrosive reagents. The pressure of argon is 
controlled by the software and determines the flow rate of the corresponding 
solvent or reagent. There are eight positions available for solvents.  The reagents are 
divided in three blocks: the basic block, consisting of 6 positions for basic reagents; 
the acid block, consisting of six positions for acidic reagents; the aqueous block, 
consisting of four positions for reagents containing water. The acidic block contains 
a thermoelectric cooling device (Peltier) where two reagent bottles can be stored at 
0 °C (intended for activator solutions). 
Building blocks are loaded into specific vials that are placed in a carousel with 
64 vial positions. The carousel positions the appropriate vial below a two-way 
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needle that can deliver solvents to dissolve solid building blocks and uptakes the 
building block solution and delivers it to the reaction vessel.  
 
Figure 1.3 The automated solid phase oligosaccharide synthesizer Glyconeer. 
The central piece of the Glyconeer is the reaction vessel (RV), located in the 
centre of the instrument. The RV is a 15 mL triple jacketed cylindrical vessel fitted 
with a frit at the bottom. The inner compartment closes with a conical cap that has 
two openings, each connected to a PTFE line: an exhaust line that leads to the 
exterior and an “in line” through which solvents, reagents and building blocks are 
delivered into the RV. The temperature of the RV is controlled through a coolant that 
flows through the middle compartment. The coolant is pumped by an external 
cryostat with a temperature range from -40 °C to +80 °C. The external compartment 
of the RV is a vacuum compartment to increase the insulation. 
Below the RV, an on-line UV detector measures the UV transmittance of the 
solution discharged from the RV after cleavage of the Fmoc protecting group. The 
decrease in transmittance caused by the generated dibenzofulvene provides an 
indirect measure of the coupling efficiency. 
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1.4.2. Pre-Programmed Modules 
The synthesis of oligosaccharides using the Glyconeer is based on the 
repetition of an elongation cycle that incorporates one building block into the 
growing oligosaccharide chain. During the elongation cycle, the building block is 
activated and glycosylates the hydroxyl group of the acceptor, and the temporary 
protecting group is removed to prepare the introduction of another building block 
during the following elongation cycle. These repetitive tasks are done according to 
a synthesis plan that is scheduled in the Glycosoft (the software that operates the 
Glyconeer) by combining pre-programmed modules in the appropriate order. Each 
module completes a specific task. When scheduling a synthesis, the software enables 
the user to modify a certain number of variables in each module. The pre-
programmed modules are described in Table 1.1. 
Table 1.1 Description of the pre-programmed modules used in the Glyconeer 
Module Description 
1. Resin swelling DCM is delivered to the reaction vessel and the resin is incubated 
for 30 min at 25 °C. 
2. Acid Wash The resin is washed with a solution of TMSOTf in DCM at -20 °C. 




Building block and the activator solution (NIS/TfOH) are 
delivered to the reaction vessel at temperature T1 and incubated 
for a period of time t1. The temperature is then raised to T2 and 
an incubation time of t2 min is followed. 
4. Glycosylation with 
phosphates 
 
Building block and the activator solution (TMSOTf in DCM) are 
delivered to the reaction vessel at temperature T1 and incubated 
for a period of time t1. The temperature is then raised to T2 and 
an incubation time of t2 min is followed. 
5. Capping Resin is washed with a 10% solution of pyridine in DMF and 
then capped by acetylation with a solution of Ac2O and MsOH in 
DCM at 25 °C. 
6. Fmoc Deprotection 
 
Fmoc is cleaved with piperidine 20% (v/v) in DMF.  
7. Lev Deprotection Lev is deprotected with 0.15 M hydrazine acetate in 
Py/AcOH/H2O 
 
In the “resin swelling” module, DCM is delivered to the RV and the resin is 
allowed to swell. The incubation time is standardized (30 min) but can be changed 
by the user. The “acid wash” module washes the resin and reaction vessel with a 
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solution of TMSOTf to quench any base left over from previous steps that would 
interfere with acid-mediated activation34. In the “glycosylation” module, DCM is 
delivered to the RV while the temperature is set to the appropriate value. When the 
temperature is reached, DCM is drained, and the BB solution and activator are 
sequentially added. The temperature is gradually increased to drive the 
glycosylation to completion. The “capping” module washes the resin with a solution 
of pyridine in DMF and proceeds with acetylation of the unreacted hydroxyl groups 
with acetic anhydride and methanesulfonic acid35. The “Fmoc deprotection” module 
delivers a solution of piperidine in DMF that cleaves the Fmoc group. The “Lev 
deprotection” promotes cleavage of Lev with hydrazine acetate in a pyridine/acetic 
acid buffer. 
 
1.4.3. Validation of the Glyconeer 
The Glyconeer was validated with the synthesis of motifs of the Mycobacterium 
tuberculosis cell surface and α-Gal epitopes expressed in cancer cells.34 The three 
oligosaccharides (Figure 1.4) constitute various degrees of complexity and each 
requires several different building blocks. The linear hexasaccharide 1.15 contains 
multiple 1,2-trans linkages, hexasaccharide 1.14 is a branched structure with 1,2-
trans linkages, and trisaccharide 1.16 contains both 1,2-trans and 1,2-cis linkages. 
The three oligosaccharides were assembled in the Glyconeer with the BBs depicted 
in Figure 1.4. After the synthesis, they were cleaved from the solid support in a 
photoreactor and purified by normal phase HPLC to eliminate deletion sequences 
and unwanted stereoisomers. The protected hexasaccharide 1.12 was obtained in 
38% yield. The protected branched hexasaccharide 1.11 was obtained in 24% yield. 
The protected trisaccharide 1.13 was obtained in 25% yield (yields based on resin 
loading). The protecting groups were removed by methanolysis with NaOMe 
followed by hydrogenation with Pd/C. Purification by reverse-phase HPLC afforded 





Figure 1.4 Glycans synthesized with the Glyconeer.34 
 
1.5. Aim of the Thesis 
Chemically defined oligosaccharides are pivotal for the elucidation of 
functional epitopes and for the development of safer and more efficient 
carbohydrate vaccines. The overall goal of this work is to develop and standardize 
methods for automated glycan assembly in order to used them as tools to advance 
the field of vaccine development, particularly in the case of Group B Streptococcus. 
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In the first part of the thesis, the focus is on standardizing the production of 
differentially protected building blocks. The methods are critically revisited, 
alternative strategies are compared, procedures are tested for reproducibility and 
scalability.  
In the second and third chapters of this thesis, the emphasis is on the 
automated glycan assembly. The target is the synthesis of oligosaccharides from 
type IV and type III GBS capsular polysaccharide using the Glyconeer. Special 
attention is given to develop standardized conditions for the formation of each 
glycosidic linkage. In the case of GBS type III, different frameshifts of the repeating 





   
 








One of the biggest advantages of automation is time saving. The Glyconeer 
constitutes a platform for rapid production of oligosaccharides. In a few hours, 
disaccharides, trisaccharides, or tetrasaccharides can be synthesized. Compared to 
solution-phase methods, AGA makes use of a large excess of donor (typically 6.5 to 
10 equivalents). Starting materials, that is, building blocks and functionalized resin, 
are required in bulk to do automated experiments in a continuous way.  
“Approved” building blocks are differentially protected building blocks that 
can be used in AGA in a versatile and reliable fashion. Also, they should be accessible 
cheaply and fast: this translates into reproducible and high yielding synthetic 
schemes. Thioglycosides as commonly used glycosyl donors. 
Fluorenylmethyloxycarbonyl (Fmoc) and levulinoyl (Lev) groups are convenient 
temporary protecting groups. Acyl groups such as benzoyl, acetyl, or trichloroacetyl 
(TCA) are used as permanent participating groups and benzyl ethers are used as 
permanent non-participating groups.30,33 Protecting group manipulations in 
carbohydrate chemistry have been extensively studied and there are published 
procedures for the transformations needed to prepare the “approved” building 
blocks. However, the lack of mechanistic novelty led to a declining interest in 
optimizing those procedures.  
This chapter deals with pre-automation work necessary for the synthesis of 
GBS type IV CPS. Aiming at generating knowledge for routine production and 
developing standard operating procedures in an industrial setting, the main goals 
are the optimization and upscaling of procedures. Special emphasis is given to 
developing crystallization conditions to avoid chromatographic purifications and 
facilitate large scale production, to reduce the amount of reagents in order to reduce 
cost in large scale production, and to assess reproducibility to allow for competitive 
price calculations.  
In the first part of this chapter, the focus is on the first two transformations of 
the free monosaccharides, peracetylation and thioglycosylation. In the second part, 
a retrosynthetic analysis of GBS type IV CPS is discussed as well as the synthesis of 
 26 
the corresponding building blocks. In the last part, the upscaling of the resin 
functionalization is presented.  
 
2.2. Peracetylation and Thioglycosylation of 
Monosaccharides 
Thioglycosides are the most common used glycosyl donors in AGA. They are 
bench stable, which means they can be mass produced for commercial purposes, 
reinforcing the need for standard large-scale production procedures. Because 
thioglycosides are compatible with most of the conditions used in protecting group 
manipulations, they are installed in the earlier steps of the synthetic schemes. 
Thioglycosides are easily prepared by reaction of the peracetylated sugar with an 
appropriate thiol in the presence of a suitable acid. Therefore, the first reactions to 
produce an “approved” building block from a free sugar are peracetylation and 
thioglycosylation.  
Acetyl esterification is a very common reaction and usually very 
straightforward. However, the acetylation of reducing sugars has a higher 
complexity due to the existence of anomers and regioisomers (namely pyranosides 
and furanosides). The most widely used methods for peracetylation are: i) Ac2O and 
NaOAc at high temperature; ii) Ac2O and pyridine; c) Ac2O and acid catalyst. Each 
method gives a different ratio of α/β anomers (Scheme 2.1). 
  
Scheme 2.1 Peracetylation of D-glucopyranose leads to α or β pentaacetate. 36 
Sodium acetate catalyses the anomerization of the free sugar but not in the 
acetylated stage. As the β anomer is more reactive, it is acetylated first and, in these 
conditions, the β peracetate is obtained. In acid medium, anomerization of the 
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acetates takes place and leads to the thermodynamic product which, in case of 
glucose and galactose, is the α peracetate. The pyridine method does not seem to 
promote isomerization as it is reported to afford the same α/β ratio as the parent 
free sugar.36,37 
Acid catalysis appears as an attractive method for the peracetylation since it 
avoids the use of stoichiometric amounts of pyridine (whose toxicity is well known) 
and requires no heating, compared to the sodium acetate method. The use of metal 
triflates38 and particularly In(OTf)339 leads to high yielding peracetylations with 
very simple procedures. In(OTf)3 has low toxicity, is non-corrosive and water 
tolerant. Therefore, it was anticipated that it could be used in large scale 
peracetylations. Here a scale up study of this method, together with a comparison 
with sodium acetate and pyridine methods is presented. 
 
2.2.1. Peracetylation of Monosaccharides 
Indium Triflate Method 
Peracetylation of galactose was performed in neat Ac2O with 5% In(OTf)3 
following the reported procedure39 (Table 2.1). The work up was difficult, as the 
large excess of acetic anhydride required a large volume of sodium carbonate 
solution for neutralization. To avoid this problem, the amount of Ac2O was reduced 
to eight equivalents. Because the anhydride was being used both as reagent and 
solvent, the decrease of Ac2O was compensated with the use of an organic solvent. 
DCM, toluene and ACN were tested. In the three cases, the reaction was complete by 
TLC. However, after isolation of the product, the reaction with toluene gave a lower 
yield. The reaction with ACN was faster so it was chosen to proceed with 
optimization. 
Keeping ACN a solvent, the amount of In(OTf)3 catalyst was reduced to 2.5% 
and then 1.3% (Table 2.2 entries 1 and 4). The experiments showed complete 
conversion and high isolated yields. The amount of Ac2O was further reduced to 
seven equivalents with similar results. The procedure was then scaled up to a 50 g 
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batch leading to the isolation of the galactose pentaacetate in quantitative yield 
(Table 2.2, entry 4). 
Table 2.1 Solvent screening in D-galactose peracetylation with In(OTf)3. 
 
Entry Ac2O Solvent Reaction time Yield α/β Ratio 
1 30 equiv neat 1.5 h 88% 7:1 
2 8 equiv DCM ON 98% 10:1 
3 8 equiv Toluene 5.5 h 77% 10:1 
4 8 equiv ACN 3 h 93% 10:1 
 
Just seven equivalents of Ac2O and just 1.3 mol% of In(OTf)3 are enough to 
drive the reaction to completion in a short amount of time (1.5 to 2h). As the reaction 
proceeds, the reaction mixture evolves from a suspension to a solution and this 
observation can be safely used as an indicator of the endpoint. It is speculated that 
the first acetylation is rate limiting. The first acetylation should increase the 
solubility of the sugar and, once in solution, the subsequent acetylation steps should 
be fast. This is consistent with the fact that only the starting material and the final 
product can be observed by TLC, regardless of the progress stage of the reaction. 
The reaction can be easily scaled up although the extraction procedure becomes 
more inconvenient as the scale increases.  
Table 2.2 Optimization of D-galactose peracetylation with In(OTf)3. 
 
Entry Ac2O In(OTf)3 Reaction time Yield α/β Ratio 
1 10 equiv 2.5% 2 h 79%a 10:1 
2 10 equiv 1.3% 2.5 h quant. 10:1 
3 7 equiv 1.3% 1.5 hb 96% 8:1 
Scale up to 50 g 
4 7 equiv 1.3% 2 h quant. 8:1 
aComplete conversion by TLC, lower yield attributed to losses during work up. bCooling 
bath removed 30 min earlier than before. 
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Sodium acetate method 
D-Galactose was peracetylated with acetic anhydride and sodium acetate 
following a procedure described for glucose40. The free sugar was added to a 
refluxing mixture of acetic anhydride and NaOAc. Upon precipitation with ice, β-D-
galactopyranose pentaacetate was isolated (Table 2.3, entry 1). The highest yield 
was obtained when the reaction mixture was quenched with sodium bicarbonate 
and extracted with DCM (entry 2). Crystallization of the crude so obtained led to 
60% isolated yield. The lower yield compared with the In(OTf)3 method is attributed 
to the formation of isomeric penta-acetetates of D-galactose, namely D-
galactofuranose, which also occurs with the pyridine method36.   
Table 2.3 Reaction conditions for peracetylation of D-galactose with NaOAc. 
 
Entry Scale Isolation Yield α/β Ratio 
1 2 g Precipitation with ice and filtration 38% Pure β 
2 2 g Extraction with organic solvent 60% Pure β 
 
The peracetylation of glucose with the sodium acetate method led to the 
isolation of pure β-D-glucopyranose pentaacetate in 71% after crystallization 
(Table 2.4, entry 1). The filtrate obtained after isolating the crystals was identified 
as a mixture of α and β D-glucopyranose pentaacetates and accounted for 25% yield. 
When this reaction was scaled up to 50 g, the pure β D-glucopyranose pentaacetate 
was isolated in 76% yield (entry 2).  
Table 2.4 Reaction conditions for peracetylation of D-glucose with NaOAc. 
 
Entry Scale Yield α/β Ratio 
1 2 g 71% Pure β 




Pyridine is a volatile liquid that is toxic by inhalation, causes irritation to the 
skin and the eyes, and causes infertility in male humans. Pyridine is highly 
flammable and forms explosive mixtures with air. Thus, handling large volumes of 
pyridine creates a series of risks. Still, the pyridine method is one of the most widely 
used for acetylation of sugars. 
When the pyridine method was used with galactose, an α/β ratio favouring the 
α anomer was observed (Table 2.5). The yields were very high both in small large 
scale.  
Table 2.5 Reaction conditions for peracetylation of D-glucose with the pyridine method. 
 
Entry Scale Reaction time Yield α/β Ratio 
1 2 g ON 88%  2.5:1 
2 10 g  ON 97%  2.8:1 
 
2.2.2. Thioglycosylation 
Several thioglycosides have been used as donors, with ethyl, toluyl and 5-tert-
butyl-2-methylphenyl (Mpb) being the most common thioglycoside aglycons. The 
substituent on the sulphur can provide orthogonality within different 
thioglycosides. For instance, an ethyl thioglycoside can be selectively activated in 
the presence of a toluyl thioglycoside acceptor, that is subsequently activated in a 
second glycosylation reaction.25 The sulphur substituent is also known to affect 
aglycon transfer. Bulky substituents such as Mpb prevent aglycon transference 
when the thioglycoside is used as an acceptor increasing the yield of the intended 
glycosylation.26 In order to establish standard “approved” building blocks for AGA, 
the question of which aglycon leads to a more appropriate leaving group was posed. 
To answer that question, ethyl, toluyl and Mpb thioglycosides of galactose and 
glucose were synthesized. 
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The synthesis of the thioglycosides was accomplished by combining the 
peracetates of D-galactose and D-glucose with the appropriate thiols in the presence 
of boron trifluoride etherate. 
 
Galactose 
In the first attempt to generate ethyl thiogalactoside, α-D-galactose 
pentaacetate was used as a starting material. After incubating for 18 h, the reaction 
was not complete and a 42% conversion was observed by NMR (Table 2.6, entry 1). 
When the β-galactose pentaacetate was used, the reaction was over in 3.5 h and 
ethyl thiogalactoside was isolated in 95% yield as a 1:1 α/β mixture (entry 2). In an 
effort to find a stereoselective procedure, the reaction was repeated at 0 °C. 
However, no change in the α/β ratio was observed (entry 3). 
Table 2.6 Thioglycosylation of D-galactose pentaacetate with EtSH. 
 
Entry Pentaacetate α/β ratio Temperature Time Yield Product α/β ratio 
1 25:1 rt 18 h 42%a 4:3a 
2 Beta rt 3.5 h 95% 1:1 
3 Beta 0 °C 3.5 h 95% 1:1 
aEstimated by NMR analysis of the crude reaction mixture. 
 
Glucose 
The lack of stereoselectivity was also observed with glucose (Table 2.7, entry 
1). The resulting α and β thioglucosides could not be purified by crystallization. Also, 
they showed a similar rf value which hindered purification by column 
chromatography. When toluyl thiol (entry 2) or Mpb thiol (entry 3) were used, the 
reaction was selective and the β-thioglucoside could be purified by crystallization. 
The toluyl glucoside gave a higher isolated yield. 
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Table 2.7 Thioglycosylation of D-glucose pentaacetate with EtSH. 
 
Entry R Purification and yield 
1 Et Column: α 22%, β 12%, α/β mixed fractions 37% 
2 Tol Crystallization: β 73%  
3 Mpb Crystallization: β 53%  
 
2.2.3. Discussion 
Peracetylation and thioglycosylation are the first transformations in the route 
to the production of thioglycosides. Hence, universal, robust and high-yielding 
procedures that can be scaled up to multi gram production are very important to 
reduce the cost of building blocks. 
Peracetylations with In(OTf)3 led to very high yields with very simple 
procedures (that is, no heating or special equipment were required). The method is 
stereoselective for the α peracetate and when it was reacted with the thiol it showed 
very low reactivity. The higher stability of the alpha anomer prevents the conversion 
into the thioglycoside under the tested conditions. This finding implicates that α 
promoting peracetylation methods (i.e. acid methods) are not appropriate when 
thioglycosides are to be generated. The pyridine method is easy to set up and gives 
good yields.  Furthermore, the method is reliable and scalable. The resulting ratios 
for galactose favour the α anomer but it can vary according to the α/β ratio of the 
parent sugar. The pyridine method requires manipulation of large volumes of 
pyridine, which is more problematic for large scale reactions. The NaOAc method 
requires heating and yields can vary. For example, galactose forms isomeric acetates 
such as D-galactofuranose which decrease the yield of the target galactopyranose 
pentaacetate. On the other hand, the NaOAc method is selective for the β peracetate, 
which reacts easily in the thioglycosylation step. Hence, the NaOAc method is 
recommended as the method of choice for the preparation of thioglycosides. 
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The generation of ethyl glycosides of galactose and glucose led to mixtures of 
α/β anomers without any selectivity. Furthermore, the products were not 
crystalline and had to be purified by column chromatography. On the other hand, 
the reaction with toluyl and Mpb thiols gave stereo selective formation of the 
corresponding thiogalactosides (unpublished data) and thioglucosides. Moreover, 
the thioglycosides crystalized and were easily isolated by filtration with toluyl 
derivatives giving higher isolated yields. From a building block synthesis 
perspective, the use of toluyl thioglycosides proved to be the best option. 
 
2.3. Synthesis of Building Blocks to Assemble GBS type IV 
Capsular Polysaccharide 
2.3.1. Retrosynthetic Analysis 
A retrosynthetic analysis of the repeating unit of GBS type IV CPS led to the 
design of the building blocks 2.1-2.5 as depicted in Scheme 2.2. 
 
Scheme 2.2 Retrosynthetic analysis of the repeating unit of GBS type IV CPS. 
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Fluorenylmethyloxycarbonyl (Fmoc) was used as the temporary protecting 
group of choice. To assure stereoselectivity in the glycosidic bond formation, 
benzoyl (Bz) groups were used in O2 for β linkages in glucose and galactose. For 
glucosamine, the trichloroacetyl (TCA) group served as participating group. To 
generate the α-glucoside, an acetyl group was used in O6 as it is known to enhance 
the alpha stereoselectivity via remote participation.28 
 
2.3.2. Synthesis of the Glucosamine Building Block 
Building block 2.4 was prepared from peracetylated glucosamine 
hydrochloride derivative 2.4a in seven steps (Scheme 2.3). The synthetic route was 
scouted in a 10 g batch and scaled up to 40 g batch. 
 
Scheme 2.3 Synthetic route to glucosamine building block 2.4. 
The introduction of the TCA group was performed with trichloroacetyl 
chloride and triethylamine in DCM. The literature reports 82% isolated yield after 
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crystallization.41 However, here the crude product after work up showed high purity 
by NMR. Avoiding crystallization led to an increase of isolated yield from 82% 
(reported) to 90% (in the 10 g batch) or 97% (in the 40 g batch). Compound 2.4b so 
obtained was successfully transformed into the corresponding ethyl thioglycoside 
2.4c. The product was selectively generated as the β anomer and isolated in 81% 
yield (10 g batch) and 84% yield (40 g batch) after crystallization. This is in 
agreement with reported 85% yield.42  
Thioglycoside 2.4c was deacetylated using Zemplén conditions and isolated in 
quantitative yields without the need for any purification procedure. It was then 
transformed into the benzylidene intermediate 2.4e by reacting with benzaldehyde 
dimethyl acetal in the presence of camphorsulfonic acid (CSA). This reaction is 
typically performed in DMF using a sulfonic acid catalyst.43 Here, THF was used as a 
solvent to avoid the use of DMF. TLC analysis of the reaction mixture showed trace 
amounts of the starting material 2.4d even after 18 h of reaction. Crystallization of 
the crude material, obtained after aqueous work-up, led to the benzylidene 
compound 2.4e in 72% (10 g batch) or 74% (40 g batch) yield. The difference 
between these values and literature values (85% after column chromatography43) 
support the choice of crystallization as a purification method.  
The introduction of benzyl group was done with BnBr and NaH in THF. In this 
particular case, the amount of NaH required for the reaction had to be 
superstoichiometric as the hydride base is strong enough to deprotonate both the 
alcohol and the amide proton. Regarding the solvent, THF and DMF lead to different 
reaction paths. In THF, the alcohol reacts with benzyl bromide and the O-benzyl 
derivative is formed. The use of DMF favours N-alkylation.44 The benzylated 
compound 2.4f was isolated by crystallization in 75% (10 g batch) or 77% yield (40 
g batch). Reductive cleavage of the benzylidene ring to release the 4-OH group was 
achieved with Et3Si and TFA. Crystallization from EtOH gave the unreacted 2.4f and 
the intended product 2.4g was purified by column chromatography resulting in a 
yield of 58% (10 g batch) or 71% (40 g batch). In the last transformation of the 
synthetic route, 2.4g was reacted with FmocCl in the presence of pyridine to give 
final building block 2.4. The isolation of the final compound 2.4 by crystallization 
proved cumbersome. In the first trial (Table 2.8, entry 1), crystallization with 
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EtOAc/hexane 1:4 failed, as well as EtOAc/hexane 1:1. Crystallization with ethanol 
was successful in generating crystals but the recovery was very low and was 
contaminated with a side product originating from the excess of FmocCl reagent. In 
a second reaction (Table 2.8, entry 2), the amount of FmocCl was reduced to 1.1 
equivalents and the reaction was complete by TLC. Crystallization from 
EtOAc/hexane 1:2 failed to afford the product. Surprisingly, in the large scale 
reaction (Table 2.8, entry 3),  the product crystalized in a pure state from 
EtOAc/hexane 1:1, after 13 days at 4 °C and was isolated in 70% yield. To conclude, 
crystallization of 2.4 showed to be unreliable and difficult to implement as a routine 
purification strategy.  
Table 2.8 Scanned conditions for the introduction of Fmoc group on 4-OH group of 
glucosamine building block 2.4.  
 
Entry Scale Conditionsa Crystallization 
1 470 mg FmocCl (2 eq) EA/Hex 1:4 → failed  
EA/Hex 1:1 → failed 
EtOH → product and Fmoc reagent co-
crystalized, low recovery 
2 470 mg FmocCl (1.1 eq) EA/Hex 1:2 → failed 
3 5.8 g  FmocCl (1.1 eq) EA/Hex 1:1 → crystallized on the 13th day, 
70% isolated yield 
 
2.3.3. Synthesis of the Galactose Building Blocks 
The synthesis of galactose building block 2.5 was based on a reported 
procedure for the preparation of the toluyl analogue.45 Here, the synthetic route is 
tested and optimized starting from the ethyl thioglycoside 2.5a (Scheme 2.4).  
The introduction of the benzylidene acetal was performed with benzaldehyde 
dimethyl acetal and camphorsulfonic acid (CSA) in THF, as previously optimized at 
GlycoUniverse.46 The reaction was performed on 40 g scale and the benzylidene 
2.5b was isolated by crystallization in 81% yield. 
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The following steps were performed in a small batch (5 g) and then scaled up 
to a large 20 g batch. The introduction of the t-butyl-dimethylsilyl (TBS) group was 
performed with the corresponding silyl chloride. The conversion was quantitative 
by TLC after 17 h aqueous work up led to the target intermediate 2.5c together with 
substoichiometric amounts of the TBSCl or, most likely, the corresponding 
hydrolyzed derivative. To decrease the excess of silyl reagent and get a cleaner 
sample of 2.5c, the reaction was repeated with only one equivalent of TBSCl. After 
24h, the conversion was not complete. 
 
Scheme 2.4 Synthetic route to galactose building block 2.5. 
The crude sample of 2.5c (as obtained in the first trial) was used as such in the 
benzoylation and TLC indicated quantitative conversion. The benzoyl derivative 
2.5d crystallized from EtOH in 66% (5 g batch) or 70% (20 g batch) over two steps. 
The benzylidene ring was subsequently opened by reductive cleavage with borane 
tetrahydrofuran and TMSOTf to give 2.5e in 97% (5 g batch) or quantitative yield 
(20 g batch). In the next step, the 6-OH group was benzylated. The conversion into 
2.5f was complete and the crude product was treated with boron trifluoride 
etherate to cleave the TBS group and expose the 3-OH group. The resulting 
compound 2.5g was purified by crystallization and was obtained in 42% yield (over 
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2 steps). The introduction of the Fmoc protecting group was subject for optimization 
(Table 2.9).  While the reference procedure employed 2.5 equivalents of FmocCl for 
the transformation23, it was hypothesized that the reaction could work with less 
reagent. When galactoside 2.5g was reacted with 1.1 equivalents of FmocCl, the 
reaction did not go to completion after 24 h of incubation time. When 1.5 equivalents 
were used, TLC showed complete conversion after 2h. The low isolated yield (48%) 
in the small batch (entry 3) can be explained by the excess of solvent used in the 
crystallization. In the large-scale batch (entry 4), the amount of solvent was 
decreased in proportion to the scale and the isolated yield for the final BB 2.5 was 
78%. 
Table 2.9 Optimization of Fmoc introduction reaction. 
 
Entry Scale FmocCl (equiv) Time Results Isolated Yield 
1 180 mg 1.1 Overnight Not complete (TLC) - 
2 180 mg 1.5 2 h Complete (TLC) - 
3 740 mg 1.5 5 h Complete (TLC) 48% 
4 8.3 g 1.5 5 h Complete (TLC) 78% 
 
The synthesis of the branching building block 4.2 followed the synthetic route 
depicted in Scheme 2.5. 
 
Scheme 2.5 Synthetic route to galactose building block 2.2. 
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The benzylidene intermediate 2.5b was di-benzoylated with benzoic 
anhydride. The resulting derivative 2.2a crystalized from EtOAc/hexane 1:3 in 88% 
yield. The next transformation was the removal of the benzylidene acetal. In the first 
attempt, the reaction was done in DCM with H2O and TFA (Table 2.10, entry 1). 
When the reaction was followed by TLC, no starting material could be seen. 
However, after aqueous workup, the TLC showed the presence of the starting 
material. Purification by column gave the target diol 2.2b in only 36% yield.  
Table 2.10 Optimization of the benzylidene removal to prepare derivative 2.2b. 
 













3 No work up 40% (filtered from reaction mixture) 




No work up 84% filtered from reaction mix 
 
A different method was tried and benzylidene intermediate 2.2a was 
combined with EtSH and CSA in DCM (Table 2.10, entry 2). The reaction was stirred 
overnight, and a white precipitate formed. An extraction with 10% NaOH was done 
to neutralize and remove the excess of thiol. During the extraction process, a stable 
emulsion was formed. Brine was added but only upon resting for two to three hours 
the emulsion broke. After work up, TLC showed the product had evolved into several 
different structures. The strong basic medium had likely led to benzoyl migrations 
to the O-4 and O-6 as well as hydrolysis of one or both the benzoyl ester. The same 
reaction was repeated, and the white precipitate formed was directly filtered and 
washed with DCM, without prior work up (Table 2.10, entry 3). The solid was 
identified as the pure product (40%). The filtrate was evaporated and crystalized 
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with DCM/hexane leading to the isolation of a second portion of the product (47%). 
To try and isolate the majority of the product in the first filtration, the reaction was 
done with less solvent (Table 2.10, entry 4). Upon completion of the reaction, the 
solid was directly filtered from the reaction mixture and washed with cold hexane 
to give 84% pure product. The same conditions were applied to a large batch (48 g) 
and the isolated yield was 75%.  
Table 2.11 Optimization of the introduction of Lev protecting group to generate 2.2c. 
 
Entry Scale Conditions Yield 
1 1 g LevOH (1.2 equiv) 
CMPI (2.5 equiv) 
DABCO (4.0 equiv) 
DCM (anh. 0.11 M) 
quant. 
2 1 g LevOH (1.1 equiv) 
CMPI (1.2 equiv) 
DABCO (2.4 equiv) 
DCM (anh. 0.31 M) 
quant. 
3 28 g LevOH (1.1 equiv) 
CMPI (1.2 equiv) 
DABCO (2.5 equiv) 
DCM (anh. 0.31 M) 
17% 
 
(CMPI was likely inactivated by 
water contamination from DABCO.) 
 
The levulinoyl ester at O6 was introduced using 2-chloro-1-methylpyridinium 
iodide (CMPI). A recent procedure47 was reproduced in the first trial (Table 2.11, 
entry 1) which led to a complete conversion. After aqueous work up, the galactoside 
derivative 2.2c was isolated in a 1:1 mixture with the by-product N-methyl-2-
pyridinone. The procedure followed uses a large excess of the CMPI and DABCO. 
However, according to the original paper by Teruaki Mukaiyama48 only 1.2 
equivalents of the CMPI and 2.4 equivalents of base are required. To economize 
reagents, a new experiment using those conditions was done (Table 2.11, entry 2).  
The concentration of the reaction was also increased to facilitate scale up. The 
reaction was complete and the levulinoyl-galactoside 2.2c was isolated in a 
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quantitative yield. When the reaction was scaled up, a water contamination in 
DABCO inactivated the CMPI and the yield was low (17%, after column).  
The last transformation was the introduction of the Fmoc protecting group. In 
the case of the glucosamine building block 2.4, it was possible to use as little as 1.1 
equivalents of FmocCl for this transformation. For the galactoside 2.2c, 1.1 equiv of 
FmocCl did not lead to complete conversion after 24h (Table 2.12, entry 1). 
Increasing the reagent to 1.5 equiv led to a complete conversion (Table 2.12, entry 
2). In both cases, crystallization with EtOAc/Hexane or EtOAc/EtOH led to a mixture 
of the 2.2 and impurities from the FmocCl reagent. The reaction was successfully 
scaled up and the product was isolated by column in 88% yield.  
Table 2.12 Introduction of Fmoc protecting in building block 2.2. 
 
Entry Scale FmocCl Time Results 
1 1 g 1.5 equiv 18 h Complete conversion 
2 1 g 1.1 equiv 24 h Complete conversion 
 
2.3.4. Synthesis of the Glucose Building Blocks 
To generate the α glucoside linkage, thioglucoside 2.3 was designed and 
synthesized from the commercial benzylidene intermediate 2.3a according to the 
route in Scheme 2.6. 
The first transformation was the di-O-benzylation, a reaction typically 
performed in DMF. Inspired by the results with glucosamine building block, where 
benzylation was successful in THF, a series of experiments were conducted to 
ascertain whether DMF could be replaced (Table 2.13). 
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Scheme 2.6 Synthetic route to glucose building block 2.3. 
When the diol 2.3a was combined with NaH and BnBr in THF, the reaction was 
not complete after 24 h and the starting material was recovered in 50% by 
crystallization (Table 2.13, entry 1). To try and facilitate the reaction, catalytic 
tetrabutylammonium iodide was used to generate the more reactive benzyl iodide 
(entry 2). Although the strategy works for other sugar derivatives,49 it was not 
successful here. In fact, TLC analysis of the reaction mixture after 96 h showed the 
presence of the unreacted starting material and the formation of unwanted side 
products. Only when the reaction was performed in DMF, the conversion was 
complete. After work up, DMF was removed under reduced pressure and the 
dibenzyl intermediate 2.3b crystallized from EtOH in 88% yield (entry 3).  
In the scale up experiments (entries 4, 5, and 6), the conversion was complete 
(by TLC) and good reproducibility was observed. However, evaporating DMF 
became cumbersome and an isolation strategy was developed. After work up with 
DCM and aqueous NH4Cl, the organic layer was evaporated under reduced pressure 
until all DCM was removed. Afterwards, a 6:1 mixture of EtOH:H2O was dropwise 
added to the resulting DMF solution, under vigorous stirring. Under these 
conditions, the derivative 2.3b precipitated and was isolated by filtration. A final 
wash with cold hexane to remove the mineral oil from NaH gave the product in 
yields from 87 to 97%, in different batch sizes (10 to 40 g).  
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Table 2.13 Benzylation of glucoside derivative 2.3a. 
 
Entry Scale NaH BnBr Solvent Conditions Results 
1 1 g 
5 equiv 3 equiv 
THF 
 
24 h 50% Starting 
material 
recovered  






3 1 g DMF 18 h 2.3ii 88% 
4 10 g 
3 equiv 2.2 equiv DMF 
2.5 h 2.3ii 97% 
5 20 g 2.5 h 2.3ii 87% 
6 40 g 4.5 h 2.3ii 96%  
 
The following step was the removal of the benzylidene group. In the first 
attempt, hydrolysis in DCM spiked with H2O and TFA was performed, based on a 
reported procedure.28 This strategy resulted in incomplete conversion and 46% of 
the starting material was isolated, along with 29% of the expected diol 2.3c (Table 
2.14, entry 1). The procedure was repeated with double the reported reaction time 
(4.5 h) but again the reaction was far from complete and the product was isolated in 
51% yield (entry 2). When the reaction was performed at a higher temperature, TLC 
analysis was consistent with the previous experiments (entry 3). Another strategy 
using p-TSA in an homogeneus medium (MeOH/DCM) was attempted (entry 4) and 
led to the diol 2.3c in an unsatisfying yield of 50%.  A third method, with EtSH, gave 
the best results. The diol 2.3c was isolated as a colourless oil in quantitative yield 
after column purification (entry 5). The reaction was scaled up to 28 g to afford the 





Table 2.14 Removal of benzylidene group to generate 2.3c. 
 
Entry Scale Reagents Conditions Results 
1 2 g DCM/Water/TFA 
0.11M, 34eq, 32eq 
0 °C, 2 h 2.3c 29%a 
Reported yield: 
82%28 
2 1 g DCM/Water/TFA 
0.11M, 34eq, 32eq 
0 °C, 4.5 h 2.3c 51% b 
3 1 g DCM/Water/TFA 
0.11M, 34eq, 32eq 
rt, 6 h Incomplete reaction 
by TLC. 
Not quantified. 
4 1 g p-TSA, MeOH/DCM 
1 eq, 4:3 0.15 M 
35 °C 24 h 2.3c 50% b 
Reported yield: 
83%50 
5 2 g EtSH, CSA, DCM (0.3M) rt, 18 h 2.3c quant. 
6 28 g EtSH, CSA, DCM (0.3M) rt, 18 h 2.3c quant. 
 a Estimated by NMR of the crystallized mixture of product and starting material. b Isolated 
yields by column chromatography. 
 
Introduction of the remote-participating group at O6 and the Fmoc at O4 were 
performed as described in the literature for an identical building block.28 The acetyl 
group was introduced using 2-chloro-1-methylpyridinium idodide (CMPI) to 
activate the acetic acid, at -15 °C. Under these conditions, the reaction is selective for 
the more reactive primary alcohol. Upon aqueous work up, the 6-O-acetyl derivative 
2.3d was isolated in a mixture with the by-product N-methyl-2-pyridone. The 
proportion of the mixture was estimated by NMR and based on that, the yield was 
estimated to be quantitative (Scheme 2.7). 
 
Scheme 2.7 Introduction of 6-O-acetyl and 4-O-Fmoc groups in glucose building block. 
Fmoc group was introduced by combining the crude compound 2.3d with 
FmocCl and pyridine. In the scouting batch, TLC showed complete conversion and a 
clean reaction. The product was purified by crystallization from 
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DCM/Isopropanol/hexane and obtained as white crystals in 60% yield. In the larger 
batch, the product was purified by flash chromatography which increased the 
isolated yield to 78%. 
Building block 2.1 was synthesized from glucose diacetonide to facilitate the 
selective benzylation at O3 (Scheme 2.8). 
 
Scheme 2.8 Synthetic route to glucose building block 2.1. 
Thioglycoside 2.1d was obtained by benzylation, acidic hydrolysis, 
peracetylation, and thioglycosylation. The benzylation was performed with BnBr 
and NaH in THF with cat. NBu4I. The conversion was complete the reaction was clean 
by TLC. Acid treatment with Amberlyte IR 120 cleaved the acetals and led to the 
more stable pyranose ring. Peracetylation with Ac2O and NaOAc gave the 
tetraacetate 2.1c as a 1:4 α/β mixture. The introduction of the ethylthio leaving 
group led to mixture of the unreacted α tetraacetate 2.1c, and the α and β 
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thioglycosides. The β anomer 2.1d was isolated by column chromatography in 24% 
over 4 steps.  
Thioglycoside 2.1d was subjected to methanolysis under Zemplén conditions. 
After two hours of reaction, TLC showed absence of the starting material and a single 
long spot for a new product. After work up, NMR showed a mixture of the expected 
compound 2.5e and a monoacetyl intermediate. The crude material was again 
subjected to the Zemplén conditions. After 6h at 40 °C, TLC showed a single round 
spot. After neutralization, the obtained material was identified by NMR as the pure 
triol 2.5e. 
Introduction of the benzylidene protecting group was achieved using 
benzaldehyde dimethyl acetal and camphorsulfonic acid (CSA) in THF, according to 
the procedure used previously for galactose and glucosamine. Compound 2.1f was 
purified by crystallization and isolated in 70% yield. Position O2 was benzoylated 
with benzoic anhydride, triethylamine and catalysis of DMAP in DCM.  The resulting 
ester 2.1g crystalized and was obtained in 85% yield. The benzylidene acetal was 
cleaved with Et3Si and TFA and compound 2.1h was isolated by column 
chromatography in 86% yield. Introduction of Fmoc group with FmocCl and 
pyridine led to the final building block 2.1 which was purified by column 
chromatography and isolated in 81% yield.  
 
2.4. Functionalization of the solid phase 
The most frequently used solid support in AGA is a cross-linked polystyrene 
resin (Merrifield resin) functionalized with a photocleavable linker (compound 2.8). 
The linker has a 5-aminopentanol chain that provides the first hydroxyl acceptor in 
the AGA process. The nitrogen is connected to a photolabile o-nitrobenzyl moiety 
that is, in turn, directly connected to the polystyrene polymer through an ether 
bond. The nitrogen is protected with a Cbz group. Here, the reproducibility and 
scalability of the functionalization of Merrifield resin with 2.9 is addressed.  
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Resin 2.8 was prepared as reported43. Compound 2.9 was activated with 
Cs2CO3 in DMF. Tetrabutylammonium iodide replaces the chlorine and is 
subsequently displaced by the phenolate of 2.9 (Scheme 2.9). A sample of the 
resulting resin 2.8 was used for loading quantification following an established 
procedure51,52.   
 
Scheme 2.9 Functionalization of the Merrifield resin with a photocleavable linker. 
The reaction was first done in a 5 g batch and the resulting loading was 0.40 
mmol/g. The reaction was then scaled up to a 50 g batch. Extra care was taken in the 
washing and drying steps to avoid contaminations that could interfere with the 
loading determination. The loading for the 50 g batch was also 0.40 mmol/g.  
The procedure for functionalization of the Merrifield resin with the 
photocleavable linker showed a high reproducibility and scalability, with maximum 
functionalization yield.  
 
2.5. Conclusion 
The number of procedures for carbohydrate protecting group manipulations 
in the literature is very vast and can be overwhelming. With the work here 
described, procedures from the literature are optimized and combined in the best 
way possible to establish a streamlined and universal strategy for the synthesis of 
approved building blocks for AGA.  
The very first transformations of free monosaccharides are peracetylation and 
thioglycosylation. The sodium acetate method proved to be the best choice for the 
peracetylation as it is high yielding and highly β selective, which guaranties success 
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in the introduction of the thioglycoside. Toluyl group was established as the aglycon 
of choice for thioglycosides due to the selective formation of the β anomer in glucose 
and galactose, and high yields in crystallization. Exception is made for glucosamine, 
for which the thioglycosylation with ethyl thiol led to stereoselective formation of 
the β-thioglycoside. 
In general, the efforts to implement crystallization led to synthetic schemes 
with slightly lower yields but minimal chromatographic purifications. Standard 
procedures were optimized and successfully applied for similar transformations in 
different building blocks. For example, the benzoylation procedure was used for 
galactose, glucose, and glucosamine derivatives. The procedure proved to be robust 
enough to be used in single and di-benzoylations and the resulting esters were easily 
isolated by crystallization. In benzylation reactions, the case where DMF cannot be 
replaced by THF was identified (2,3-di-O-benzylation of glucose). In other cases, 
THF was successfully used. 
 
Scheme 2.10 Overview of the building block synthesis. 
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Building block 2.4 was obtained in 28% yield over seven steps with only one 
chromatographic purification. Building block 2.5 was obtained in 19% over seven 
steps from 2.5a without any column purification. The benzylidene intermediate 
2.5b, which was optimized and upscaled, was used to prepare building block 2.2 in 
68% over four steps with only one column purification in the last step. The glucose 
building block 2.3 was obtained from intermediate 2.3a in 76% over four steps and 
required three column purifications. Finally, glucose building block 2.1 was 
obtained from the glucose diacetonide in 10% over nine steps with three column 
purifications.  
Merrifield resin functionalized with a photocleavable linker was prepared on 
large scale with 100% yield and is now cheaply available at GlycoUniverse. 
With bulk amounts of building blocks and solid support in hands full focus can 
be turned to experimentation in the Glyconeer. 
 
2.6. Experimental Section 
General Materials and Methods 
All reagents and solvents were acquired from commercial sources, unless 
stated otherwise. Anhydrous solvents were dried with 10% (m/v) pre-activated 4 
or 3 Å molecular sieves. Amberlite IR-120 (Across Organics) protonic exchange 
resin was rinsed thoroughly with methanol before use. TLC was performed on 0.25 
mm Kieselgel 60 F 254 glass-supported plates (Macherey-Nagel), with detection via 
UV light (254 nm) and H2SO4 (10% in EtOH) staining. Flash chromatography 
purifications were performed with silica gel VWR 60-200 µm or Fluka 200-430 
mesh (for difficult separations). NMR spectra were obtained using Ascend 400 
(Bruker) and Agilent 400 MHz NMR Magnet (Agilent Technologies) spectrometers 
at 400 MHz (1H) and 100 MHz (13C) or a Varian 600 (Agilent) at 600 MHz (1H) and 
150 MHz (13C), or a Ascend 700 (Bruker) at 700 MHz (1H) and 176 MHz (13C). CDCl3 
or D2O were used as solvents and chemical shifts (δ) referenced to residual non-
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deuterated solvent peak unless stated otherwise. NMR chemical shifts (δ) are 
reported in ppm and coupling constants (J) are reported in Hz. Assignments were 
supported by COSY and HSQC experiments and compared with literature data when 
available. ESI-HRMS were performed with a Xevo G2-XS Q-Tof (Waters). 
 
Peracetylation 
α/β Ratios were estimated by NMR. 
General procedure for the In(OTf)3 method 
D-Galactose was taken in a 3-neck rb flask and flushed with Ar. Anhydrous ACN 
was added under Ar to give a 0.33 M mixture. The resulting white suspension stirred 
in an ice bath for 5 min. Ac2O was added and the reaction mixture was further stirred 
for another 5 min. Indium triflate was added and after 30 min the ice bath was 
removed. When the reaction was complete, Na2CO3 20% (aq) was added and the 
mixture stired for c.a. 1h. The aqueous layer was isolated and extracted with DCM 
(2X). The combined organic layers were washed with Brine (2X), dried over MgSO4, 
evaporated and dried in high vacuum. The resulting oil was identified as the pure 
product. 
 
Sodium acetate method 
Acetic anhydride (10 equiv) was refluxed with NaOAc (0.5 equiv) and D-
galactose or D-glucose was portion wise added over 15 min. The mixture was 
refluxed for an appropriate amount of time (see Table 2.3 and Table 2.4) and then 
cooled to rt. The reaction was quenched by addition of ice. The product precipitated 
from the mixture and was filtered and recrystalized from ethanol. Alternatively, the 
reaction mixture was diluted with EtOAc and washed with sat. aq. NaHCO3 (3X), 





D-Galactose was taken in a 3-neck rb flask and flushed with Ar. Pyridine 
(anhydrous, 10 equiv) was added and the resulting white suspension stirred in an 
ice bath (ca. 10 min). Acetic anhydride (10 equiv) was dropwise added over 5 min 
and after 30 min the cooling bath was removed. The reaction mixture was stirred at 
rt and followed by TLC. When the conversion was complete, the reaction mixture 
was concentrated on the rotavap and co-evaporated with toluene. The resulting 
material was combined with EtOAc and extracted with HCl 1 M (2X) then with sat. 
NaHCO3 (2X) then with brine. The organic layer was dried over MgSO4, evaporated 
on rotavap and dried under high vacuum overnight to afford the product as a 
colorless oil.  
D-Galactopyranose pentaacetate analytical data in agreement with the 




General procedure for thioglycosylation 
A 0.2 M solution of the parent peracetylated glycoside in DCM (anhydrous) was 
cooled in an ice bath for ca. 10 min. The appropriate thiol (1.5 equiv) was added and 
then boron trifluoride etherate was dropwise added over 5 min. After 15 min, the 
cooling bath was removed, and the reaction mixture was stirred at rt until 
completion by TLC or for a maximum of 24 h. The reaction mixture quenched with 
H2O. The organic layer was washed with sat. aq. NaHCO3 (2x) and brine, dried over 
MgSO4, and concentrated under reduced pressure. The thioglycoside was purified 




The product was purified by column chromatography (0 to 50% EtoAOc in 
Hexane). to give a 1:1 α/β mixture of the thioglycoside (95% yield). Analytical data 




The product was purified by column chromatography (EtOAc/hexane) to give 
α 22%, β 12%, α/β mixed fractions 37%. Analytical data in agreement with the 
literature. 
 
Toluyl 2,3,4,6-tetra-O-acetyl-1-thio- β-D-glucopyranoside 
 
Purified by crystallization. The crude material was dissolved in hot EtOAc (7 
mL) and hexane (25 mL) was then dropwise added. Resulting suspension was kept 
in the fridge overnight then filtered to afford the pure product (73%). Analytical 






Purified by crystallization from hot EtOH. After 24 h in the fridge, the 
suspension was filtered to afford the pure product (53%). Analytical data in 
agreement with the literature. 
Synthesis of BB 2.4 
1,3,4,6-tetra-O-acetyl-2-deoxy-2-trichloroacetamido-D-glucopyranose 2.4b 
 
1,3,4,6-tetra-O-acetyl-2-deoxy-2-amino-D-glucopyranose hydrochloride 2.4a 
(40.1 g, 104 mmol) was weighed in a 3-neck 1L rb flask then flushed with Ar. DCM 
(anhydrous, 380 mL) was added and the resulting suspension stirred in an 
ice/water bath for 10 min. Triethylamine (29.3 mL, 210 mmol) was added and after 
5 min trichloroacetyl chloride (15.8 mL, 141 mmol) was dropwise added over 10 
min. The reaction mixture was stirred for another 3 h. The reaction was quenched 
with water (350 mL). After a few minutes stirring, the organic layer was isolated and 
extracted with sat. NaHCO3 (2X 350 mL), HCl 1N (2X 350 mL) and brine (350 mL). 
The organic layer was then dried over MgSO4, concentrated on rotavap to a yellow 
oil and dried on high vacuum overnight. The resulting off white foam was identified 
as the pure product (50.1 g, 97%).  
1H NMR (400 MHz, Chloroform-d) δ 7.36 (d, J = 9.6 Hz, 1H, NH), 5.80 (d, J = 
8.8 Hz, 1H, H1), 5.43 (dd, J = 10.9, 9.4 Hz, 1H, H-3), 5.14 (t, J = 9.7 Hz, 1H, H-4), 4.32 
(ddd, J = 10.9, 9.6, 8.8 Hz, 2H, H-2), 4.27 (dd, J = 12.5, 5.0 Hz, 1H, H-6a), 4.15 (dd, J = 
12.5, 2.2 Hz, 1H, H-6b), 3.90 (ddd, J = 10.1, 5.0, 2.2 Hz, 1H, H-5), 2.10 (s, 2H), 2.09 (s, 







2.4b (49.0 g, 99.5 mmol) was weighed in 3-neck 1 L rb flask then flushed with Ar. 
DCM (anhydrous, 22 mL) was added and the resulting pale yellow solution stirred 
in an ice bath for 15 min. Ethanethiol (7.9 mL, 110 mmol) was added and boron 
trifluoride etherate (9.9 mL, 80 mmol) was dropwise added over 5 min. After ca. 30 
min, the cooling bath was removed, and the solution was stirred overnight. The 
reaction was quenched with H2O (100 mL). The organic layer was isolated and 
extracted wit sat. NaHCO3 (2X 100 mL) and with brine (100 mL). Organic layer was 
dried over MgSO4, concentrated under reduced pressure, and dried in high vacuum 
overnight. The crude solid was dissolved in EtOAc (60 mL) at a 50 °C bath. Then, 
hexane (ca 300 mL) was added dropwise while stirring vigorously. The resulting 
suspension was kept in the fridge overnight then filtered to afford the pure product 
(40.6 g, 83%). 
1H NMR (400 MHz, Chloroform-d) δ 6.93 (d, J = 9.3 Hz, 1H, NH), 5.33 (t, J = 
10.0 Hz, 1H), 5.12 (t, J = 9.7 Hz, 1H), 4.67 (d, J = 10.3 Hz, 1H, H-1), 4.25 (dd, J = 12.4, 
5.1 Hz, 1H, H-6a), 4.15 (dd, J = 12.3, 2.4 Hz, 1H, H-6b), 4.11 (q, J = 10.2 Hz, 1H, H-2), 
3.75 (ddd, J = 10.1, 5.1, 2.4 Hz, 1H, H-5), 2.81 – 2.63 (m, 2H, SCH2), 2.08 (s, 3H), 2.03 
(s, 3H), 2.02 (s, 3H), 1.27 (t, J = 7.4 Hz, 3H, CH3). 
 
Ethyl 2-deoxy-2-trichloroacetamido-1-thio-β-D-glucopyranose 2.4d 
 
Ethyl 3,4,6-tri-O-acetyl-2-deoxy-2-trichloroacetamido-1-thio-β-D-gluco-
pyranose 2.4c (39.0 g, 78.8 mmol) was weighed in a 3-neck 500 mL rb flask and 
flushed with Ar. Anhydrous MeOH (190 mL) was added and then sodium methoxide 
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(57.5 mL, 0.5 M in MeOH). The resulting mixture was stirred at rt. After 1h, TLC 
(DCM/EA 9:1) showed complete conversion (product rf = 0.021). The reaction 
mixture was filtered through Amberlyte IR 120 (ca 25 g, previously washed with 2X 
50 mL MeOH) until pH = 6. The resin was washed with MeOH (2X ca. 20 mL) and the 
washings were combined with the reaction mixture. Solvent was evaporated on 
rotavap and the resulting off-white solid dried in high vacuum. The solid was 
identified as the pure product 2.4d (28.8 g, 99%). 
1H NMR (400 MHz, Deuterium Oxide) δ 4.77 (m, 1H, H-1), 3.92 (m, 1H), 3.81 
(t, J = 10.2 Hz, 1H, H3), 3.77 – 3.68 (m, 2H, H6), 3.56 – 3.41 (m, 2H), 2.84 – 2.64 (m, 





Ethyl 2-deoxy-2-trichloroacetamido-1-thio-β-D-glucopyranose 2.4d (26.6 g, 
72.1 mmol) and camphorsulfonic acid (2.96 g, 12.7 mmol) were dissolved in THF 
(anhydrous, 140 mL). Benzaldehyde dimethyl acetal (21.5 mL, 143 mmol) was 
added and the resulting solution was stirred at rt overnight. After 18h, TLC analysis 
of the crude mixture showed traces of starting material. The reaction was quenched 
with sat. aq. NaHCO3 (25 mL). The aqueous layer was isolated and extracted with 
EtOAc (25 mL). Combined organic layers were washed with brine (50 mL), dried 
over MgSO4, concentrated on rotavap and dried under high vacuum. The resulting 
white solid was crystallized from DCM/Hex to afford the pure ethyl 4,6-O-
benzylidene-2-deoxy-2-trichloroacetamido-1-thio-β-D-glucopyranoside (4.03g, 
74%). 
1H NMR (700 MHz, DMSO-d6) δ 8.88 (d, J = 9.3 Hz, 1H, -NH), 7.46 (dd, J = 7.4, 
2.2 Hz, 2H, -Ar), 7.41 – 7.35(m, 3H, -Ar), 5.62 (s, 1H, -PhCH), 5.53 (d, J = 6.3 Hz, 1H, -
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OH), 4.78 (d, J = 10.4 Hz, 1H, H-1), 4.22 (dd, J = 10.1, 5.0 Hz, 1H, H-6a), 3.84 (td, J = 
9.3, 6.3 Hz, 1H, H-3), 3.73 (q, J = 9.7 Hz, 2H, H-2, H-5), 3.51 (t, J = 9.3 Hz, 1H, H-4), 







glucopyranoside 2.4e (20.1 g, 44.0 mmol) was weighed in a 3-neck rb flask then 
flushed with Ar. THF (anhydrous, 196 mL) was added to form a colorless solution 
that was stirred in an ice bath for 10 min. NaH 60% in mineral oil (4.57 g, 114 mmol) 
was added and after 10 min, benzyl bromide (7.8 mL, 65.7 mmol) was dropwise 
added over 10 min. After 1.5h, the cooling bath was removed. After the mixture was 
stirred for another 4 h, TLC showed complete conversion (Hex/EA 4:1, rf 0.61). 
Reaction mixture was diluted with DCM (100 mL) and quenched sat. aq NH4Cl (110 
mL). The aqueous phase was then isolated and extracted with DCM (100 mL). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated on rotavap to a yellow solid. Crystallization from EA/Hex (740 
mL/300 mL) afforded the pure product 2.4f as a white crystalline solid (13.4 g, 
56%). Filtrate was concentrated and dried and the resulting yellow solid crystallized 
from EA/Hex (165 mL/410 mL) to afford a second fraction of the product 2.4f as a 
yellowish precipitate (5.16 g, 21%). 
1H NMR (400 MHz, Chloroform-d) δ  7.51 – 7.48 (m, 2H), 7.43 – 7.37 (m, 3H), 
7.33 – 7.27 (m, 5H), 6.86 (d, J = 8.2 Hz, 1H, NH), 5.60 (s, 1H, PhCH), 5.01 (d, J = 10.4 
Hz, 1H, H-1), 4.91 (d, J = 11.3 Hz, 1H, PhCHH), 4.72 (d, J = 11.3 Hz, 1H, PhCHH), 4.38 
(dd, J = 10.5, 4.9 Hz, 1H, H-6a), 4.15 (t, J = 9.4 Hz, 1H, H-3), 3.84 – 3.75 (m, 2H, H-4, 
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H-6b), 3.71 (td, J = 10.0, 8.1 Hz, 1H, H-2), 3.58 (td, J = 9.7, 5.0 Hz, 1H, H-5), 2.83 – 2.63 
(m, 2H, SCH2), 1.27 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (101 MHz, Chloroform-d) δ 161.81, 137.79, 137.26, 129.22, 128.62, 
128.45, 128.43, 128.10, 126.12, 101.39, 83.53, 82.65, 77.48, 77.37, 77.16, 76.84, 






D-glucopyranoside 2.4f (11.9 g, 21.7 mmol) was combined with DCM (anhydrous, 
170 mL) in the presence of 4 Å molecular sieves and the resulting suspension was 
stirred for 10 min and triethylsilane (14.0 mL, 87.7 mmol) was added. The reaction 
mixture was cooled in an ice bath and after 30 min, TFA (7.0 mL, 91 mmol) was 
dropwise added over 5 min. The cooling bath was removed after 15 min and the 
reaction mixture was stirred at rt. After 3h, TLC showed the product and trace 
amounts of the starting material. The reaction mixture was quenched by dropwise 
addition Et3N (ca. 40 mL) till no more gas evolved. Then the reaction mixture was 
diluted with DCM (130 mL) and washed with H2O (2X 300 mL), aq. sat. NaHCO3 (2X 
300 mL), and brine (300 mL). The organic layer was dried over MgSO4, concentrated 
on rotavap and dried in high vacuum. Purification by column chromatography 
(Hex/EtOAc 6:1 to 2:1) gave the pure compound 2.4g (8.47 g, 71%). 
1H NMR (700 MHz, DMSO-d6) δ 9.06 (d, J = 9.0 Hz, 1H, -NHCO), 7.35 (d, J = 5.3 
Hz, 3H, -Ar), 7.29 – 7.28 (m, 4H, -Ar), 7.25 – 7.22 (m, 1H, -Ar), 5.56 (d, J = 6.3 Hz, 1H, 
-OH), 4.80 (dd, J = 11.1, 1.9 Hz, 1H, -CH2Bn), 4.68 (d, J = 9.9 Hz, 1H, H-1), 4.61 (dd, J 
= 11.1, 6.2 Hz, 1H), 4.54 (d, J = 1.3 Hz, 2H), 3.77 (dd, J = 11.1, 1.5 Hz, 1H), 3.58 (dd, J 
= 11.0, 5.7 Hz, 1H), 3.43 – 3.36 (m, 2H), 2.63 (ddq, J = 42.3, 12.8, 7.4 Hz, 2H), 1.22 – 






Compound 2.4g (5.80 g, 10.6 mmol) was kept under high vacuum for ca. 1 h 
then DCM (anhydrous, 75 mL) was added and the resulting pale yellow solution kept 
under Ar. Pyridine (anhydrous, 2.6 mL, 32 mmol) was added and then FmocCl (3.01 
g, 11.6 mmol) was added. In a few seconds the solution became bright yellow. After 
a few minutes the solution turned orange and then redish. The solution was stirred 
at rt and after 3 h TLC showed complete conversion. The reaction was diluted with 
DCM (75 mL), extracted with water (2X 150 mL) and brine (150 mL), dried over 
MgSO4, and filtered. The solvent was removed on rotavap to afford a yellow oil that 
was co-evaporated with toluene (3X 15 mL) and then dried in high vacuum 
overnight. The resulting yellow vitreous solid was crystallized from EtOAc (11 mL) 
and Hexane (11 mL) at 70 °C. After 4 days in the fridge and after inducing 
crystallization with spatula, the crystalline product was filtered and washed with 
cold EtOAc/Hex 1.1 (ca. 60 mL). After drying in the desiccator under vaccum, the 
solid was identified as the pure product (5.67 g, 70%). 
1H NMR (500 MHz, Chloroform-d) δ 7.75 (ddt, J = 7.7, 3.0, 0.9 Hz, 2H), 7.57 
(dd, J = 7.5, 1.0 Hz, 1H), 7.52 (dd, J = 7.5, 1.0 Hz, 1H), 7.39 (td, J = 7.5, 1.0 Hz, 2H), 7.36 
– 7.17 (m, 12H), 6.93 (d, J = 7.9 Hz, 1H, NH), 5.04 (d, J = 10.3 Hz, 1H, H-1), 4.94 (dd, J 
= 9.9, 9.0 Hz, 1H, H-4), 4.64 (s, 2H, 3-OCH2Ph), 4.53 (s, 2H, 6-OCH2Ph), 4.33 (dd, J = 
9.6, 6.4 Hz, 1H, Fmoc CHH), 4.29 (dd, J = 9.6, 6.4 Hz, 1H, Fmoc CHH), 4.24 (dd, J = 
10.0, 9.0 Hz, 1H, H-3), 4.11 (t, J = 7.2 Hz, 1H, Fmoc CH), 3.77 (ddd, J = 9.9, 5.2, 3.8 Hz, 
1H, H-5), 3.70 – 3.61 (m, 3H, H-2, H-6a, H-6b), 2.73 (qq, J = 12.7, 7.4 Hz, 2H, SCH2), 
1.29 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (126 MHz, Chloroform-d) δ 161.80 (C=O amide), 154.39 (C=O 
carbonate), 143.38, 143.19, 141.42, 141.38, 137.96, 137.41, 128.55, 128.45, 128.05, 
127.97, 127.77, 127.76, 127.32, 127.30, 125.23, 125.12, 120.22, 120.20, 92.41 (Cl3C), 
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82.56 (C1), 78.88 (C3), 77.41 (C2), 76.26 (C4), 74.84 (3-OCH2), 73.70 (6-OCH2), 
70.24 (Fmoc CH2), 69.71 (C6), 57.74 (C5), 46.77 (Fmoc CH), 24.88 (SCH2), 15.31 
(CH3). 
 
Synthesis of BB 2.5 
Ethyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside 2.5b 
 
Ethyl β-D-galactoside 2.5a (40.2 g, 179 mmol) was taken in a 500 mL rb flask. 
CSA (7.26 g, 31.2 mmol) was added, then THF (anhydrous, 300 mL), then 
PhCH(OCH3)2 (55.0 mL, 366 mmol). The resulting mixture was stirred at rt for 4h. 
The reaction mixture poured into 1 L Erlenmeyer flask then EtOAc (200 mL) was 
added followed by sat. NaHCO3 (200 mL). The organic layer was isolated and 
extracted with sat. NaHCO3, (250 mL), water (2X250 mL) and brine (2X250 mL). 
Then dried over MgSO4, concentrated on rotavap and the resulting white solid dried 
in high vacuum overnight. The crude material was dissolved in boiling DCM (ca. 340 
mL). Hexane was subsequently dropwise added (650 mL) under constant stirring 
allowing the formation of a fine precipitate. The resulting suspension was kept in 
the fridge overnight. The white solid was then filtered and washed with cold 
hexane/DCM 4:1 (ca 300 mL). The solid was dried under vacuum overnight to afford 
the pure product (45.3 g, 81% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.52 – 7.43 (m, 2H), 7.36 (dd, J = 4.8, 2.2 
Hz, 3H), 5.51 (s, 1H, PhCH), 4.32 (d, J = 9.6 Hz, 1H, H-1), 4.31 (dd, J = 12.5, 1.5 Hz, 1H, 
H-6a), 4.20 (dd, J = 3.7, 1.2 Hz, 1H, H-4), 4.00 (dd, J = 12.6, 1.9 Hz, 1H, H-6b), 3.79 (t, 
J = 9.4 Hz, 1H, H-2), 3.65 (dd, J = 9.2, 3.7 Hz, 1H, H-4), 3.47 (q, J = 1.6 Hz, 1H, H-5), 
2.89 – 2.66 (m, 4H, SCH2, 2-OH, 3-OH), 1.33 (t, J = 7.5 Hz, 3H, CH3). 
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13C NMR (101 MHz, Chloroform-d) δ 137.72, 129.39, 128.39, 126.54, 101.55 





Ethyl benzylidene 1-thio-β-D-galactoside (20.0g, 64.0 mmol) was taken in a rbf 
and flushed with Ar. DCM (anhydrous, 230 mL) was added and the resulting 
suspension was stirred under an ice bath for ca. 10 min. TBSCl (14.5 g, 96.2 mmol) 
was added followed by imidazole (9.18 g, 135 mmol). After ca. 20 min, the cooling 
bath was removed, and the suspension was stirred overnight. After 17h, TLC showed 
complete conversion. The reaction mixture was quenched with sat. aq. NaHCO3 
(100 mL). The aqueous layer was extracted with DCM (100 mL) and the combined 
organic layers were washed with brine (200 mL), dried over MgSO4, concentrated 
on rotavap and dried under high vacuum. The resulting colourless oil was identified 
as the product.  
1H NMR (700 MHz, Chloroform-d) δ 7.50 (ddd, J = 8.0, 1.6, 0.6 Hz, 2H), 7.38 – 
7.31 (m, 3H), 5.50 (s, 1H, PhCH), 4.35 (d, J = 9.5 Hz, 1H, H-1), 4.34 (dd, J = 12.4, 1.5 
Hz, 1H, H-6a), 4.07 (dd, J = 3.6, 0.9 Hz, 2H, H-4), 4.01 (dd, J = 12.4, 1.9 Hz, 1H, H-6a), 
3.88 (t, J = 9.3 Hz, 1H, H-2), 3.72 (dd, J = 9.0, 3.6 Hz, 1H, H-3), 3.47 (q, J = 1.7 Hz, 1H, 
H-5), 2.82 (dq, J = 12.6, 7.4 Hz, 1H, SCHH), 2.73 (dq, J = 12.6, 7.5 Hz, 1H, , SCHH), 1.31 
(t, J = 7.5 Hz, 3H, CH3), 0.92 (s, 9H, t-BuSi), 0.13 (s, 3H, SiCH3), 0.13 (s, 3H, SiCH3). 
13C NMR (176 MHz, Chloroform-d) δ 138.10, 128.86, 128.18, 126.26, 126.19, 
101.06 (PhCH), 85.39 (C1), 76.94 (C4), 75.59 (C3), 70.34 (C5), 69.55 (C6), 68.95 
(C2), 25.85 (SiC(CH3)3), 23.24 (SCH2), 18.34 (SiC(CH3)3), 15.35 (SCH2CH3), -4.24 





Crude starting material was dissolved in DCM (anhydrous, 160 mL) under Ar. 
The solution was cooled in an ice bath and benzoic anhydride (29.1 gm 129 mmol), 
DMAP (1.44 g, 12.8 mmol) and triethylamine (27 mL, 194 mmol) were successively 
added. After 1h, the cooling bath was removed, and the reaction was stirred at rt 
overnight. The reaction washed with sat. aq. NaHCO3 (160 mL). The aqueous layer 
was extracted with DCM (160 mL) and the combined organic layers were washed 
with brine (300 mL). The organic layer was dried over MgSO4, concentrated on 
rotavap and dried in high vacuum. Crystallization from ethanol gave 2.5d (24.0 g, 
70% over 2 steps). 
1H NMR (700 MHz, Chloroform-d) δ 8.04 (dd, J = 8.2, 1.1 Hz, 2H), 7.57 – 7.52 
(m, 3H), 7.44 (td, J = 7.6, 1.7 Hz, 2H), 7.41 – 7.34 (m, 3H), 5.60 (t, J = 9.6 Hz, 1H, H-2), 
5.53 (s, 1H, PhCH), 4.56 (d, J = 9.9 Hz, 1H, H-1), 4.39 (dd, J = 12.2, 1.6 Hz, 1H, H-6a), 
4.14 (dd, J = 3.7, 1.1 Hz, 1H, H-4), 4.05 (dd, J = 12.2, 1.8 Hz, 1H, H-6b), 4.02 (d, J = 9.0, 
2.6 Hz, 1H, H-3), 3.55 (q, J = 1.5 Hz, 1H, H-5), 2.91 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 
2.75 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 1.26 (t, J = 7.5 Hz, 3H, SCH2CH3), 0.75 (s, 9H), 
0.05 (s, 3H), -0.12 (s, 3H). 
13C NMR (176 MHz, Chloroform-d) δ 165.39 (C=O), 138.02, 133.01, 130.45, 
129.87, 128.97, 128.40, 128.27, 126.38, 101.21 (PhCH), 82.90 (C1), 76.98 (C4), 73.64 
(C3), 70.36 (C5), 70.20 (C2), 69.52 (C6), 25.56 (SiC(CH3)3), 22.86 (SCH2), 18.04 








pyranoside (20.9 g, 39.4 mmol) was weighed in a 3-neck 250 mL rb flask and flushed 
with Ar. Then DCM (anhydrous, 97 mL) was added and the resulting colorless 
solution stirred in an ice bath for 15 min. Borane tetrahydrofuran (1 M in THF, 160 
mL) was then dropwise added over 10 min followed by the addition of TMSOTf (3.6 
mL, 20 mmol). After 1.5 h TLC showed complete conversion. The reaction was 
quenched by dropwise addition of a 1:10 mixture of NEt3/MeOH until no further gas 
evolved. The resulting solution was concentrated under reduced pressure, 
redissolved in DCM (60 mL), washed with sat. aq. NaHCO3 (60 mL), brine (60 mL), 
and dried over MgSO4. The solution was then concentrated unde reduced pressure 
and dried under high vacuum to afford the product as a white foam (22.0 g, quant.). 
1H NMR (700 MHz, Chloroform-d) δ 8.05 (dd, J = 8.4, 1.3 Hz, 1H), 7.59 – 7.53 
(m, 1H), 7.47 – 7.42 (m, 3H), 7.41 – 7.34 (m, 4H), 7.33 – 7.28 (m, 1H), 5.66 (br s, 1H, 
H-2), 5.10 (d, J = 11.7 Hz, 1H, 4-OCHHPh), 4.60 (d, J = 11.7 Hz, 1H, 4-OCHHPh), 4.51 
(d, J = 9.4 Hz, 1H, H-1), 3.98 (brd, J = 9.4 Hz, 1H, H-3), 3.85 (dd, J = 11.2, 6.7 Hz, 1H, 
H-6a), 3.78 (dd, J = 2.8, 1.1 Hz, 1H, H-4), 3.61 (ddd, J = 6.6, 5.2, 1.2 Hz, 1H, H-5), 3.57 
(dd, J = 11.2, 5.3 Hz, 1H, H-6b), 2.76 (dq, J = 12.4, 7.4 Hz, 1H, SCHH), 2.69 (dq, J = 12.4, 
7.5 Hz, 1H, SCHH), 1.21 (t, J = 7.5 Hz, 3H, SCH2CH3), 0.79 (s, 9H), 0.12 (s, 3H), -0.07 
(s, 3H). 
13C NMR (176 MHz, Chloroform-d) δ 165.31 (C=O), 138.45, 132.90, 130.23, 
129.74, 128.36, 128.24, 127.93, 127.71, 83.70 (C1), 78.96 (C5), 76.80 (C4), 75.70 
(C3), 74.78 (4-OCH2Ph), 70.85 (C2), 62.16 (C6), 25.47 (SiC(CH3)3), 23.55 (SCH2), 






galactopyranoside 2.5e (21.0 g, 39.4 mmol) was taken in a 3-neck rb flask and 
flushed with Ar for 5 min. THF (anhydrous, 190 mL) was added resulting in a 
colorless solution that was stirred in an ice bath for 5 min. NaH (60% in mineral oil, 
4.11 g, 103 mmol) was then added forming a grey suspension. After another 5 min 
BnBr (5.2 mL, 44 mmol) was dropwise added over 5 min. The cooling bath was 
removed after 30 min and 4 h later, TLC (Hex/EA 4:1) showed the product at rf = 
0.89 and no starting material. The reaction mixture was diluted with DCM (100 mL) 
and quenched by dropwise addition of sat. aq. NH4Cl (200 mL). The aqueous phase 
extracted with DCM (200 mL) and the combined organic layers were washed with 
brine (400 mL), dried over MgSO4, evaporated and dried in high vacuum overnight 
to afford a yellowish oil. The crude product 2.5f was used as such in the next step. 
 
Ethyl 2-O-benzoyl-4,6-di-O-benzyl-1-thio-β-D-galactopyranoside 2.5g 
 
The crude material 2.5f (39.4 mmol based on 100% yield) was taken in MeCN 
(anhydrous, 213 mL) and the resulting pale yellow solution was stirred in an ice 
bath for ca. 10 min. Boron trifluoride etherate (5.4 mL, 43.8 mmol) was added and 
the reaction mixture was quenched after 7 min by dropwise addition of sat. aq. 
NaHCO3 (215 mL). The aqueous layer was isolated and extracted with DCM (215 
mL). The combined organic layers were washed with brine (400 mL), dried over 
 64 
MgSO4, concentrated on rotavap and dried under high vacuum. The crude material 
was crystalized from EtOAc/Hex 1:2 to afford the pure 2.5g (9.33 g, 47% over two 
steps). 
1H NMR (500 MHz, DMSO-d6) δ 7.98 (dd, J = 8.2, 1.0 Hz, 2H), 7.67 (tt, J = 7.7, 
7.3, 1.3 Hz, 1H), 7.58 – 7.50 (m, 2H), 7.41 – 7.17 (m, 10H), 5.55 (d, J = 5.4 Hz, 1H, 3-
OH), 5.19 (t, J = 9.7 Hz, 1H, H-2), 4.93 (d, J = 11.4 Hz, 1H, PhCHH), 4.70 (d, J = 10.0 Hz, 
1H, H-1), 4.52 (d, J = 11.5 Hz, 1H, PhCHH), 4.50 (d, J = 12.1 Hz, 1H, PhCHH), 4.44 (d, 
J = 12.0 Hz, 1H, PhCHH), 3.97 (ddd, J = 9.7, 5.5, 3.1 Hz, 1H, H-3), 3.89 (td, J = 6.1, 1.1 
Hz, 1H, H-5), 3.83 (dd, J = 3.2, 1.1 Hz, 1H, H-4), 3.54 (d, J = 6.1 Hz, 2H, H-6), 2.68 – 
2.52 (m, 2H, SCH2), 1.14 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (126 MHz, DMSO-d6) δ 165.14, 138.98, 138.20, 133.23, 130.05, 
129.35, 128.61, 128.24, 128.13, 127.63, 127.62, 127.49, 127.35, 82.77, 77.34, 76.70, 
74.42, 72.61, 72.29, 71.67, 68.82, 40.02, 39.85, 39.69, 39.52, 39.35, 39.19, 39.02, 
23.51, 15.10. 
 
Ethyl 2-O-benzoyl-4,6-di-O-benzyl-1-thio-β-D-galactopyranoside 2.5 
 
Pyridine (4.0 mL, 49 mmol) and FmocCl (6.38 g, 24.7 mmol) were sequentially 
added to a solution of ethyl 2-O-benzoyl-4,6-di-O-benzyl-1-thio-β-D-
galactopyranoside 2.5g (8.37 g, 16.4 mmol) in DCM (anhydrous, 136 mmol) under 
inert atmosphere. The colorless solution turned yellow and after a few minutes 
turned red. After 4.5 h stirring at rt, TLC showed complete conversion. The reaction 
mixture was diluted with DCM (70 mL), extracted with water (3 X 200 mL) and brine 
(200 mL). Then dried over MgSO4, filtered and the solvent was removed on rotavap. 
The resulting yellow oil was co-evaporated with toluene (3 X 20 mL) and dried in 
high vacuum (72 h). The resulting yellow solid was crystallized from EtOH (300 mL, 
70 °C) to afford the product as an off-white solid (10.5 g, 87%). 
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1H NMR (400 MHz, Chloroform-d) δ 8.09 – 7.98 (m, 2H), 7.73 – 7.63 (m, 2H), 
7.58 – 7.48 (m, 1H), 7.49 – 7.26 (m, 16H), 7.10 – 7.15 (m, 2H), 5.75 (t, J = 9.9 Hz, 1H, 
H-2), 5.07 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 4.79 (d, J = 11.5 Hz, 1H, PhCHH), 4.60 (d, J = 
9.9 Hz, 1H, H-1), 4.56 – 4.44 (m, 3H, PhCH2, PhCHH), 4.30 (dd, J = 10.4, 7.1 Hz, 1H, H-
6a), 4.22 (dd, J = 10.4, 7.8 Hz, 1H, H-6b), 4.14 (d, J = 2.9 Hz, 1H, H-4), 4.06 (t, J = 7.4 
Hz, 1H, H-5), 3.82 (t, J = 6.6 Hz, 1H, Fmoc-CH), 3.67 (d, J = 6.6 Hz, 2H, Fmoc-CH2), 2.74 
(dtt, J = 19.8, 12.5, 7.5 Hz, 2H, SCH2), 1.23 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (101 MHz, Chloroform-d) δ 165.34, 154.63, 143.36, 142.92, 141.30, 
141.19, 138.01, 137.81, 133.31, 130.04, 129.66, 128.56, 128.48, 128.40, 128.25, 
127.99, 127.97, 127.90, 127.82, 127.20, 127.17, 125.27, 125.05, 120.05, 83.81, 
79.11, 77.45, 77.33, 77.13, 76.81, 75.17, 74.07, 73.65, 70.19, 68.65, 68.14, 46.55, 
23.97, 14.89. 
HRMS (ESI) m/z calcd. for [M+Na]+ 753.2498. Found 753.2498. 
 
Synthesis of BB 2.2 
Ethyl 2,3-di-O-benzoyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside 2.2a 
 
 
A solution of compound 2.5b (34.2 g, 109 mmol) and Bz2O (73.6 g, 3 equiv) in 
DCM (anhydrous, 340 mL) was stirred under Ar. Et3N (60 mL, 4 equiv) and DMAP 
(740 mg, 3 mol% per OH group) were added and the reaction was stirred at rt. After 
4 h, the mixture was washed with HCl 1 M (2 X 300 mL), sat. aq. NaHCO3 (2 X 300 
mL), and brine (300 mL). The organic layer was dried over MgSO4, concentrated 
under reduced pressure and dried under high vacuum. The resulting solid was 
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crystallized from EtOAc/Hex 1:2 to give pure compound 2.2a as a white solid (50.4 
g, 88%).  
1H NMR (700 MHz, Chloroform-d) δ 7.99 – 7.96 (m, 4H), 7.52 – 7.47 (m, 4H), 
7.40 – 7.33 (m, 7H), 5.96 (t, J = 9.9 Hz, 1H, H-2), 5.54 (s, 1H), 5.40 (dd, J = 10.0, 3.5 
Hz, 1H, H-3), 4.73 (d, J = 9.9 Hz, 1H, H-1), 4.63 (dd, J = 3.5, 1.1 Hz, 1H, H-4), 4.42 (dd, 
J = 12.4, 1.6 Hz, 1H, H-6a), 4.10 (dd, J = 12.4, 1.8 Hz, 1H, H-6b), 3.73 (q, J = 1.6 Hz, 1H, 
H-5), 2.95 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 2.81 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 1.31 
(t, J = 7.5 Hz, 3H, SCH2CH3). 
13C NMR  (176 MHz, Chloroform-d) δ 166.29 (C=O), 165.47 (C=O), 137.73, 
133.49, 133.28, 130.05, 129.92, 129.70, 129.29, 129.17, 128.53, 128.47, 128.33, 
126.43, 101.17 (4,6-O-CHPh), 83.07 (C1), 74.01, 73.99 (C4, C2), 70.08 (C5), 69.35 
(C6), 67.33 (C3), 23.08 (CH2), 15.02 (CH3). 
 
Ethyl 2,3-di-O-benzoyl-1-thio-β-D-galactopyranoside 2.2b 
 
 
Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside (48 g, 
92 mmol) was dissolved in DCM (230 mL) and the resulting solution stirred at rt. 
EtSH (69 mL, 918 mmol) and CSA (4.28 g, 18.4 mmol) were sequentially added and 
the reaction mixture was vigorously stirred overnight. The resulting white 
suspension was cooled to 4 °C. The white solid was filtered and washed with cold 
hexane. After drying, the solid was identified as the pure compound 2.2b (29.8 g, 
88%). 
1H NMR (500 MHz, DMSO-d6) δ 7.91 – 7.85 (m, 4H), 7.62 – 7.57 (m, 2H), 7.49 
– 7.43 (m, 4H), 5.58 (t, J = 9.9 Hz, 1H, H-2), 5.38 (d, J = 5.6 Hz, 1H, 4-OH), 5.29 (dd, J 
= 9.8, 3.1 Hz, 1H, H-3), 4.94 (d, J = 9.9 Hz, 1H, H-1), 4.76 (dd, J = 6.1, 5.1 Hz, 1H, 6-
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OH), 4.20 (ddd, J = 5.7, 3.1, 1.0 Hz, 1H, H-4), 3.79 (t, J = 6.3 Hz, 1H, H-5), 3.62 – 3.53 
(m, 2H, H-6a, H-6b), 2.75 – 2.60 (m, 2H, SCH2), 1.18 (t, J = 7.4 Hz, 3H, SCH2CH3).  
13C NMR (176 MHz, DMSO) δ 165.17 (C=O), 164.99 (C=O), 133.53, 133.43, 
129.39, 129.22, 129.17, 129.14, 128.76, 128.61, 82.22 (C1), 78.76, 75.80, 68.64, 





Ethyl 2,3-di-O-benzoyl-1-thio-β-D-galactopyranoside (808 mg, 1.87 mmol), 
DABCO (505 mg, 4.50 mmol), and 2-chloro-1-methylpyridium iodide (CMPI, 570 mg, 
2.23 mmol) were combined with DCM (anhydrous, 6 mL) under a positive pressure 
of Ar and the resulting suspension was cooled in an ice bath. LevOH (8.40 g, 72.3 
mmol) was added and the mixture was allowed to react for 6 h, while the 
temperature rose to rt. The mixture was then diluted with DCM (10 mL) and washed 
with sat. at. NaHCO3 (15 mL). The aqueous layer was extracted with DCM (15 mL) 
and the combined organic layers were dried over MgSO4, concentrated under 
reduced pressure and dried under high vacuum. The resulting oil was identified as 
a mixture of the product and N-methyl-2-pyridone (1.15 g, 1:1 mixture, quant.). 
When procedure was scaled up to 28 g, a water contamination in DABCO led 
to an incomplete reaction. After column chromatography (hexane/DCM/EtOAc 
10:1:10), the pure product was obtained (5.7 g, 17%). 
1H NMR (700 MHz, DMSO-d 6 ) δ 7.89 – 7.86 (m, 4H), 7.67 (ddd, J = 6.7, 2.1, 
0.7 Hz, 1H, H-3 pyridone), 7.63 – 7.54 (m, 2H), 7.51 – 7.43 (m, 4H), 7.39 (ddd, J = 8.9, 
6.6, 2.1 Hz, 1H, H-5 pyridone), 6.36 (ddd, J = 9.1, 1.4, 0.7 Hz, 1H, H-6 pyridone), 6.18 
(td, J = 6.7, 1.4 Hz, 1H, H-4 pyridone), 5.65 (d, J = 5.7 Hz, 1H, 4-OH), 5.56 (t, J = 9.9 Hz, 
1H, H-2), 5.36 (dd, J = 9.9, 3.2 Hz, 1H, H-3), 5.00 (d, J = 10.0 Hz, 1H, H-1), 4.20 (dd, J 
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= 11.4, 7.5 Hz, 1H, H-6a), 4.18 – 4.17 (m, 1H, H-4), 4.15 (dd, J = 11.4, 4.6 Hz, 1H, H-
6b), 4.07 (dd, J = 7.6, 4.5 Hz, 1H, H-5), 3.41 (s, 3H, CH3 pyridone), 2.73 (t, J = 6.4 Hz, 
2H, CH2 Lev), 2.71 – 2.68 (m, 1H, SCHH), 2.65 (dq, J = 12.8, 7.4 Hz, 1H, SCHH), 2.52 – 
2.50 (m, 2H, CH2 Lev), 2.12 (s, 3H, CH3 Lev), 1.19 (t, J = 7.4 Hz, 3H, SCH2CH3). 
13C NMR (176 MHz, DMSO) δ 206.68 (C=O ketone), 172.16 (C=O Lev ester), 
165.08 (C=O Bz), 164.96 (C=O Bz), 161.86 (C=O pyridone), 139.82, 139.78, 133.56, 
133.48, 129.25, 129.19, 129.12, 128.76, 128.62, 119.13, 104.94, 82.24 (C1), 75.56 
(C5), 75.09 (C3), 68.39 (C2), 66.17 (C4), 63.43 (C6), 54.89, 37.36 (CH2 Lev), 36.69  





Compound 2.2c (5.60 g, mmol) was dissolved in DCM (anhydrous, 50 mL) 
under Ar. FmocCl (4.16 g, 1.5 equiv) and pyridine (2.6 mL, 3 equiv) were 
sequentially added and the resulting solution was stirred at rt overnight. The 
reaction mixture was diluted with DCM (50 mL), extracted with HCl 1M (2 X 100 
mL), and brine (100 mL). The organic layer was dried over MgSO4 and concentrated 
under reduced pressure. The crude material was purified by column 
chromatography (Hexane:DCM:EtOAc 4:1:1 to 4:1:5) to afford the pure product as a 
white solid (6.96 g, 88%). 
1H NMR (700 MHz, Chloroform-d) δ 8.00 (dd, J = 8.0, 1.4 Hz, 2H), 7.82 – 7.75 
(m, 4H), 7.64 (d, J = 7.4 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.54 – 7.50 (m, 1H), 7.45 – 
7.31 (m, 7H), 7.08 (t, J = 7.7 Hz, 2H), 5.88 (t, J = 9.8 Hz, 1H, H-2), 5.52 (d, J = 7.9 Hz, 
2H, H-3, H-4), 4.80 (d, J = 9.9 Hz, 1H, H-1), 4.40 (dd, J = 11.4, 6.5 Hz, 1H, H-6a), 4.29 
– 4.24 (m, 2H, H-6b, FmocCH), 4.20 – 4.12 (m, 3H, H-5, Fmoc CH2), 2.87 (dq, J = 12.3, 
7.4 Hz, 1H, SCHH), 2.81 (dq, J = 12.4, 7.5 Hz, 1H, SCHH), 2.75 (td, J = 6.4, 1.6 Hz, 2H, 
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OLev), 2.59 (t, J = 6.5 Hz, 2H, OLev), 2.17 (s, 3H, OLev), 1.33 (t, J = 7.4 Hz, 3H, 
SCH2CH3). 
13C NMR (176 MHz, Chloroform-d) δ 206.51 (C=O Lev ketone), 172.35 (C=O 
Lev ester), 165.56 (C=O Bz), 165.34 (C=O Bz), 154.83 (C=O carbonate), 143.50, 
143.21, 141.36, 141.31, 133.44, 133.41, 129.97, 129.80, 129.47, 128.85, 128.52, 
128.37, 128.06, 127.59, 127.45, 125.55, 125.44, 120.13, 120.10, 84.26 (C1), 74.51 
(C5), 72.86, 71.82, 70.74 (C6), 67.85 (CH2 Fmoc), 61.79 (C6), 46.56 (CH Fmoc), 38.02 
(CH2 Lev), 29.90 (CH3 Lev), 27.97 (CH2 Lev), 24.47 (SCH2), 15.08 (SCH2CH3).  
HRMS (ESI) m/z calcd. for [M+K]+ 791.1923. Found 791.1898. 
 
Synthesis of BB 2.3 
General procedure for the optimization of the benzylation 
A solution of starting material in the respective anhydrous solvent was stirred 
in an ice bath under Ar. NaH (60% in mineral oil) was added and after 10 min, BnBr 
(1.5 equiv) was dropwise added over 10 to 30 min. After 30 min, the cooling bath 
was removed, and the mixture was stirred at rt for the time stated for each 
experiment. For large scale reactions (≥ 1 g) an exhaust tube connected to a gas 
bubbler was attached to the reaction vessel to avoid accumulation of hydrogen. 
Crystallization led to the isolation of 50% of the starting material. b TLC showed the 
reaction was incomplete and side products were formed. cFor safety reasons, in this 
reaction the cooling bath was kept for longer (1 h). 
 
A solution of ethyl 4,6-O-benzylidene-1-thioglucopyranoside (39.9 g, 128 
mmol) in DMF (anhydrous, 335 mL) was stirred under Ar and cooled in an ice bath 
for 5 to 10 min. NaH (60% in mineral oil, 16.0 g, 400 mmol) was added and after 
another 5 min BnBr (33.0 mL, 278 mmol) was added. After 30 min the cooling bath 
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was removed.  After another 4.5 h, TLC showed complete conversion. The reaction 
was diluted with DCM (200 mL) and quenched by portion wise addition of sat. aq. 
NH4Cl (400 mL). The aqueous layer was isolated and extracted with DCM (250 mL). 
The combined organic layers were washed with brine (500 mL), dried over MgSO4, 
and concentrated under reduced pressure. The resulting yellow solution was 
transferred to a 2 L flask. Ethanol (1.4 L) was dropwise added while stirring 
vigorously. Then H2O (200 mL) was dropwise added. The resulting white 
suspension was kept at 4 °C overnight. The white solid was filtered and washed with 
cold EtOH/H2O 3:1 (ca. 300 mL) and with cold hexane (ca. 200 mL). After drying 
under vacuum, the white solid was identified as the pure product (60.6 g, 96%). 
1H NMR (700 MHz, Chloroform-d) δ  7.52 – 7.48 (m, 2H), 7.42 – 7.32 (m, 9H), 
7.33 – 7.26 (m, 4H), 5.59 (s, 1H, PhCH), 4.96 (d, J = 11.3 Hz, 1H, PhCH2), 4.90 (d, J = 
10.2 Hz, 1H, PhCH2), 4.83 (d, J = 10.3 Hz, 1H, PhCH2), 4.82 (d, J = 11.2 Hz, 1H, PhCH2), 
4.58 (d, J = 9.8 Hz, 1H, H-1), 4.37 (dd, J = 10.5, 5.0 Hz, 1H, H-6a), 3.82 (dd, J = 9.4, 8.4 
Hz, 1H, H-3), 3.79 (t, J = 10.3 Hz, 1H, H-6b), 3.73 (t, J = 9.4 Hz, 1H, ), 3.48 (dd, J = 9.8, 
8.3 Hz, 1H, H-2), 3.47 (td, J = 9.7, 5.1 Hz, 1H, H-5), 2.80 (dq, J = 13.2, 7.8 Hz, 1H, SCH2), 
2.75 (dq, J = 12.6, 7.7 Hz, 1H, SCH2), 1.33 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (176 MHz, Chloroform-d) δ 138.54, 138.10, 137.42, 129.08, 128.49, 
128.44, 128.38, 128.18, 128.02, 127.99, 127.83, 126.12, 101.25 (PhCH), 85.99 (C1), 
82.95 (C3), 81.75 (C4), 81.43 (C2), 76.10 (CH2Ph), 75.36 (CH2Ph), 70.37 (C5), 68.86 
(C6), 25.31 (SCH2), 15.26 (CH3). 
 
Ethyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside 2.3c 
 
Compound 2.3b (27.8 g, 56.4 mmol) was dissolved in DCM (140 mL) and the 
resulting colourless solution was stirred at rt. EtSH (43 mL, 580 mL) 
camphorsulfonic acid (2.65 g, 11.4 mmol) were sequentially added and the resulting 
solution was stirred overnight. The reaction mixture was concentrated under 
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reduced pressure and purified by a short column chromatography (Hex:EA 80:20 to 
25:75). Compound 2.3c was collected, concentrated, and dried under high vacuum 
and obtained as a white solid (22.6 g, 99%). 
1H NMR (700 MHz, Chloroform-d) δ 7.44 – 7.38 (m, 2H), 7.38 – 7.29 (m, 8H), 
4.98 – 4.95 (m, 2H, PhCH2), 4.74 – 4.71 (m, 2H, PhCH2), 4.52 (d, J = 9.7 Hz, 1H, H-1), 
3.87 (dd, J = 11.9, 3.5 Hz, 1H, H-6a), 3.75 (dd, J = 11.9, 5.2 Hz, 1H, H-6b), 3.58 (t, J = 
9.3 Hz, 1H, H-4), 3.50 (t, J = 8.9 Hz, 1H, H-3), 3.40 (dd, J = 9.7, 8.7 Hz, 1H, H-2), 3.34 
(ddd, J = 9.5, 5.2, 3.5 Hz, 1H, H-5), 2.83 – 2.70 (m, 2H, S CH2), 2.36 (s, 1H, OH), 2.11 
(br s, 1H, OH), 1.33 (t, J = 7.4 Hz, 1H, CH3). 
13C NMR (176 MHz, Chloroform-d) δ 138.53, 137.94, 128.84, 128.58, 128.47, 
128.18, 128.09, 128.02, 86.07 (C3), 85.50 (C1), 81.65 (C2), 79.19 (C5), 75.56, 75.52 
(2x PhCH2), 70.71 (C4), 62.93 (C6), 25.38 (SCH2), 15.29 (CH3). 
 
Ethyl 6-O-acetyl-2,3-di-O-benzyl-1-thio-β-D-glucopyranoside 2.3d 
 
Ethyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside (3.07 g, 7.59 mmol), DABCO 
(3.38 g, 30.1 mmol), and 2-chloro-1-methylpyridium iodide (CMPI, 4.74 g, 18.6 
mmol) were dissolved in DCM (anhydrous, 65 mL) with pre-activated 4 Å MS (7 g) 
and the resulting mixture was cooled to -15 °C under a positive pressure of Ar. AcOH 
(470 µL) was portion wise added and the mixture was allowed to react for 4h, while 
the temperature rose to -10 °C. The mixture was then diluted with DCM (35 mL) and 
washed with sat. at. NaHCO3 (100 mL). The aqueous layer was extracted with DCM 
(100 mL) and the combined organic layers were dried over MgSO4, concentrated 
under reduced pressure and dried under high vacuum to afford the product in a 
1:0.74 mixture with N-methyl-2-pyridone (3.94 g, 98%). 
1H NMR (500 MHz, DMSO-d6) δ 7.67 (dd, J = 6.6, 2.1 Hz, 1H, Pyridone), 7.40 
(ddd, J = 8.9, 6.6, 2.2 Hz, 1H, Pyridone), 7.37 – 7.24 (m, 10H), 6.37 (dt, J = 9.2, 1.0 Hz, 
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1H, Pyridone), 6.19 (td, J = 6.7, 1.4 Hz, 1H, Pyridone), 5.59 (d, J = 6.5 Hz, 1H, 4-OH), 
4.89 (d, J = 11.4 Hz, 1H, 3-OCHHPh), 4.75 (d, J = 10.9 Hz, 1H, 2-OCHHPh), 4.74 (d, J = 
11.4 Hz, 1H, 3-OCHHPh), 4.67 (d, J = 10.8 Hz, 1H, 2-OCHHPh), 4.58 (d, J = 9.8 Hz, 1H, 
H-1), 4.29 (dd, J = 11.9, 2.0 Hz, 1H, H-6a), 4.08 (dd, J = 11.9, 6.6 Hz, 1H, H-6b), 3.50 
(ddd, J = 9.7, 6.7, 2.0 Hz, 1H, H-5), 3.49 (t, J = 8.8 Hz, 1H, H-3), 3.44 – 3.35 (m, 4H, H-
4, NCH3 pyridone), 3.26 (dd, J = 9.8, 8.8 Hz, 1H, H-2), 2.74 – 2.60 (m, 2H, SCH2), 2.03 
(s, 3H, 6-OCOCH3), 1.23 (t, J = 7.4 Hz, 3H, SCH2CH3). 
13C NMR (126 MHz, DMSO-d6) δ 170.25 (C=O Ac), 161.89 (C=O pyridone), 
139.83, 138.96, 138.31, 128.08, 128.03, 127.67, 127.51, 127.45, 127.24, 119.14, 
104.97, 85.68 (C3), 83.69 (C1), 80.68 (C2), 77.26 (C5), 74.32 (3-OCH2Ph), 74.13 (2-
OCH2Ph), 70.20 (C4), 63.50 (C6), 36.69 (NCH3 pyridone), 23.94 (SCH2), 20.66 (6-





Crude ethyl 6-O-acetyl-2,3-di-O-benzyl-1-thio-β-D-glucopyranoside (7.32 
mmol) was dissolved in DCM (anhydrous, 35 mL) under Ar. FmocCl (3.78 g, 14.6 
mmol) was added followed by pyridine (1.8 mL, 22 mmol). The resulting solution 
was stirred at rt overnight. Reaction mixture was extracted with HCl 1M (2X 40 mL), 
sat. NaHCO3 (2X 40 mL) and brine (40 mL). The organic layer was dried over MgSO4, 
concentrated under reduced pressure and purified by column (Hexane/DCM/EtOAc 
10:1:0.5 to 10:1:2.5) to give the pure product was a white solid (3.81 g, 78%). 
1H NMR (500 MHz, Chloroform-d) δ 7.76 (dd, J = 7.6, 0.9 Hz, 2H), 7.59 (dt, J 
= 7.5, 0.9 Hz, 1H), 7.55 (dt, J = 7.5, 0.9 Hz, 1H), 7.40 – 7.17 (m, 14H), 4.96 – 4.86 (m, 
2H, H-4, PhCHH), 4.83 (d, J = 11.2 Hz, 1H, PhCHH), 4.73 (d, J = 10.2 Hz, 1H, PhCHH), 
4.67 (d, J = 11.2 Hz, 1H, PhCHH), 4.50 (d, J = 9.8 Hz, 1H, H-1), 4.45 (dd, J = 10.4, 7.0 
Hz, 1H, Fmoc CHH), 4.37 – 4.24 (m, 2H, H-6a, Fmoc CHH), 4.23 – 4.12 (m, 2H, H-6b, 
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Fmoc CH), 3.72 (t, J = 9.1 Hz, 1H, H-3), 3.66 (ddd, J = 10.0, 5.4, 2.6 Hz, 1H, H-5), 3.50 
(dd, J = 9.9, 8.7 Hz, 1H, H-2), 2.86 – 2.67 (m, 2H, SCH2), 2.06 (s, 3H, COCH3), 1.34 (t, J 
= 7.4 Hz, 3H, SCH2CH3). 
13C NMR (126 MHz, Chloroform-d) δ 170.81 (C=O Ac), 154.47 (C=O Fmoc), 
143.39, 143.27, 141.41, 137.99, 128.57, 128.52, 128.44, 128.13, 128.05, 128.03, 
127.84, 127.82, 127.33, 125.23, 125.10, 120.21, 120.19, 85.49 (C1), 83.82 (C3), 
81.35 (C2), 75.75, 75.73, 75.57, 74.64, 70.38 (CH2 Fmoc), 62.78 (C6), 46.82 (Fmoc 
CH), 25.33 (SCH2), 20.91 (COCH3), 15.23 (SCH2CH3). 
 
Synthesis of BB 2.1 
Ethyl 2,4,6-tri-O-acetyl-3-O-benzyl-1-thio-β-D-glucopyranoside 2.1d 
 
A solution of 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (10 g, 39 mmol) 
in THF (anhydrous, 67 mL) under Ar was cooled in an ice bath. NaH (60% in mineral 
oil, 1.69 g, 70.4 mmol) was added and, after 5 min, BnBr (5.0 mL, 42 mmol) and 
INBu4 (284 mg, 0.769 mmol) were added. After 45 min, the cooling bath was 
removed, and the reaction was stirred at rt. After 3 h, TLC showed complete 
conversion. The reaction was diluted with EtOAc (70 mL) and quenched with sat. aq. 
NH4Cl (140 mL). The aqueous layer was extracted with EtOAc (70 mL). The 
combined organic layers were dried over MgSO4, concentrated under reduced 
pressure and dried under high vacuum. The crude 3-O-benzyl-1:2,5:6-di-O-
isopropylideneglucofuranose was combined with water (120 mL). Amberlyte IR 
120 (16 g, pre-washed with MeOH and H2O) was added and the resulting mixture 
was vigorously stirred under an 80 °C heating bath. After 6 h, TLC showed absence 
of starting material. The reaction mixture was filtered, evaporated under reduced 
pressure, and dried under high vacuum. The resulting material was combined with 
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Ac2O (61.0 mL, 645 mmol) and NaOAc (1.3 g, 16 mmol), and stirred under a 100 °C 
heating bath for 1.5 h. The reaction mixture was poured into a beaker with ice to 
induce crystallization without success. The resulting solution was extracted with 
EtOAc. The organic layer was washed with sat. aq. NaHCO3, concentrated under 
reduced pressure and dried under high vacuum. NMR analysis of the resulting oil 
showed a 1:4 α/β mixture of the target tetraacetate. The crude material was 
combined with DCM (anhydrous, 154 mL) and EtSH (3.9 mL, 54 mmol) under Ar, 
and the resulting solution was cooled in an ice bath. BF3·OEt2 (7.5 mL, 61 mL) was 
dropwise added over 10 min. After 30 min, the cooling bath was removed, and the 
mixture was stirred at rt for 5 h. The reaction was quenched with H2O (150 mL). The 
organic layer washed with sat. aq. NaHCO3 (150 mL) and brine (150 mL), dried over 
MgSO4, concentrated under reduced pressure, and dried in high vacuum overnight. 
The resulting material was purified by column chromatography (EtOAc in Hexane, 
20% to 35%). Compound 2.1d was isolated as a white solid (4.32 g, 24% over 4 
steps). 
1H NMR (500 MHz, Chloroform-d) δ 7.37 – 7.23 (m, 3H), 7.27 – 7.18 (m, 2H), 
5.10 (t, J = 9.7 Hz, 1H, H-2), 5.08 (t, J = 9.6 Hz, 1H, H-4), 4.67 – 4.54 (AB q, 2H, PhCH2), 
4.40 (d, J = 10.3 Hz, 1H, H-1), 4.18 (dd, J = 12.3, 5.3 Hz, 1H, H-6a), 4.11 (dd, J = 12.3, 
2.5 Hz, 1H, H-6b), 3.70 (t, J = 9.3 Hz, 1H, H-3), 3.60 (ddd, J = 10.0, 5.3, 2.5 Hz, 1H, H-
5), 2.79 – 2.60 (m, 2H, SCH2), 2.07 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.96 (s, 3H, Ac), 1.25 
(t, J = 7.5 Hz, 3H, SCH2CH3). 
13C NMR (126 MHz, DMSO-d6) δ 170.86 (C=O), 169.43 (C=O), 169.39 (C=O), 
137.86, 128.54, 127.94, 127.82, 83.77 (C1), 81.60 (C3), 76.29 (C5), 74.27 (PhCH2), 








Ethyl 3-O-benzyl-1-thio-β-D-glucopyranoside 2.1e 
 
Ethyl 2,4,6-tri-O-acetyl-3-O-benzyl-1-thio-β-D-glucopyranoside 2.1d (3.98 g, 
9.03 mmol) was suspended in MeOH (anhydrous, 30 mL). NaOMe (5.4 M in MeOH, 
300 µL, 1.62 mmol) was added and the resulting suspension was stirred at rt for 2 
h. The resulting solution was neutralized with Amberlyte IR 120, concentrated 
under reduced pressure and dried under high vacuum. NMR analysis showed a 
mixture of the target trial and a monoacetyl intermediate. The crude material was 
dissolved in MeOH (anhydrous, 30 mL) and NaOMe (5.4 M in MeOH, 1 mL, 5.4 
mmol). The resulting solution was stirred under a 40 °C bath for 6h. The reaction 
mixture was neutralized with Amberlyte IR 120, concentrated under reduced 
pressure and dried under high vacuum. The resulting oil was identified as the pure 
compound 2.1e (2.80 mg, 99%). 
1H NMR (500 MHz, DMSO-d6) δ 7.42 – 7.40 (m, 2H), 7.33 – 7.29 (m, 2H), 7.28 
– 7.21 (m, 1H), 5.31 (brs, 1H, OH), 5.14 (brs, 1H, OH), 4.85 – 4.74 (ABq, 2H, PhCH2), 
4.32 (d, J = 9.5 Hz, 1H, H-1), 3.68 (dd, J = 11.9, 2.1 Hz, 1H, H-6a), 3.45 (dd, J = 11.9, 
5.9 Hz, 1H, H-6a), 3.28 – 3.22 (m, 2H, H-3, H-4), 3.20 – 3.14 (m, 2H, H-2, H-5), 2.72 – 
2.58 (m, 2H, SCH2), 1.20 (t, J = 7.4 Hz, 3H, SCH2CH3). 
13C NMR (126 MHz, CDCl3) δ 139.54, 127.91, 127.47, 127.04, 86.63 (C1), 
85.02, 81.02, 73.88 (PhCH2), 72.81, 69.71, 61.06, 22.96 (SCH2), 14.97 (SCH2CH3). 
 
Ethyl 3-O-benzyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside 2.1f 
 
Ethyl 3-O-benzyl-1-thio-β-D-glucopyranoside (2.74 g, 8.72 mmol) was taken 
in a round-bottom flask and purged with Ar. CSA (373 mg, 1.61 mmol) was added 
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followed by anhydrous THF (19 mL). The resulting mixture was stirred at rt and 
after a few minutes a pale orange solution was formed. Benzaldehyde dimethyl 
acetal (2.9 mL, 19 mmol) was then added and the resulting solution stirred at rt. 
After 21 h, TLC (Hex/ EtOAc 2:1) showed the product (rf = 0.36) as major 
component. Reaction mixture was diluted with EtOAc (20 mL), extracted with aq. 
sat. NaHCO3 (2x 40 mL), brine (40 mL), dried over MgSO4 and concentrated to 
dryness under reduced pressure to give a white to pale yellow solid (4.39 g). The 
crude material was crystallized from EtOAc (11 mL, 70 °C) and hexane (50 mL) to 
give the pure product as a white solid (2.37 g, 68%). The mother liquor was 
concentrated and further subjected to crystallization from EtOAc (2.5 mL, 70 °C) and 
hexane (12.5 mL) to give a second portion of the pure product as white crystals (105 
mg, 3%). 
1H NMR (700 MHz, DMSO-d6) δ 7.43 – 7.36 (m, 7H, Ar-H), 7.31 – 7.28 (m, 2H, 
Ar-H), 7.27 – 7.24 (m, 1H, Ar-H), 5.67 (br s, 1H, 2-OH), 5.67 (s, 1H, PhCH), 4.82 (d, J 
= 12.0 Hz, 1H, PhCHH), 4.79 (d, J = 12.1 Hz, 1H, PhCHH), 4.56 (d, J = 9.7 Hz, 1H, H-1), 
4.22 (dd, J = 10.1, 5.0 Hz, 1H, H-6a), 3.71 (t, J = 10.2 Hz, 1H, H-6b), 3.65 (t, J = 9.4 Hz, 
1H, H-4), 3.56 (dd, J = 9.4, 8.3 Hz, 1H, H-3), 3.49 (ddd, J = 10.1, 9.3, 5.0 Hz, 1H, H-5), 
3.37 – 3.34 (m, 1H, H-2), 2.67 (dq, J = 12.7, 7.4 Hz, 1H, SCHH), 2.63 (dq, J = 12.8, 7.5 
Hz, 1H, SCHH), 1.22 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (176 MHz, DMSO-d6) δ 139.50, 138.14, 129.18, 128.53, 128.44, 
127.94, 127.67, 126.41 (8X Ar-C), 100.54 (PhCH), 86.29 (C1), 82.70 (C3), 80.78 (C4), 





Ethyl 3-O-benzyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (2.32 g, 5.76 
mmol) and benzoic anhydride (19.8 g, 8.75 mmol) were taken in a 3-neck round-
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bottom flask and purged with Ar (ca. 5 min). Anhydrous DCM (18 mL) resulting in a 
colourless solution that was stirred at rt under a positive pressure of Ar. 
Triethylamine (1.6 mL, 11 mmol) and DMAP (21 mg, 3 mol%) were subsequently 
added. After 7 h, TLC (hexane/EtOAc 4:1) showed complete conversion (Rf = 0.32). 
The reaction mixture was extracted with 1 M HCl (2X 20 mL), sat. aq. NaHCO3 (2X 
20 mL), dried over MgSO4 and concentrated under reduced pressure and further 
dried under high vacuum to give a white solid (3.21 g). The crude product was 
dissolved in EtOAc (4 mL, 70 °C) and hexane (32 mL) was dropwise added while 
stirring vigourously. The resulting suspension was kept at 4 °C overnight and 
filtered. The white solid powder residue was dried in the desiccator under vacuum 
overnight and identified as the pure product (2.49, 85%). 
1H NMR (700 MHz, CDCl3) δ 8.06 – 8.01 (m, 2H), 7.65 – 7.60 (m, 1H), 7.56 – 
7.52 (m, 2H), 7.51 – 7.46 (m, 2H), 7.46 – 7.38 (m, 3H), 7.19 – 7.14 (m, 3H), 7.14 – 
7.08 (m, 2H), 5.65 (s, 1H, PhCH), 5.37 (dd, J = 10.1, 8.7 Hz, 1H, H-2), 4.86 (d, J = 11.9 
Hz, 1H, 3-OCHH), 4.73 (d, J = 12.0 Hz, 1H, 3-OCHH), 4.65 (d, J = 10.1 Hz, 1H, H-1), 4.44 
(dd, J = 10.5, 5.0 Hz, 1H, H-6a), 3.93 (dd, J = 9.3, 8.6 Hz, 1H, H-3), 3.88 (t, J = 9.3 Hz, 
1H, H-4), 3.86 (t, J = 10.3 Hz, 1H, H-6b), 3.59 (ddd, J = 10.0, 9.2, 5.0 Hz, 1H, H-5), 2.80 
– 2.70 (m, 2H, SCH2), 1.25 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3) δ 165.25 (C=O), 137.86, 137.28, 133.28, 130.01, 
129.84, 129.14, 128.46, 128.38, 128.25, 128.14, 127.66, 126.10, 101.37 (PhCH), 
84.40 (C1), 81.76 (C4), 79.31 (C3), 74.31 (PhCH2), 71.96 (C2), 70.81 (C5), 68.74 (C6), 






was taken in a 100 mL 3-neck round-bottom flask and flushed with Ar (ca. 5 min). 
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DCM (anhydrous, 9.5 mL) was added resulting in a slightly viscous colourless 
solution to which activated 4 Å MS (1.5 g) were added. The mixture was stirred in 
an ice bath under Ar for 5 min. Et3SiH (3.0 mL, 19 mmol) was added and after 20 
min, TFA (1 450 µL, 19 mmol) was dropwise added over 1 min. After stirring 
overnight, the cooling bath had warmed up to rt and TLC (hexane/EtOAc 2:1) 
showed absence of the starting material and the product at Rf = 0.30.  The reaction 
was diluted with MeOH (10 mL) and quenched by dropwise addition of Et3N (2.6 
mL). After stirring for ca. 15 min with the flask open, the reaction mixture was 
concentrated under reduced pressure and purified by column (hexane/EtOAc 80:20 
to 70:30) to give the pure product as a colorless oil (2.08 g, 86%). 
1H NMR (700 MHz, CDCl3) δ 8.08 – 8.06 (m, 2H), 7.62 – 7.59 (m, 1H), 7.50 – 
7.47 (m, 2H), 7.40 – 7.36 (m, 4H), 7.34 – 7.31 (m, 1H), 7.23 – 7.20 (m, 5H), 5.31 (dd, 
J = 10.0, 9.1 Hz, 1H, PhCH), 4.76 (d, J = 11.5 Hz, 1H, 3-OCHH), 4.72 (d, J = 11.5 Hz, 1H, 
3-OCHH), 4.65 (d, J = 12.0 Hz, 1H, 6-OCHH), 4.61 (d, J = 12.0 Hz, 1H, 6-OCHH), 4.58 
(d, J = 10.0 Hz, 1H, H-1), 3.85 – 3.80 (m, 3H, H-4, H-6a, H-6b), 3.73 (t, J = 9.0 Hz, 1H, 
H-3), 3.60 (ddd, J = 9.6, 5.1, 4.5 Hz, 1H, H-4), 2.83 (d, J = 2.4 Hz, 1H, 4-OH), 2.79 – 2.67 
(m, 2H, SCH2), 1.25 (t, J = 7.5 Hz, 1H, CH3). 
13C NMR (176 MHz, CDCl3) δ 165.27 (C=O), 137.95, 137.71, 133.19, 129.86, 
128.48, 128.42, 128.40, 127.98, 127.85, 127.78, 83.64 (C1), 83.56 (C3), 78.21 (C5), 
74.67 (3-OCH2), 73.78 (6-OCH2), 72.33 (C4), 72.02 (C2), 70.55 (C6),23.97 (SCH2), 





Ethyl 2-O-benzoyl-3,6-di-O-benzyl-1-thio-β-D-glucopyranoside (2.01, 3.95 
mmol) was taken in a 100 mL round-bottom flask and purged with Ar (ca. 5 min). 
Anhydrous DCM (20 mL) was added and the resulting colorless solution stirred at 
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rt under a positive pressure of Ar. FmocCl (1.53 g, 5.88 mmol) was added followed 
by anhydrous pyridine (0.95 mL, 12 mmol). The solution turned yellow and within 
a few minutes turned reddish. After 5 h, TLC showed complete conversion (Rf = 
0.33). Reaction mixture was diluted with DCM (20 mL), extracted with HCl 1M (2X 
40 mL), sat. NaHCO3 (2X 40 mL) and brine (40 mL). The organic layer was dried over 
MgSO4, concentrated under reduced pressure and further dried in high vacuum to 
afford a yellow oil (3.04 g). The crude product was purified by column 
(Hexane/DCM/EtOAc 10:1:0.5 to 10:1:3) to give the pure product was a white solid 
(2.35 g, 81%). 
1H NMR (700 MHz, CDCl3) δ 8.06 – 8.04 (m, 2H), 7.78 (ddt, J = 7.6, 7.0, 0.9 Hz, 
2H), 7.63 – 7.60 (m, 2H), 7.57 (dq, J = 7.5, 0.9 Hz, 1H), 7.50 – 7.47 (m, 2H), 7.42 (tddd, 
J = 7.5, 4.9, 1.1, 0.6 Hz, 2H), 7.37 – 7.35 (m, 2H), 7.34 – 7.29 (m, 4H), 7.28 – 7.23 (m, 
1H), 7.12 – 7.06 (m, 5H), 5.37 (dd, J = 10.0, 9.1 Hz, 1H, H-2), 5.03 (dd, J = 9.9, 9.2 Hz, 
1H, H-4), 4.63 (d, J = 11.5 Hz, 1H, 3-OCHHPh), 4.60 (d, J = 10.0 Hz, 1H, H-1), 4.59 (d, 
J = 11.5 Hz, 1H, 3-OCHHPh), 4.58 (s, 2H, 6-OCH2Ph), 4.39 – 4.33 (m, 2H, Fmoc-CH2), 
4.16 (t, J = 7.2 Hz, 1H, fluorene H-9), 3.95 (t, J = 9.1 Hz, 1H, H-3), 3.79 (ddd, J = 10.0, 
5.2, 3.9 Hz, 1H, H-5), 3.73 – 3.68 (m, 2H, H-6a, H-6b), 2.80 – 2.70 (m, 2H, SCH2), 1.27 
(t, J = 7.4 Hz, 3H, CH3). 
13C NMR (176 MHz, CDCl3) δ 165.03 (C=O Bz), 154.24 (C=O Fmoc), 143.30, 
143.14, 141.32, 141.29, 137.90, 137.39, 133.25, 129.89, 129.70, 128.42, 128.33, 
128.15, 127.92, 127.83, 127.62, 127.18, 125.10, 125.01, 120.08, 83.70 (C1), 81.13 
(C3), 77.44 (C5), 75.58 (C4), 74.39 (3-OCH2Ph), 73.62 (6-OCH2Ph), 71.92 (C2), 70.05 
(CH2 Fmoc), 69.73 (C6), 46.73 (CH Fmoc), 24.07 (SCH2), 14.91 (SCH2CH3). 







Functionalization of the solid phase 
 
5g batch 
Merrifield Resin (0.46 mmol/g, 5.06 g, 2.33 mmol) was washed swollen in DMF 
(anhydrous, 20 mL) for ca. 20 min. Benzyl (5-hydroxy-2-nitrobenzyl)-(5-
hydroxypentyl)carbamate (7.6 g, 8 equiv), Cs2CO2 (2.35 g, 3 equiv) and TBAI (482 
mg, 0.5 equiv) were added to the suspension. The resulting mixture was gently 
stirred at 60 °C overnight. Afterwards, the resin was allowed to cool, filtered, washed 
four times each with 1:1 THF:H20, THF, DMF, DCM and MeOH. The resin was dried 
in a desiccator under vacuum and protected from light. 
Loading determination 
A sample of the dried resin (200 mg) was taken into a 20 mL filter syringe. The 
syringe with the resin was purged with Ar and anhydrous DCM (15 mL) was 
uptaken. The syringe was wrapped in aluminum foil and shaken in an orbital shaker. 
After 30 min, the solvent was dispensed. A solution of FmocCl (600 mg) and pyridine 
(400 µL) in anhydrous DCM (15 mL) was uptaken and the syringe placed back in the 
shaker. After 18 h, the syringe was drained, and the resin abundantly washed with 
DCM and MeOH. The resin was dried under vacuum, protected from light, and the 
loading was determined by cleavage of Fmoc with DBU, according to a reported 
protocol51,52. The loading was 0.40 mmol/g. 
50g batch 
Merrifield resin (50.3 g, 0.46 mmol/g) suspended in DMF (anhydrous, 100 mL) 
in a round-bottom flask. Benzyl (5-hydroxy-2-nitrobenzyl)-(5-hydroxypentyl)-
carbamate (50.1 g), Cs2CO3 (50.0 g) and TBAI (10.1 g) were added resulting in a 
strong yellow coloured mixture. After swirling the mixture for a few minutes, most 
of the added solids were dissolved and the flask was attached to a rotavap with a 
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heating bath at 60 °C and slow rotation. The vacuum was set to 600 mbar and the 
vacuum pump was turned off after the set point was reached. The reaction mixture 
was protected from light with aluminium foil and allowed to react in the rotavap. 
After 22h, the resin was filtered through a pore 1 sintered funnel and washed four 
times each with THF, H2O, THF, DMF, and then 4X alternating cycles of DCM and 
MeOH. A last portion of DCM was added, and the resin allowed to swell for a few 
minutes. The solvent was drained, and the resin transferred into a round-bottom 
flask. DMF (anhydrous, 150 mL) and CsOAc (24.0 g) were added and the mixture 
rotavaped for a few minutes to remove DCM. The vacuum pump was turned off, and 
the mixture allowed to react in the rotavap with a 60 °C heating bath and slow 
rotation, protected from light with aluminium foil. After 24 h, the mixture was 
removed from the rotavap. The resin was filtered through a pore 1 sintered funnel 
and washed four times each with THF, THF:H2O 1:1, H2O, THF, DMF, and then 4X 
alternating cycles of DCM (300 mL) and MeOH (300 mL). The resin was dried in a 
desiccator under vacuum and protected from light for 48h. 
Loading determination 





   
 
3. Automated Glycan Assembly of 









The capsular polysaccharide of GBS type IV has received little attention from 
synthetic groups because this serotype represents only 1.1% of GBS disease cases. 
However, the prevalence is rising both in neonate and adult disease cases.2,5  
So far, no synthetic route has been described to prepare GBS type IV CPS 
oligosaccharides. The repeating unit of GBS type IV consists of a branched 
hexasaccharide that bears an α-glucoside residue and the Neu5Ac-α-2,3-Gal motif 
that is common to all GBS serotypes54 (Figure 3.1). These are the most challenging 
linkages in the repeating unit structure. 
 
Figure 3.1 Repeating unit of GBS type IV CPS. 
This chapter describes a strategy to assemble the backbone trimer of GBS type 
IV repeating unit using the Glyconeer. The synthesis of oligosaccharides using the 
Glyconeer is based on the optimization of an elongation cycle that incorporates each 
building block (BB) into the growing oligosaccharide chain. Each cycle is comprised 
of four modules: acid wash, glycosylation, capping and deprotection. Based on data 
from the Fmoc sensor and HPLC analysis of the crude material obtained after 
photocleavage, key parameters related to the glycosylation module were optimized: 







Initially, all the building blocks were coupled using the same conditions: single 
coupling with 6.5 equiv of donor, and temperature -20 to 0 °C (Scheme 3.1, Table 
3.1). The Fmoc sensor data (normalized for the first coupling), showed a very low 
efficiency for the coupling of BB 2.3. The corresponding HPLC showed the formation 
of the disaccharide deletion sequence but not the product.   
 
Scheme 3.1 AGA trisaccharide 3.1 using BBs 2.1, 2.2 and 2.3. Circular arrows represent 
the elongation cycle (acid wash, glycosylation, capping, deprotection) for each BB. 
Table 3.1 AGA of GBS type IV backbone trisaccharide 3.1. 
Entry Conditions UV Sensor Data HPLC of crude material 
1 2.1 1x 6.5 equiv 
-20 to 0 °C 
 
2.2 1x 6.5 equiv 
-20 to 0 °C 
 
2.3 1x 6.5 equiv 








Judging by the UV data and the HPLC data, the major bottleneck is the coupling 
of glucoside 2.3. With that in mind, a series of experiments were conducted to 
optimize this coupling (Table 3.2).  
Table 3.2 Optimization of the coupling of the third BB (glucoside 2.3). 
 
When BB 2.3 was used in a double coupling (Table 3.2, entry 1), a marked 
increase in the glycosylation efficiency was observed (according to the UV sensor). 
Next, the temperature effect was probed. When 2.3 was coupled at -30 to -10 °C 
there was a further increase in the coupling efficiency (Table 3.2, entry 2). When 
the temperature was decreased to -40 to -20 °C, no change was observed in the 
coupling efficiency compared with -30 to -10 °C (Table 3.2, entry 3). 
Entry Conditions UV Sensor Data HPLC of crude material 
1 2.1 1x 6.5 equiv 
-20 to 0 °C 
 
2.2 1x 6.5 equiv 
-20 to 0 °C 
 
2.3 2x 6.5 equiv 
-20 to 0 °C 
 
 
2 2.1 1x 6.5 equiv 
-20 to 0 °C 
 
2.2 1x 6.5 equiv 
-20 to 0 °C 
 
2.3 2x 6.5 equiv 
-30 to -10 °C 
 
 
3 2.1 1x 6.5 equiv 
-20 to 0 °C 
 
2.2 1x 6.5 equiv 
-20 to 0 °C 
 
2.3 2x 6.5 equiv 




Target product 3.1 
Target product 3.1 
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A common peak in all the HPLC traces was identified as the capped linker 3.4 
(retention time 4 min). When the first BB was used in a double coupling, this peak 
was negligible (Table 3.3). 
Table 3.3 Optimization of the coupling of the first BB (glucoside 2.1). 
 
At this point, the conditions for the first and second coupling were satisfactory. 
Fmoc sensor data shows that glucoside 2.3 performs best when used in a double 
coupling and with temperature -30 to -10 °C.  However, HPLC data is difficult to 
interpret owing to the existence of several peaks. Some of the peaks could not be 
assigned due to low resolution in the HPLC or low abundance. The deletion 
sequences 3.2 and 3.3 are present in all HPLC traces. The existence of these deletion 
sequences, together with the possible formation of α and β linkages with BB 2.3 
justify the low abundance of the analytes. To try to understand better what happens 
in the course of the assembly of trisaccharide 3.1, a synthesis of the precursor 
disaccharide 3.3 was set up (Table 3.4). In this experiment, the crude HPLC showed 
a dominant peak. Interestingly, the major peak and a minor peak at 23 min showed 
an m/z value consistent with the target disaccharide 3.3. NMR analysis confirmed 
the major peak was disaccharide 3.3 (49% yield). The minor peak was identified as 
the isomer 3.5, which arose from Bz migrated to O4 (7% yield). 
The synthesis of 3.3 proved that there was Bz migration when Fmoc was 
cleaved from the galactose unit. The extent of Bz migration was relatively low. 
However, the migration can be further enhanced by the acid wash treatment at the 
beginning of the following elongation cycle. More Bz migration would lead to a 
higher proportion of disaccharide 3.5 which would elongate from O3 to form 
unwanted chains. This effect decreases the yield of the target product and, on the 
Entry Conditions UV Sensor Data HPLC of crude material 
1 2.1 2x 6.5 equiv 
-20 to 0 °C 
 
2.2 1x 6.5 equiv 
-20 to 0 °C 
 
2.3 2x 6.5 equiv 
-30 to -10 °C 




other hand, generates similar size by-products that are generally more difficult to 
separate chromatographically.  Using a galactose BB with an ether at O3 could be a 
solution to avoid this problem. Hence, a new BB was synthesized. 
Table 3.4 AGA of disaccharide 3.3. 
Entry Conditions UV Sensor Data HPLC of crude material 
1 2.1 2x 6.5 equiv 
-20 to 0 °C 
 
2.2 1x 6.5 equiv 










Galactoside 3.6 was prepared from intermediate 2.5b as described in Scheme 
3.2.  Condensation with dibutyltin oxide and subsequent alkylation with BnBr in the 
presence of CsF led the regioselective benzylation at O3. The resulting compound 
3.6a was crystallized from EtOAc/hexane in 58% yield (over two steps). Subsequent 
transformations were performed using optimized procedures described in chapter 
2. The final BB 3.5 was obtained in 32% over 6 steps. 
 








Scheme 3.3 AGA of GBS type IV backbone trisaccharide with galactoside 3.6. 
With the new BB 3.6, the synthesis of the trisaccharide led to a more conlsusive 
HPLC trace (Scheme 3.3, Table 3.5, entry 1). However, the coupling of the last BB, 
glucoside 2.3, was not efficient and the major product was the disaccharide deletion 
sequence. Since phosphate donors tend to be more reactive than thioglycosides, BB 
2.3 was converted into the corresponding phosphate 3.9 (Scheme 3.4). The use of 
3.9 (Table 3.5, entry 2) did not lead to a complete glycosylation of the O4 position 
of galactose and again the disaccharide was the major product. 
Table 3.5 AGA of GBS type IV backbone trisaccharide using galactoside 3.5. 
Entry Conditions UV Sensor Data HPLC of crude material 
1 2.1 2x 6.5 equiv 
-20 to 0 °C 
 
3.6 2x 6.5 equiv 
-20 to 0 °C  
 
2.3 2x 6.5 equiv 
-30 to -10 °C 
(Not available)  
 
2 2.1 2x 6.5 equiv 
-20 to 0 °C 
 
3.5 2x 6.5 equiv 
-20 to 0 °C  
 
3.9 1x 3.8 equiv 
-30 to -15 °C 

















Scheme 3.4 Synthesis of the phosphate building block 3.9. 
 
3.3. Conclusion 
The synthesis of oligosaccharides using the Glyconeer is based on the 
optimized elongation cycles that introduce each BB in the growing oligosaccharide 
chain. The work here described shows the process of optimizing conditions for the 
synthesis of GBS type IV backbone trisaccharide. 
Benzoyl migration was observed between oxygens in vicinal positions during 
the deprotection of the Fmoc group from one of the oxygen atoms. Replacement of 
the benzoyl for a benzyl prevented the migration. This finding shapes the 
retrosynthetic analysis for future building blocks. 
The major bottle neck in the synthesis of target trisaccharide was the Glc-α-
1,4-Gal cis linkage. Using thioglycoside as a donor (BB 2.3) led to low yields even 
when using a double coupling and after adjusting the glycosylation temperature. 
The use of a phosphate donor (BB 3.9) in a single coupling led to a similar result. 
However, further improvements in the glycosylation conditions can lead to a 
satisfactory coupling yield. Another possible strategy to introduce the cis linkage is 
to assemble the Glc-α-1,4-Gal disaccharide in solution and use it as a building block 
in the Glyconeer. 
The optimization of the assembly of trisaccharide 3.7 is crucial to the assemble 
of the whole repeating unit. The work in this chapter can be used as a novel starting 




3.4. Experimental Section 
General Materials and Methods 
All reagents and solvents were acquired from commercial sources, unless 
stated otherwise. The synthesis of the building blocks and functionalization of resin 
are described in Chapter 2. Anhydrous solvents were obtained from a Solvent 
Dispensing System (J.C. Meyer). Amberlite IR-120 (Across Organics) protonic 
exchange resin was rinsed with THF, water, methanol and dichloromethane before 
use. NMR spectra were obtained using Ascend 400 (Bruker) and Agilent 400 MHz 
NMR Magnet (Agilent Technologies) spectrometers at 400 MHz (1H) and 100 MHz 
(13C) or a Varian 600 (Agilent) at 600 MHz (1H) and 150 MHz (13C), or a Ascend 700 
(Bruker) at 700 MHz (1H) and 176 MHz (13C). CDCl3 or D2O were used as solvents 
and chemical shifts (δ) referenced to residual non-deuterated solvent peak unless 
stated otherwise. Splitting patterns are indicated as s, singlet; d, doublet; t, triplet; 
q, quartet; m, multiplet; br, broad singlet for 1 H-NMR data. NMR chemical shifts (δ) 
are reported in ppm and coupling constants (J) are reported in Hz. Assignments 
were supported by COSY and HSQC experiments and compared with literature data 
when available. MALDI-TOF spectra were obtained with a Daltonics Autoflex Speed 
spectrometer (Bruker) using 2,5-dihydroxybenzoic acid (DHB) as matrix. All MALDI 
measurements were done in reflectron mode except for the protected octamers 
whose data was acquired using the linear mode. ESI-HRMS were performed with a 








Synthesis of galactose BB 3.6 
Synthesis of compound 3.6a 
 
A mixture of 2.5b (19.7 g, 63.0 mmol) and Bu2SnO (19.5 g, 78.3 mmol) in 
toluene (anhydrous 50 mL) and 4 Å MS (25 g) was refluxed for 6 h. The solvent was 
evaporated under reduced pressure. The residue was combined with CsF (29.3 g, 
193 mmol) and BnBr (11.5 mL, 96.7 mmol) in DMF (100 mL) and stirred at rt. After 
18 h, TLC showed complete conversion. The reaction mixture was filtered through 
a pad of celite. The resulting solution was diluted with DCM (200 mL), washed with 
sat. aq. NaHCO3, and 1 M HCl. The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. The resulting material was crystallized from 
EtOAc/hexane 1:3 to give the pure product as a white solid (14.7 g, 58%). 
1H NMR (700 MHz, CDCl3) δ 7.52 – 7.49 (m, 2H), 7.40 (d, J = 7.1 Hz, 2H), 7.38 
– 7.28 (m, 6H), 5.45 (s, 1H, PhCH), 4.81 – 4.74 (m, 2H, PhCH2), 4.35 (d, J = 9.6 Hz, 1H, 
H-1), 4.31 (dd, J = 12.4, 1.6 Hz, 1H, H-6a), 4.18 (d, J = 3.5 Hz, 1H, H-4), 4.07 (td, J = 
9.3, 1.7 Hz, 1H, H-2), 3.97 (dd, J = 12.4, 1.9 Hz, 1H, H-6b), 3.50 (dd, J = 9.2, 3.4 Hz, 1H, 
H-3), 3.44 – 3.37 (m, 1H, H-5), 2.84 (dq, J = 12.5, 7.5 Hz, 1H, SCHH), 2.75 (dq, J = 12.5, 
7.5 Hz, 1H, SCHH), 2.57 (d, J = 1.9 Hz, 1H, 2-OH), 1.33 (t, J = 7.5 Hz, 3H, CH3). 
13C NMR (176 MHz, CDCl3) δ 138.09, 137.86, 129.01, 128.48, 128.18, 127.89, 
126.41, 101.28 (PhCH), 85.33 (C1), 80.35 (C3), 73.55 (C4), 71.56 (PhCH2), 70.16 






Synthesis of compound 3.6b55 
 
A solution of 3.6a (14.7 g, 36.6 mmol) and Bz2O (12.3 g, 1.5 equiv) in DCM 
(anhydrous, 115 mL) was stirred under Ar. Et3N (11 mL, 2 equiv) and DMAP (126 
mg, 3 mol%) were sequentially added and the reaction was stirred under a 35 °C 
bath. After 4 h, the mixture was diluted with DCM (50 mL), washed with HCl 1 M (2 
X 160 mL), sat. aq. NaHCO3 (160 mL), and brine (160 mL). The organic layer was 
dried over MgSO4, concentrated under reduced pressure and dried under high 
vacuum. The resulting solid was crystallized from EtOAc/Hex 1:2 to give the pure 
product 3.5b as a white solid (14.8 g, 80%).  
1H NMR (700 MHz, CDCl3) δ 8.04 (d, J = 7.8 Hz, 2H), 7.59 (t, J = 7.5 Hz, 1H), 
7.56 (d, J = 7.2 Hz, 2H), 7.46 (t, J = 7.7 Hz, 2H), 7.38 (q, J = 9.9, 8.4 Hz, 3H), 7.21 (dt, J 
= 22.8, 7.4 Hz, 5H), 5.74 (t, J = 9.7 Hz, 1H, H-2), 5.52 (s, 1H, PhCH), 4.68 (d, J = 12.8 
Hz, 1H, PhCHH), 4.62 (d, J = 12.8 Hz, 1H, PhCHH), 4.54 (d, J = 9.9 Hz, 1H, H-1), 4.36 
(dd, J = 12.2, 1.6 Hz, 1H, H-6a), 4.27 (d, J = 3.4 Hz, 1H, H-4), 4.02 (dd, J = 12.2, 1.7 Hz, 
1H, H-6b), 3.75 (dd, J = 9.6, 3.4 Hz, 1H, H-3), 3.49 – 3.46 (m, 1H, H-5), 2.92 (dq, J = 
14.9, 7.5 Hz, 1H, SCHH), 2.77 (dq, J = 14.2, 7.5 Hz, 1H, SCHH), 1.27 (t, J = 7.5 Hz, 3H, 
CH3). 
13C NMR (176 MHz, CDCl3) δ 165.26 (C=O), 137.83, 137.75, 133.01, 130.15, 
129.88, 129.07, 128.33, 128.23, 127.74, 127.69, 126.49, 101.38 (PhCH), 82.91 (C1), 
78.15 (C3), 73.46 (C4), 71.03, 70.17, 69.40, 68.76, 22.72 (SCH2), 14.88 (CH3). 
 
Synthesis of compound 3.6c 
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Compound 3.6b (13.0 g, 25.7 mmol) was dissolved in DCM (50 mL) and the 
resulting solution was stirred at rt. CSA (1.21 g, 0.2 equiv) and EtSH (19 mL, 10 
equiv) were sequentially added and the resulting solution was allowed to react 
overnight. Then, the mixture was concentrated under reduced pressure and purified 
by column chromatography from Hexane/EtOAc 5:1 to 5:20. The product was 
isolated as a white solid (8.29 g, 77%). 
1H NMR (700 MHz, Chloroform-d) δ 8.04 (dd, J = 8.1, 1.4 Hz, 2H), 7.62 (t, J = 
7.5 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.23 (ddt, J = 8.8, 7.4, 2.4 Hz, 1H), 7.19 (d, J = 5.7 
Hz, 4H), 5.56 (t, J = 9.7 Hz, 1H, H-2), 4.69 (d, J = 12.3 Hz, 1H, PhCHH), 4.57 (d, J = 12.3 
Hz, 1H, PhCHH), 4.53 (d, J = 10.0 Hz, 1H, H-1), 4.19 (d, J = 3.3 Hz, 1H, H-4), 4.03 (dd, 
J = 11.8, 6.7 Hz, 1H, H-6a), 3.87 (dd, J = 11.7, 4.7 Hz, 1H, H-6b), 3.70 (dd, J = 9.3, 3.3 
Hz, 1H, H-3), 3.63 (td, J = 5.0, 2.5 Hz, 1H, H-5), 2.79 (dq, J = 12.3, 7.4 Hz, 1H, SCHH), 
2.73 (dq, J = 12.4, 7.5 Hz, 1H, , SCHH), 2.58 (s, 2H, 2x OH), 1.25 (t, J = 7.5 Hz, 3H, CH3). 
13C NMR (176 MHz, Chloroform-d) δ 165.46 (C=O), 137.03, 133.16, 129.89, 
128.47, 128.39, 128.04, 127.87, 83.53 (C1), 79.22 (C3), 78.42 (C5), 71.46 (PhCH2), 
69.49 (C2), 66.88 (C4), 62.52 (C6), 23.69 (SCH2), 14.86 (CH3). 
 
Synthesis of compound 3.6d 
 
Compound 3.6c (7.03 g, 13.6 mmol), DABCO (6.20 g, 55.3 mmol), and 2-chloro-
1-methylpyridium iodide (8.80 g, 34.4 mmol) were combined with DCM (anhydrous, 
43 mL) under a positive pressure of Ar and the resulting suspension was cooled in 
an ice bath. LevOH (1.94 g, 16.7 mmol) was added and the mixture was allowed to 
react for 6 h, while the temperature rose to 0 °C. The mixture was then diluted with 
DCM (40 mL) and washed with H2O (80 mL) and brine (80 mL). The organic layer 
was dried over MgSO4, concentrated under reduced pressure and dried under high 
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vacuum. The resulting oil was identified as a mixture of the product and N-methyl-
2-pyridone (9.33 g, 1:1 mixture, quant.). 
 
Synthesis of compound 3.6 
 
Crude 3.6d (7.75 g, 13.6 mmol) was dissolved in DCM (anhydrous, 74 mL) and 
the resulting solution was stirred at rt under Ar. FmocCl (7.00 g, 2 equiv) and 
pyridine (2.4 mL, 3 equiv) were sequentially and the mixture was allowed to react 
for 24h. The mixture was diluted with DCM (70 mL) washed with HCl 1 M (2x 140 
mL), and brine (140 mL), dried over MgSO4, amd concentrated under reduced 
pressure. The crude material was purified by column chromatography from 
hexane/DCM/EtOAc 10:1:0.5 to 10:1:5 to give the pure compound 3.6 as a white 
powder (9.00g, 90%). 
1H NMR (700 MHz, Chloroform-d) δ 8.02 – 7.98 (m, 2H), 7.78 – 7.75 (m, 2H), 
7.70 (dd, J = 7.4, 1.0 Hz, 1H), 7.64 (dt, J = 7.5, 0.9 Hz, 1H), 7.60 (tt, J = 7.4, 1.3 Hz, 1H), 
7.48 – 7.45 (m, 2H), 7.44 – 7.36 (m, 3H), 7.32 (td, J = 7.5, 1.1 Hz, 1H), 7.13 (ddd, J = 
14.5, 7.6, 1.3 Hz, 3H), 7.03 (dd, J = 8.3, 6.9 Hz, 2H), 5.59 (t, J = 9.8 Hz, 1H, H-2), 5.49 
(dd, J = 3.3, 1.2 Hz, 1H, H-4), 4.68 (d, J = 12.5 Hz, 1H, PhCHH), 4.57 (d, J = 10.0 Hz, 1H, 
H-1), 4.51 (d, J = 12.6 Hz, 1H, PhCHH), 4.50 – 4.45 (m, 1H, Fmoc CH), 4.39 (dd, J = 
11.2, 6.5 Hz, 1H, H-6a), 4.31 – 4.27 (m, 2H, Fmoc CH2), 4.24 (dd, J = 11.3, 6.9 Hz, 1H, 
H-6b), 3.93 (td, J = 6.7, 1.2 Hz, 1H, H-5), 3.76 (dd, J = 9.6, 3.2 Hz, 1H, H-3), 2.84 – 2.70 
(m, 4H, SCH2, Lev CH2), 2.64 – 2.53 (m, 2H, Lev CH2), 2.19 (s, 3H, Lev CH3), 1.27 (t, J 
= 7.5 Hz, 3H, SCH2CH3). 
13C NMR (176 MHz, Chloroform-d) δ 206.77 (C=O ketone), 172.49 (C=O Lev 
ester), 165.29 (C=O Bz), 155.14 (C=O Fmoc), 143.74, 143.29, 141.42, 141.31, 137.29, 
133.23, 130.08, 130.01, 128.46, 128.32, 128.17, 127.96, 127.93, 127.81, 127.46, 
127.41, 125.80, 125.45, 120.05, 84.11 (C1), 77.34 (C2), 74.33  (C5), 71.16, 70.53, 
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70.44 (C4, PhCH2, Fmoc CH2), 69.30 (C2), 62.09 (C6), 46.67 (Fmoc CH), 38.15 (Lev 
CH2), 29.92, 28.08 (SCH2, Lev CH2), 24.23 (Lev CH3), 15.03 (SCH2CH3).  
HRMS (ESI/QTOF) m/z: [M+Na]+ Calcd 761.2391. Found 761.2400. 
 
Synthesis of glucose BB 3.9 
 
A solution of SM (1.00 g, 1.50 mmol) in DCM (anhydrous, 9 mL) cooled to 0 °C. 
A 1.26 M solution of dibutyl phosphate in DCM was dried with 4 Å MS one hour prior 
to use. From this solution, dibutyl phosphate (2.4 mL, 3.02 mmol) was added to the 
reaction mixture, then NIS (444 mg, 1.97 mmol) and then TfOH (40 µL, 0.45 mmol). 
The reaction mixture was stirred at 0 °C for one hour and TLC showed complete 
conversion. The reaction was diluted with DCM and washed with a 1:1 mixture of 
sat. aq. NaHCO3 and 10% Na2S2O5. The organic layer was dried over MgSO4, 
concentrated and purified by column chromatography to give the product as a 1:1 
anomeric mixture (1.04 g, 85%). 
 HRMS (ESI/QTOF) m/z: [M+Na]+ Calcd for C13H17NO3Na 839.3172 ; Found 
839.3196. 
 
General procedure for setting up the Glyconeer 
All solvents were loaded in the respective bottle and attached in the 
corresponding position of the Glyconeer prior to the synthesis. For each synthesis, 
the building blocks were co-evaporated with toluene, dried under high vacuum for 
2h, dissolved in anhydrous DCM (1 mL) and transferred to oven-dried building block 
vials. The vials were then placed in the appropriate position in the building block 
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carousel. The reagent solutions were prepared as described below. A polystyrene 
base resin functionalized with 0.40 mmol/g of a photocleavable linker was used. The 
resin (12.5 µmol of hydroxyl groups, unless otherwise stated) was weighed and 
transferred into the reaction vessel and the synthesis programme was initiated.  
 
Preparation of reagent solutions: 
TMSOTf solution: Anhydrous DCM (40 mL) was transferred into an oven-dried 
reagent bottle under Ar. TMSOTf (0.45 mL) was added and the bottle was placed in 
the predetermined acid-wash position and attached to the Glyconeer. 
Activation solution: N-Iodosuccinimide (NIS, 1.35 g) was added to an oven-
dried reagent bottle. Anhydrous dioxane (13 mL) and anhydrous DCM (26 mL) were 
added and the mixture gently stirred. Triflic acid (TfOH, 55 μL) was added and the 
bottle placed in the cooling block, in the predetermined position, and attached to the 
Glyconeer. 
Pyridine solution: Pyridine (5 mL) was diluted in 45 mL of DMF and the 
resulting solution was transferred into a reagent bottle. The bottle was placed in the 
predetermined position and attached to the Glyconeer. 
Capping solution: Anhydrous DCM (36 mL) was transferred into an oven-dried 
reagent bottle under Ar. Ac2O (4 mL) was added followed by MsOH (0.8 mL). The 
bottle was placed in the predetermined position and attached to the Glyconeer. 
Piperidine solution: Piperidine (50 mL) was diluted with 200 mL of DMF and 
the resulting solution was transferred into the reagent bottle. The bottle was placed 
in the predetermined position and attached to the Glyconeer. 
Hydrazine solution: Hydrazine acetate (550 mg) was transferred into a 
reagent bottle and pyridine (32 mL) was added. AcOH (8 mL) was carefully added 
followed by H2O (2 mL). The resulting mixture was gently stirred for a few minutes 




All experiments in the Glyconeer start with a “Resin swelling” module. During 
this module, DCM (2 mL) is delivered in the reaction vessel and the resin is 
incubated at 25 °C for 30 min. During the incubation time, the machine rinses the 
manifolds. Afterwards syntheses were programmed by combining the pre-defined 
modules described below. For each monosaccharide to be added to the target 
glycan, the cycle Acid Wash, Glycosylation, Capping, Deprotection was repeated. 
Module 1 – Acid Wash: the temperature is set to -20 °C and the resin is washed 
with the TMSOTf solution (1 mL). 
Module 2 – Glycosylation: The temperature is adjusted to the addition 
temperature T1 (-20 °C unless otherwise stated), the building block solution (1 mL) 
is delivered and then the activator solution (1 mL). An incubation period t1 = 5 min 
is followed. The temperature is then adjusted to T2 (0 °C unless otherwise stated) 
and an incubation period t2 = 20 min is followed. The resin is then washed with a 
1:1 solution of DCM/Dioxane, and then with DCM. When a double coupling was 
required, the procedure was repeated. When a quadruple couple was required, the 
procedure was repeated to a total of four times. 
Module 3 – Capping: The temperature is set to 25 °C. The resin is washed with 
DMF, then with the pyridine solution (2 mL), then with DCM. The capping solution 
is added (4 mL) and resin is incubated for 20 min. The resin is finally washed with 
DCM. 
Module 4 – Fmoc Deprotection: The temperature is set to 25 °C. The resin is 
washed with DMF and then the piperidine solution (2 mL) is added. The resin is 
incubated for 5 min and afterwards washed with DMF and DCM. 
Module 5 – Lev Deprotection: The temperature is set to 25 °C. The resin is 
washed with DCM and drained. DCM (1.3 mL) is added followed by the hydrazine 
solution (0.8 mL). The resin is incubated for 30 min and the procedure is repeated 
another two times. The resin is finally washed with DMF and DCM. 
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General procedure for cleavage from the solid support and 
purification 
After automated synthesis in the Glyconeer, the solid-support was suspended 
in DCM and injected into a continuous-flow photoreactor as described previously51 
to release the generated oligosaccharides. The resulting crude material was 
analysed by analytical HPLC using a YMC-Diol-300 column (150 x 4.6 mm) and the 
following elution method: flow rate 1 mL/min, elution started with 20% EtOAc in 
hexane for 5 min (isocratic), then linear gradient to 55% EtOAc in hexane for 35 min, 
then linear gradient to 100% EtOAc for 5 min, then 100% EtOAc for 5 min 
(isocratic). The target oligosaccharide was purified using a preparative HPLC using 
a YMC-Diol-300 column (150 x 20 mm) and the following elution method: flow rate 
15 mL/min, elution started with 20% EtOAc in hexane for 5 min (isocratic), then 
linear gradient to 55% EtOAc in hexane for 35 min, then linear gradient to 100% 
EtOAc for 5 min, then 100% EtOAc for 5 min (isocratic). The product fractions were 






1H NMR (400 MHz, CDCl3) δ 8.01 – 7.91 (m, 4H), 7.94 – 7.85 (m, 2H), 7.58 – 
7.47 (m, 3H), 7.48 – 7.28 (m, 16H), 7.24 – 7.17 (m, 2H), 7.11 (dp, J = 4.7, 1.8 Hz, 3H), 
5.70 (dd, J = 10.4, 8.0 Hz, 1H, H-2 Gal), 5.19 (dd, J = 9.4, 8.0 Hz, 1H, H-2 Glc), 5.13 (dd, 
J = 10.4, 3.2 Hz, 1H, H-3 Gal), 5.05 (s, 2H), 4.90 (d, J = 11.4 Hz, 1H), 4.79 (d, J = 8.0 Hz, 
1H, H-1 Gal), 4.71 (d, J = 12.1 Hz, 1H), 4.67 (d, J = 11.4 Hz, 1H), 4.53 (t, J = 6.1 Hz, 1H, 
NH), 4.36 (d, J = 12.1 Hz, 1H), 4.36 (d, J = 7.8 Hz, 1H, H-1 Glc), 4.26 (dd, J = 11.3, 7.0 
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Hz, 1H, H-6a), 4.17 (d, J = 3.3 Hz, 1H, H-4 Gal), 4.13 (dd, J = 9.7, 8.7 Hz, 1H, H-4 Glc), 
4.09 (dd, J = 11.3, 6.3 Hz, 1H, H-6b), 3.79 (dd, J = 9.7, 5.9 Hz, 1H, OCHH pentanylene), 
3.76 (t, J = 9.1 Hz, 1H, H-3 Glc), 3.71 – 3.61 (m, 2H, H-6a, H-5), 3.55 (dd, J = 10.9, 1.8 
Hz, 1H, H-6b), 3.36 – 3.25 (m, 2H, H-5, OCHH pentanylene), 2.87 (q, J = 6.6 Hz, 2H, 
CH2 pentanylene), 2.73 (dd, J = 7.1, 5.8 Hz, 2H, CH2 Lev), 2.54 (t, J = 6.2 Hz, 2H, CH2 
Lev), 2.17 (s, 3H, CH3 Lev), 1.53 – 1.33 (m, 2H, CH2 pentanylene), 1.32 – 1.20 (m, 2H, 
CH2 pentanylene), 1.13 (q, J = 7.6 Hz, 2H, CH2 pentanylene). 
13C NMR (101 MHz, CDCl3) δ 206.87 (C=O, Lev ketone), 172.80 (C=O, Lev 
ester), 165.79, 165.22, 165.18 (3x C=O, Bz), 156.36 (C=O Cbz) 138.54, 138.11, 
130.10, 129.32, 129.15, 128.59, 128.26, 128.21, 128.17, 128.08, 101.32 (C1), 100.53 
(C1), 80.39, 76.84, 74.82, 74.66, 74.05, 73.66, 73.38, 72.02, 70.15 (C2 Gal), 69.58, 
67.72, 66.92, 66.61, 61.97, 40.90 (NHCH2, pentenylene), 38.05 (CH2, Lev), 29.98 
(CH3, Lev), 29.47 (CH2, pentenylene), 28.95 (CH2, pentenylene), 27.99 (CH2, Lev), 
23.17 (CH2, pentenylene). 




1H NMR (400 MHz, CDCl3) δ 8.08 – 7.91 (m, 6H), 7.64 – 7.30 (m, 19H), 7.21 – 
7.14 (m, 2H), 7.08 – 6.98 (m, 3H), 5.55 (d, J = 3.6 Hz, 1H, H-4 Gal), 5.33 (dd, J = 10.0, 
7.9 Hz, 1H, H-2 Gal), 5.21 (dd, J = 9.4, 8.0 Hz, 1H, H-2 Glc), 4.94 (d, J = 11.5 Hz, 1H), 
4.82 (d, J = 8.0 Hz, 1H, H-1 Gal), 4.74 (d, J = 12.2 Hz, 1H), 4.73 (d, J = 11.5 Hz, 1H), 
4.53 (br s, 1H, NH), 4.41 (d, J = 12.2 Hz, 1H), 4.39 (d, J = 8.0 Hz, 1H, H-1 Glc), 4.03 (dd, 
J = 11.3, 6.4 Hz, 1H), 3.89 (dd, J = 10.1, 3.4 Hz, 1H, H-3 Gal), 2.88 (q, J = 6.6 Hz, 2H, 
CH2 pentanylene), 2.74 – 2.67 (m, 2H, CH2 Lev), 2.52 (t, J = 6.5 Hz, 2H, CH2 Lev), 2.17 
(s, 3H, CH3 Lev), 1.46 – 1.35 (m, 2H, CH2 pentanylene), 1.28 – 1.23 (m, 2H, CH2 
pentanylene), 1.20 – 1.12 (m, 2H, CH2 pentanylene). 
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ESI-MS [M+Na]+ calcd for C65H69NO18Na 1174.4 Found 1174.2. 
 
 
1H NMR (400 MHz, CDCl3) δ 7.98 – 7.92 (m, 2H), 7.90 – 7.83 (m, 2H), 7.65 – 
7.57 (m, 1H), 7.55 – 7.43 (m, 3H), 7.40 – 7.29 (m, 7H), 7.32 – 7.09 (m, 20H), 7.09 – 
7.02 (m, 2H), 7.02 – 6.90 (m, 3H), 5.49 (dd, J = 10.4, 7.8 Hz, 1H, H-2 Gal), 5.12 (dd, J 
= 9.5, 8.0 Hz, 1H, H-2 βGlc), 5.04 (s, 2H), 4.99 (d, J = 3.4 Hz, 1H, H-1 αGlc), 4.89 (d, J = 
11.8 Hz, 1H), 4.78 – 4.62 (m, 5H, H-1 βGlc), 4.61 – 4.40 (m, 8H), 4.28 (m, 3H), 4.17 
(d, J = 2.7 Hz, 1H, H-4 Gal), 4.08 (t, J = 9.2 Hz, 1H, H-4 βGlc), 3.84 (t, J = 9.3 Hz, 1H, H-
3 αGlc), 3.78 – 3.60 (m, 4H, OCHH pentanylene, H-3 βGlc), 3.57 (t, J = 6.9 Hz, 1H), 
3.51 (d, J = 10.7 Hz, 1H), 3.46 (dd, J = 9.8, 3.4 Hz, 1H, H-2 , αGlc), 3.43 (t, J = 9.5, 8.7 
Hz, 1H), 3.37 (dd, J = 10.4, 2.6 Hz, 1H, H-3 Gal), 3.33 – 3.20 (m, 2H, H-5 βGlc, OCHH 
pentanylene), 2.84 (qd, J = 8.5, 4.9 Hz, 3H), 2.76 – 2.64 (m, 2H, CH2 Lev), 2.56 (ddd, J 
= 16.9, 8.3, 4.9 Hz, 1H, CHH Lev), 2.47 (dt, J = 17.0, 5.9 Hz, 1H, CHH Lev), 2.20 (s, 3H, 
CH3 Lev), 2.00 (s, 3H, CH3 Ac), 1.50 – 1.29 (m, 4H, pentanylene), 1.16 – 1.03 (m, 2H, 
pentanylene). 






4. Automated Glycan Assembly of 








Serotype III is the most prevalent Group B Streptococcus (GBS) strain 
accounting  for 62% of the cases of invasive disease in young infants.5 
Understanding the structure-immunogenicity relationship of type III GBS capsular 
polysaccharide (CPS) can lead to important advances in the process of developing a 
highly efficient and safe GBS vaccine.  
The repeating unit of GBS type III CPS (Figure 4.1) is a pentasaccharide with 
a terminal Neu5Ac-α-2,3-Gal moiety56 and is structurally related to the CPS of S. 
pneumoniae type 14 (Sp14)57. In the conceptualization of the synthesis of GBS type 
III repeating unit, a combined approach was envisioned where the core structure, 
corresponding to Sp14, could be obtained by AGA and converted into a GBSIII CPS 
fragment by enzymatic sialylation. S. pneumoniae is a leading cause of serious 
invasive diseases such as bacterial pneumonia, septicaemia, and meningitis in young 
children worldwide, and is listed in the WHO global priority list of antibiotic-
resistant bacteria.58 Rising levels of antibiotic resistance reinforce the need for 
alternative treatments and prevention strategies. Thus, combining enzymatic 
sialylation with AGA could lead to a streamlined strategy for obtaining glycans from 
two important pathogens. 
 
Figure 4.1 Capsular polysaccharide repeating unit of Sp14 and GBSIII.  
Sp14 fragments have been previously prepared by a block-coupling approach 
where the repeating unit was synthesized as a thioglycoside and used both as a 
donor and a protected acceptor. The repeating unit block was first coupled to a 
spacer. Afterwards, removal of an isopropylidene acetal yielded an acceptor, which 
was elongated with the donor block to give a protected dimer of the repeating unit. 
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Iteration of this methodology yielded the trimer. In this strategy, the assembly of the 
tetrasaccharidic block was achieved in six synthetic steps starting from semi-
protected mono or disaccharides, which represents at least two weeks of highly-
specialized labour-intensive work.59 Other strategies include the use of 
differentially protected lactose and lactosamine building blocks that are coupled 
together to generate up to octasaccharide fragments.60 The synthesis of GBSIII has 
been achieved by enzymatic introduction of the sialic acid in Sp14 structures.61,62 To 
avoid sialylation in the lactose arm of the structure, the appropriate galactose was 
blocked with a methyl ether in position 3 that could not be removed in the end of 
the synthesis. Boons et al. described a fully chemical synthesis of a heptasaccharide 
fragment of GBS type III based on a convergent approach. The incorporation of sialic 
acid was based on α-NeuNAc-(2-3)-Galp methylthioglycoside dimer which had been 
assembled by coupling a methylthiosialoside and a galactose acceptor.63  
This chapter describes the synthesis of Sp14 fragments via automated glycan 
assembly using the Glyconeer, and its transformation into GBS type III glycans by 
enzymatic sialylation. The optimization of AGA is based on data from the Fmoc 
sensor and HPLC analysis of the crude material obtained after photocleavage. Key 
parameters related to the glycosylation module were studied: temperature of 
glycosylation, number of coupling repetitions, and concentration of donor. A 
reproducible procedure for the AGA of Sp14 is described. 
 
4.2. Retrosynthetic Analysis of Sp14 Glycans 
The target structures for AGA (Scheme 4.1) represent two different 
frameshifts of the repeating unit (monomer) and the corresponding dimer of Sp14 
CPS. In the branched frameshift (monomer 4.1 and dimer 4.2), the reducing 
terminus is comprised of a glucosamine unit. In the linear frameshift (monomer 4.3 
and dimer 4.4), glucose lies at the reducing terminus. The retrosynthetic analysis of 
the target structures led to three thioglycoside building blocks that can be used to 
make both frameshifts. Fmoc serves as the main temporary protecting group 
whereas Lev is used as an orthogonal temporary protecting to enable branching 
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(glucosamine). Benzyl ethers serve as permanent protecting groups. Benzoyl ester 
at O2 and trichloroacetyl (TCA) at N2 were used as participating protecting groups 
to ensure selective trans-glycosylation. One galactose building block (4.6) was used 
both for terminal positions and for positions with elongation along O3. In the first 
case, a capping step was used right after deprotecting the Fmoc group giving rise to 
a terminal 3-O-acetylated galactose residue. In all other cases, the elongation cycle 
consisted of acid wash, glycosylation, capping, and deprotection. 
 
 
Scheme 4.1 Retrosynthesis of oligosaccharides 4.1-4.4 using building blocks 4.5-4.7 and 
the functionalized Merrifield resin 2.8. 
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4.3. Automated Glycan Assembly 
4.3.1. Branched frameshift 
To assemble the branched frameshift of Sp14 monomer (Scheme 4.2), an 
initial trial was performed where all the BBs where coupled using 2x 6.5 equiv (41 
mM) at -20 to 0 °C (Table 4.1, entry 1). With these conditions, the target 
tetrasaccharide 4.8 was obtained in 12% yield. The HPLC of the crude product 
showed a significant peak for the capped linker.  
 
Scheme 4.2 AGA of the branched frameshift of Sp14 monomer. 
When the first building block 4.1 was coupled using ten equivalents (62 mM), 
the signal for the capped linker was negligible and tetrasaccharide 4.8 was isolated 
in 20% yield (Table 4.1, entry 2). This finding proved that the glycosylation 
efficiency increased upon increasing the concentration of glucosamine 4.1. To probe 
the effect of concentration for the other BBs, the synthesis of 4.8 was repeated using 
ten equivalents of donor in one single coupling for building blocks 4.2 and 4.3 
(Table 4.1, entry 3). The crude material obtained after photocleavage showed 
negligible deletion sequences and the product was isolated in 31% yield. With these 
conditions, the synthesis time was reduced from 14 to 11 h and 2.5 equivalents per 




Table 4.1 AGA of tetrasaccharide 4.8. 
 
The branched dimer 4.9 was assembled according to Scheme 4.3. In the first 
attempt, the best conditions for monomer 4.8 were applied. However, the expected 
octasaccharide was a minor product. The major product was tetrasaccharide 14 
(Table 4.2, entry 1) which arises from a low coupling efficiency of glucosamine 
building block 5 to the O3 position of galactose. The effect of the glycosylation 
temperature in the formation of this linkage was probed: -10 to 10 °C led to an 
increase in the formation of the target octasaccharide (Table 4.2, entry 2); 0 to 20 
°C led to a decrease in the formation of the target octasaccharide (Table 4.2, entry 
3). Even with the best temperature set, deletion sequence 14 was the major product. 
When glucosamine 5 was coupled at -10 °C to 10 °C and repeated in a quadruple 
Entry Conditions UV Sensor Data HPLC of crude material 
1 4.5 2x 6.5 equiv 
-20 to 0 °C 
 
4.6 2x 6.5 equiv 
-20 to 0 °C 
 
4.7 2x 6.5 equiv 
-20 to 0 °C 
 
4.6 2x 6.5 equiv 
-20 to 0 °C 
(Not available)  
 
2 4.5 2x 10 equiv 
-20 to 0 °C 
 
4.6 2x 6.5 equiv 
-20 to 0 °C 
 
4.7 2x 6.5 equiv 
-20 to 0 °C 
 
4.6 2x 6.5 equiv 
-20 to 0 °C 
 
 
3 4.5 2x 10 equiv 
-20 to 0 °C 
 
4.6 1x 10 equiv 
-20 to 0 °C 
 
4.7 1x 10 equiv 
-20 to 0 °C 
 
4.6 1x 10 equiv 
-20 to 0 °C 
 
 








coupling, the synthesis proceeded with the formation of 10 as the major product 
(Table 4.2, entry 4, 8% yield). Building block 4.7 was used again in a double 
coupling to prevent the formation of deletion sequence 4.11 and the amount of 
building block 6 was reduced to 6.5 equiv without formation of deletion sequences.  
 
Scheme 4.3 AGA of octasaccharide 4.9. 
 




Entry Conditions* UV Sensor Data HPLC of crude material 
1 4.5 2x 10 equiv 
 
4.6 1x 10 equiv 
 
4.7 1x 10 equiv 
 












Table 4.2 (Part II/II) AGA of tetrasaccharide 4.9. 
*Temperature of glycosylation -20 to 0 °C unless otherwise stated. 
 
 
Entry Conditions* UV Sensor Data HPLC of crude material 
2 4.5 2x 10 equiv 
 
4.6 1x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 
4.6 1x 6.5 equiv 
 
4.5 2x 10 equiv 
-10 to 10 °C 
 
4.6 1x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 




3 4.5 2x 10 equiv 
 
4.6 1x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 
4.6 1x 6.5 equiv 
 
4.5 2x 10 equiv 
0 to 20 °C 
 
4.6 1x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 




4 4.5 2x 10 equiv 
 
4.6 1x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 
4.6 1x 6.5 equiv 
 
4.5 4x 10 equiv 
-10 to 10 °C 
 
4.6 1x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 









4.3.2. Linear frameshift 
To generate the fragments of the linear frameshift, the best conditions for the 
synthesis of dimer 4.9 were used. The synthesis of tetrasaccharide 4.12 (Table 4.3, 
entry 1) was successful and led to 23% yield. The synthesis of 4.13 was performed 
by repeating the elongation cycles. A deletion sequence was identified as a 
tetrasaccharide with the Lev at glucosamine O6 indicating incomplete cleavage of 
this protecting group. The octasaccharide 4.3 was isolated in 8% yield. 
 
Scheme 4.4 AGA of linear frameshift of Sp14 CPS. 
Table 4.3 AGA of the linear tetrasaccharide 4.52. 
*Temperature of glycosylation -20 to 0 °C unless otherwise stated. 
Entry Conditions* HPLC of crude material 
1 4.7 2x 6.5 equiv 
 
4.6 4x 10 equiv 
 
4.5 1x 6.5 equiv 
-10 to 10 °C 
 
4.6 1x 6.5 equiv 
 
2 4.7 2x 6.5 equiv 
 
4.6 1x 6.5 equiv 
 
4.5 4x 10 equiv 
-10 to 10 °C 
 










4.3.3. Scale up experiments 
The syntheses described so far were performed on a 12.5 µmol scale and 
afforded less than 10 milligrams of the protected oligosaccharides. In order to 
procure more material, a scale-up study was conducted (Table 4.4). The linear scale 
up to 25 µmol led to successful synthesis of both the branched and linear 
tetrasaccharides. The synthesis of tetrasaccharide 4.8 was further scaled up to 50 
µmol. In this case, due to volume limitations, the amount of BBs was reduced to 2x 
5 equivalents per coupling, keeping the concentration at 41 mM. Tetrasaccharide 9 
was isolated in 33%.  
Table 4.4 Yield comparison for 12.5 µmol experiments and the scale up experiments. 
*Temperature of glycosylation -20 to 0 °C unless otherwise stated. 
 
4.4. Global deprotection 
Following AGA, cleavage from the solid support, and HPLC purification, 
compounds 4.8, 4.9, 4.12 and 4.13 were deprotected in two steps. Ester groups 
(benzoyl, acetyl and levaloyl) were cleaved with sodium methoxide in 1:1 
MeOH/DCM. In the second step, benzyl ethers, TCA and the carboxybenzyl group at 
the amino linker were removed by hydrogenation catalyzed by Pd/C. Methanolysis 
of tetrasaccharide 4.8 was complete after 24h using 25 mM NaOMe (by MALDI). The 
crude product was hydrogenated and purified using a C18 cartridge to give 4.1 in 
Entry Conditions* 12.5 µmol 25 µmol 50 µmol 
1 4.5 2x 10 equiv 
 
4.6 2x 6.5 equiv 
 
4.7 2x 6.5 equiv 
 
4.6 2x 6.5 equiv 
4.8 20% 4.8 28% 4.8 33% 
 
(2x 5 equiv for all BBs) 
2 4.7 2x 6.5 equiv 
 
4.6 1x 6.5 equiv 
 
4.5 4x 10 equiv 
-10 to 10 °C 
 
4.6 1x 6.5 equiv 
4.12 23% 4.12 21% - 
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93% yield. The linear tetrasaccharide 4.12 was subjected to the same methanolysis 
procedure but after 24h, MS spectra showed partially cleaved intermediates. The 
reaction was performed with an increase concentration of NaOMe (50 mM) but ester 
cleavage was not complete after 24 h. Upon addition of another portion of NaOMe 
(final concentration 0.1 M) and after another 24h, the conversion was complete. The 
crude product was then subjected to hydrogenation. Tetrasaccharide 4.3 was 
obtained after HPLC purification as the formate salt (71%). 
Deprotection of octasaccharides 4.9 and 4.13 proved to be cumbersome as the 
attempts to follow the methanolysis by LC-MS or MALDI were unsuccessful. For 
branched structure 4.9, the procedure used for methanolysis was the same as for 
the branched tetrasaccharide 4.8. After hydrogenation, the crude product was 
subjected to RP-HPLC but was isolated with a triethylamine contamination, 
originating from the work up procedure. The linear structure 4.13 was deprotected 
using the same conditions as for linear tetrasaccharide 4.12. After hydrogenation 
and RP-HPLC purification, the product was isolated in 22% yield. 
 
4.5. Enzymatic sialylation 
To convert the S. pneumoniae type 14 repeating unit (oligosaccharide 4.3) into 
the GBS type III repeating unit (compound 4.14), an α(2,3)-sialyltransferase from 
Pasteurella multocida (PmST1)64 was used (Scheme 4.5). The reaction was 
performed using three equivalents of CMP-Neu5Ac (3 mM) as donor in the presence 
of an alkaline phosphatase to dephosphorylate the CMP by-product. The enzyme 
was used in a concentration of 6 µg/mL and after incubation at 37 °C with a Tris-HCl 
pH 9.3 buffer, the sialoside was filtered by a polyethersulfone membrane (MWCO 10 
kDa) to remove the protein. A final purification by RP-HPLC gave 4.14 in 30% yield. 
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Scheme 4.5 Enzymatic synthesis of sialoside 4.14. α-(2,3)-Sialyltransferase PmST1, CMP-
Neu5Ac, alkaline phosphatase, Tris-HCl pH 9.3, MgCl2. 
 
4.6. Conclusion 
The success of AGA relies on general and standardized procedures. The 
coupling of BBs 4.5-4.7 was explored with the best conditions leading to 
reproducible coupling yields in two different frameshifts of Sp14 CPS 
oligosaccharides. The glucosamine BB 4.5 showed a low coupling efficiency, 
particularly when the acceptor was O3 of galactose. Using a quadruple coupling with 
a high concentration of BB led to the formation of the desired compounds. An 
investigation of the reasons for the low efficiency can lead to solutions that do not 
require such a large excess of donor. The use of only three BBs to assemble four 
different structures showcases the importance of the optimization work here 
described and proves the versatility the BBs, setting the scene for their use in 
different structures. The combination of enzymatic sialylation with AGA proved to 
be an expeditious approach to the preparation of complex glycans for vaccine 
development. The glycans produced can be used in immunologic assays such as 




4.7. Experimental Section 
All reagents and solvents were acquired from commercial sources, unless 
stated otherwise. All building blocks were obtained from GlycoUniverse stock. The 
resin equipped with a photocleavable linker (loading of 0.40 mmol/g) was also 
obtained from GlycoUniverse. Anhydrous solvents were obtained from a Solvent 
Dispensing System (J.C. Meyer). Amberlite IR-120 (Across Organics) protonic 
exchange resin was rinsed with THF, water, methanol and dichloromethane before 
use. NMR spectra were obtained using Ascend 400 (Bruker) and Agilent 400 MHz 
NMR Magnet (Agilent Technologies) spectrometers at 400 MHz (1H) and 100 MHz 
(13C) or a Varian 600 (Agilent) at 600 MHz (1H) and 150 MHz (13C), or a Ascend 700 
(Bruker) at 700 MHz (1H) and 176 MHz (13C). CDCl3 or D2O were used as solvents 
and chemical shifts (δ) referenced to residual non-deuterated solvent peak unless 
stated otherwise. Splitting patterns are indicated as s, singlet; d, doublet; t, triplet; 
q, quartet; m, multiplet; br, broad singlet for 1 H-NMR data. NMR chemical shifts (δ) 
are reported in ppm and coupling constants (J) are reported in Hz. Assignments 
were supported by COSY and HSQC experiments and compared with literature data 
when available. MALDI-TOF spectra were obtained with a Daltonics Autoflex Speed 
spectrometer (Bruker) using 2,5-dihydroxybenzoic acid (DHB) as matrix. All MALDI 
measurements were done in reflectron mode except for the protected octamers 
whose data was acquired using the linear mode. ESI-HRMS were performed with a 
Xevo G2-XS Q-Tof (Waters). HPLCs were performed on Agilent 1200 Series systems. 
 
General procedure for setting up the Glyconeer 
(See Chapter 3.4, page 97) 
 
Experiments at 25 µmol scale 
The resin (25 µmol of hydroxyl groups) was weighed and transferred into the 
reaction vessel. The building blocks were prepared as described above dissolved in 
 117 
2 mL of anhydrous DCM instead of 1 mL. The parameters of the synthesis were 
adjusted for the glycosylation, Fmoc deprotection, and Lev deprotection modules, as 
follows: 
Module 2 – Glycosylation: The temperature is adjusted to the addition 
temperature T1 (-20 °C unless otherwise stated), the building block solution (2 mL) 
is delivered and then the activator solution (2 mL). An incubation period t1 = 5 min 
is followed. The temperature is then adjusted to T2 (0 °C unless otherwise stated) 
and an incubation period t2 = 20 min is followed. The resin is then washed with a 
1:1 solution of DCM/Dioxane, and then with DCM. When a double coupling was 
required, the procedure was repeated. When a quadruple couple was required, the 
procedure was repeated to a total of four times. 
Module 4 – Fmoc Deprotection: The temperature is set to 25 °C. The resin is 
washed with DMF and then the piperidine solution (4 mL) is added. The resin is 
incubated for 5 min and afterwards washed with DMF and DCM. 
Module 5 – Lev Deprotection: The temperature is set to 25 °C. The resin is 
washed with DCM and drained. DCM (2.5 mL) is added followed by the hydrazine 
solution (1.5 mL). The resin is incubated for 30 min and the procedure is repeated 
another two times. The resin is finally washed with DMF and DCM. 
 
Experiment at 50 µmol scale 
The resin (50 µmol of hydroxyl groups) was weighed and transferred into the 
reaction vessel. The building blocks were prepared as described above and 
dissolved in 2 mL of DCM mL. The parameters of the synthesis were adjusted for the 
glycosylation, Fmoc deprotection, and Lev deprotection modules, as follows: 
Module 2 – Glycosylation: The temperature is adjusted to the addition 
temperature T1 (-20 °C unless otherwise stated), the building block solution (2 mL) 
is delivered and then the activator solution (4 mL). An incubation period t1 = 5 min 
is followed. The temperature is then adjusted to T2 (0 °C unless otherwise stated) 
and an incubation period t2 = 20 min is followed. The resin is then washed with a 
1:1 solution of DCM/Dioxane, and then with DCM. When a double coupling was 
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required, the procedure was repeated. When a quadruple coupling was required, 
the procedure was repeated up to four times. 
Module 4 – Fmoc Deprotection: The temperature is set to 25 °C. The resin is 
washed with DMF and then the piperidine solution (8 mL) is added. The resin is 
incubated for 5 min and afterwards washed with DMF and DCM. 
Module 5 – Lev Deprotection: The temperature is set to 25 °C. The resin is 
washed with DCM and drained. DCM (5 mL) is added followed by the hydrazine 
solution (3 mL). The resin is incubated for 30 min and the procedure is repeated 
another two times. The resin is finally washed with DMF and DCM. 
 
Fmoc sensor data 
The output of the UV sensor in the Glyconeer is the transmittance of the Fmoc 
deprotection solution, discharged through the UV cell after incubation with the resin 
inside the RV. The obtained transmittance value is subtracted from DMF 
transmittance (blank) and normalized to the transmittance obtained after cleaving 
Fmoc group from 0.0125 mmol of Fmoc-Gly-Wang resin (commercially available). 
 
General procedure for cleavage from the solid support and 
purification 
After automated synthesis in the Glyconeer, the solid-support was suspended 
in DCM and injected into a continuous-flow photoreactor as described previously51 
to release the generated oligosaccharides. The resulting crude material was 
analysed by analytical HPLC using a YMC-Diol-300 column (150 x 4.6 mm) and the 
following elution method: flow rate 1 mL/min, elution started with 20% EtOAc in 
hexane for 5 min (isocratic), then linear gradient to 55% EtOAc in hexane for 35 min, 
then linear gradient to 100% EtOAc for 5 min, then 100% EtOAc for 5 min 
(isocratic). The target oligosaccharide was purified using a preparative HPLC using 
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a YMC-Diol-300 column (150 x 20 mm) and the following elution method: flow rate 
15 mL/min, elution started with 20% EtOAc in hexane for 5 min (isocratic), then 
linear gradient to 55% EtOAc in hexane for 35 min, then linear gradient to 100% 
EtOAc for 5 min, then 100% EtOAc for 5 min (isocratic). The product fractions were 





1H NMR  (400 MHz, Chloroform-d) δ 8.08 – 8.01 (m, 2H), 7.99 – 7.92 (m, 2H), 
7.77 – 7.70 (m, 2H), 7.63 – 7.53 (m, 2H), 7.45 (q, J = 8.0 Hz, 5H), 7.38 – 7.17 (m, 33H), 
7.18 – 6.97 (m, 10H), 5.47 (dd, J = 10.5, 7.8 Hz, 1H), 5.28 – 5.20 (m, 2H), 5.17 (dd, J = 
9.5, 7.9 Hz, 1H), 5.06 (s, 2H), 4.93 (d, J = 11.2 Hz, 1H), 4.83 (t, J = 6.0 Hz, 1H), 4.73 – 
4.48 (m, 10H), 4.42 (d, J = 11.9 Hz, 1H), 4.38 (d, J = 11.9 Hz, 1H), 4.32 – 4.24 (m, 4H), 
4.20 (d, J = 7.9 Hz, 1H), 4.09 (t, J = 9.2 Hz, 1H), 4.01 (d, J = 3.2 Hz, 1H), 3.93 – 3.87 (m, 
2H), 3.82 (d, J = 5.4 Hz, 1H), 3.79 – 3.67 (m, 4H), 3.63 – 3.31 (m, 11H), 3.13 – 3.01 (m, 
3H), 2.83 (dt, J = 9.8, 6.2 Hz, 1H), 2.25 (d, J = 10.0 Hz, 1H, OH), 1.86 (s, 3H, COCH3), 
1.42 – 1.20 (m, 4H, pentanylene chain), 1.15 (p, J = 8.4, 7.7 Hz, 2H, pentanylene 
chain). 
13C NMR (101 MHz, CDCl 3 ) δ 170.33, 166.37, 165.57, 165.09, 161.86, 156.51, 
138.60, 138.23, 138.22, 138.21, 138.14, 137.99, 137.78, 136.80, 133.67, 133.53, 
133.32, 130.01, 129.98, 129.88, 129.75, 129.66, 129.32, 128.80, 128.72, 128.71, 
128.67, 128.63, 128.56, 128.45, 128.25, 128.21, 128.17, 128.09, 128.08, 128.05, 
128.04, 128.02, 128.00, 127.87, 127.84, 127.80, 127.47, 127.31, 101.41, 100.15, 
100.02, 99.80, 92.63, 80.40, 78.29, 77.48, 77.36, 77.16, 76.84, 76.53, 76.21, 75.70, 
75.52, 75.17, 74.88, 74.76, 74.55, 74.28, 73.61, 73.59, 73.41, 73.27, 73.23, 73.17, 
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72.91, 72.82, 71.06, 69.41, 68.36, 67.93, 67.70, 67.38, 66.62, 55.97, 41.03, 29.59, 
28.90, 23.22, 20.90. 









1H NMR (600 MHz, Chloroform-d) δ 8.13 – 8.09 (m, 2H), 8.08 – 8.02 (m, 2H), 
7.96 – 7.92 (m, 3H), 7.73 – 7.69 (m, 1H), 7.65 – 6.97 (m, 97H), 6.94 – 6.87 (m, 2H), 
5.57 (dd, J = 10.2, 7.8 Hz, 1H), 5.53 (dd, J = 10.2, 8.0 Hz, 1H), 5.45 (dd, J = 10.5, 8.0 Hz, 
1H), 5.37 – 5.31 (m, 2H), 5.25 (dd, J = 10.0, 7.9 Hz, 1H), 5.21 – 5.04 (m, 5H), 4.96 – 
4.87 (m, 3H), 4.82 – 3.87 (m, 40H), 3.81 – 3.02 (m, 35H), 2.94 – 2.82 (m, 2H), 1.92 (s, 
3H), 1.85 (s, 3H), 1.42 – 1.27 (m, 4H), 1.20 – 1.10 (m, 2H). 





1H NMR (400 MHz, Chloroform-d) δ 8.13 (dd, J = 8.4, 1.4 Hz, 2H), 7.95 (dd, J = 
8.4, 1.4 Hz, 2H), 7.91 (dd, J = 8.4, 1.3 Hz, 2H), 7.59 – 7.09 (m, 44H), 7.08 – 6.98 (m, 
3H), 6.97 – 6.89 (m, 2H), 6.57 (d, J = 8.2 Hz, 1H, NHTCA), 5.53 (dd, J = 10.2, 7.9 Hz, 
1H), 5.25 (dd, J = 9.8, 7.9 Hz, 1H), 5.14 (dd, J = 9.4, 8.1 Hz, 1H), 5.04 (s, 2H), 4.96 (d, J 
= 11.6 Hz, 1H), 4.94 (d, J = 10.9 Hz, 1H), 4.89 (d, J = 11.1 Hz, 1H), 4.80 (d, J = 7.7 Hz, 
1H), 4.69 – 4.64 (m, 2H), 4.63 (d, J = 7.8 Hz, 1H), 4.56 (d, J = 7.8 Hz, 1H), 4.57 – 4.42 
(m, 5H), 4.38 (dd, J = 12.0, 4.5 Hz, 1H), 4.37 – 4.19 (m, 5H), 4.16 (d, J = 11.6 Hz, 7H), 
4.03 – 3.58 (m, 9H), 3.52 – 3.23 (m, 7H), 3.20 – 3.14 (m, 1H), 2.86 (d, J = 6.6 Hz, 2H), 
2.75 – 2.62 (m, 1H), 2.56 – 2.38 (m, 2H), 2.35 – 2.22 (m, 1H), 2.09 (s, 3H), 1.48 – 1.19 
(m, 4H, pentanylene chain), 1.19 – 1.06 (m, 2H, pentanylene chain). 
13C NMR (151 MHz, Chloroform-d) δ 206.17, 172.25, 166.38, 165.04, 164.74, 
161.61, 156.21, 139.05, 138.60, 138.25, 138.19, 138.16, 138.08, 137.71, 136.70, 
133.40, 133.33, 132.92, 130.09, 129.96, 129.82, 129.62, 129.59, 129.47, 128.61, 
128.55, 128.53, 128.52, 128.46, 128.40, 128.34, 128.30, 128.10, 128.05, 128.01, 
127.92, 127.90, 127.88, 127.80, 127.78, 127.76, 127.72, 127.64, 127.60, 127.55, 
127.53, 127.28, 127.25, 126.87, 126.85, 101.09, 100.64, 100.54, 100.26, 91.95, 
80.52, 79.39, 77.56, 76.59, 76.44, 76.13, 75.45, 74.92, 74.88, 74.61, 74.37, 74.26, 
73.49, 73.35, 73.34, 72.57, 72.55, 69.27, 68.32, 67.81, 67.64, 66.42, 62.46, 57.45, 
40.77, 37.66, 29.71, 29.31, 28.81, 27.62, 23.01. 











MALDI: calcd for C212H215Cl6N3KO52 [M+K]+ 3883.2. Found 3886.4 
 
Oligosaccharide deprotection 
General procedure for deprotection and purification 
The purified protected oligosaccharide was dissolved in a 1:1 mixture of 
MeOH/DCM (anhydrous) and NaOMe (0.5 M in MeOH) was added. The resulting 
solution was stirred at room temperature until completion of reaction (monitored 
by MALDI). The reaction was neutralized with Amberlyte IR 120, filtered and 
concentrated under reduced pressure. The resulting material was dissolved in 
EtOAc/t-BuOH/H2O 2:1:1 and one drop of acetic acid. The resulting mixture was 
purged with H2 for ca. 15 min. The reaction vessel was equipped with two H2 
balloons and the mixture was stirred at room temperature for 24h. Then the mixture 
was filtered through a filter syringe equipped with a reverse cellulose syringe filter 
(pore size: 0.45 μm). The reaction vessel and the catalyst were washed with EtOAc 
(1 mL), t-BuOH (2x 1 mL) and H2O (4x 1 mL). The combined filtrates were 
concentrated under reduced pressure and lyophilised. 
The crude material was purified using a pre-packed 6 mL C-18 CHROMABOND 
column. To the crude material was added H2O (10 mL, first fraction) and the mixture 
was passed through the cartridge. Then 10 mL fractions of H2O, 10% MeOH in H2O, 
50% MeOH in H2O and MeOH were successively passed through the cartridge and 
analysed by MALDI. The fractions containing the product were gathered and dried 
in the lyophilizer. When needed, the product was further purified by HPLC using a 
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Synergi Hydro RP18 column (250 x 10 mm) using a flow rate of 4.0 mL/min and the 
following elution method: H2O (0.1% formic acid) for 5 min (isocratic), then linear 
gradient to 10% ACN 30 min, then linear gradient to 100% ACN for 5 min. The 
product fractions were collected and lyophilised to obtain the pure product as 
formate salt. Analytical HPLC was done with a Synergi Hydro RP18 column (250 x 
4.6 mm) using a flow rate of 1.0 mL/min and the following elution method: H2O 
(0.1% formic acid) for 5 min (isocratic), then linear gradient to 10% ACN 30 min, 
then linear gradient to 100% ACN for 5 min. Alternatively, analytical HPLC was done 
using a Hypercarb column (150 x 4.6 mm) using a flow rate of 0.7 mL/min and the 
following elution method: H2O (0.1% formic acid) for 5 min (isocratic), then linear 




Protected tetrasaccharide 4.8 (14 mg) was subjected to methanolysis with 
NaOMe (final concentration 25 mM) for 24 h, according to the general procedure. 
The resulting crude material was subjected to hydrogenation according to the 
general procedure. Purification by C18 cartridge gave compound 4.1 (5.0 mg, 93%).  
Analytical HPLC of pure product (Hypercarb column): 
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NMR data in agreement with the literature65. 
1H NMR (700 MHz, Deuterium Oxide) δ 4.62 (d, J = 7.9 Hz, 1H, GlcNAc H-1), 
4.62 – 4.57 (m, 2H, Glc H-1, Galb H-1), 4.52 (d, J = 7.8 Hz, 1H, Gala H-1), 4.35 (d, J = 
11.2 Hz, 1H, GlcNAc H-6a), 4.05 (dd, J = 12.3, 2.2 Hz, 1H, Glc H-6a), 4.02 (dd, J = 11.4, 
4.7 Hz, 1H, GlcNAc H-6b), 4.00 – 3.98 (m, 2H, Gala H-4, Galb H-4), 3.95 (dt, J = 10.6, 
6.2 Hz, 1H, pentanylene chain, OCHH), 3.90 – 3.71 (m, 15H), 3.67 (dt, J = 10.2, 6.2 Hz, 
1H, pentanylene chain, OCHH), 3.61 (dt, J = 9.4, 6.5 Hz, 2H, Gala H-2, Galb H-2), 3.44 
(t, J = 8.4 Hz, 1H, Glc H-2), 3.05 (t, J = 7.6 Hz, 2H, pentanylene chain, CH2NH2), 2.09 
(s, 3H, NHCOCH3), 1.73 (p, J = 7.7 Hz, 2H, pentanylene chain), 1.66 (p, J = 6.7 Hz, 2H, 
pentanylene chain), 1.51 – 1.42 (m, 2H, pentanylene chain, CH2NH2). Gala refers to 
Gal-β-1,4-Glc. Galb refers to Gal-β-1,4-GlcNAc. 








Protected octasaccharide 4.9 (8 mg) was subjected to methanolysis with 
NaOMe (final concentration 25 mM) for 24 h, according to the general procedure. 
The resulting crude material was subjected to hydrogenation according to the 
general procedure. The mixture was neutralized with Et3N (1.5 µL). After RP-HPLC 
purification, compound 4.2 was isolated as the formate salt (0.7 mg, 22%), 
containing traces of triethylammonium formate. 
Analytical HPLC of purified product (Synergi column):  
 
NMR data in agreement with the literature59.  
1H NMR (400 MHz, Deuterium Oxide) δ 4.66 (d, J = 8.3 Hz, 1H, H-1), 4.54 – 4.45 
(m, 5H, 5x H-1), 4.39 (m, 2H, 2x H-1), 4.23 (dd, J = 10.2, 4.6 Hz, 2H, 2x GlcNAc H-6a), 
4.11 (d, J = 3.3 Hz, 1H), 3.96 – 3.46 (m, 45H), 3.32 (t, J = 8.1 Hz, 2H, 2x Glc H-2), 2.93 
(t, J = 7.7 Hz, 2H, pentanylene chain, CH2NH2), 1.98 (s, 3H, NHCOCH3), 1.98 (s, 3H, 
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NHCOCH3), 1.66 – 1.50 (m, 4H, pentanylene chain), 1.40 – 1.30 (m, 2H, pentanylene 
chain). 







Protected tetrasaccharide 4.12 (6 mg) was subjected to methanolysis with 
NaOMe (final concentration 50 mM). After 24h, another portion of NaOMe was 
added (final concentration 100 mM) and after another 24h the conversion was 
complete, and the reaction was worked up according to the general procedure. The 
resulting crude material was subjected to hydrogenation according to the general 
procedure. After RP-HPLC purification, compound 4.3 was isolated as the formate 
salt (1.6 mg, 71%).  
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Analytical HPLC of pure product: 
 
NMR in agreement with the literature66. 
1H NMR (600 MHz, Deuterium Oxide) δ 4.73 (d, J = 8.3 Hz, 1H, H-1), 4.51 (d, J = 
8.0 Hz, 1H, H-1), 4.50 (d, J = 7.8 Hz, 1H, H-1), 4.46 (d, J = 7.9 Hz, 1H, H-1), 4.18 (d, J = 
3.3 Hz, 1H), 4.02 – 3.94 (m, 4H), 3.87 (dd, J = 12.3, 4.7 Hz, 1H), 3.84 – 3.59 (m, 18H), 
3.56 (dd, J = 9.9, 7.8 Hz, 1H), 3.32 (t, J = 8.4 Hz, 1H), 3.03 (t, J = 7.6 Hz, 2H, pentanylene 
chain, CH2NH2), 2.06 (s, 3H, NHCOCH3), 1.71 (dp, J = 13.8, 7.2, 6.7 Hz, 5H, pentanylene 
chain), 1.48 (p, J = 7.7 Hz, 2H, pentanylene chain). 






Protected tetrasaccharide 4.13 (6 mg) was subjected to methanolysis with 
NaOMe (final concentration 50 mM). After 24h, another portion of NaOMe was 
added (final concentration 100 mM) and after another 24h the conversion was 
complete, and the reaction was worked up according to the general procedure. The 
resulting crude material was subjected to hydrogenation according to the general 
procedure. Purification by C18 cartridge gave compound 4.4 (0.5 mg, 22%).  
MALDI: calcd for C57H99N3O41Na [M+Na]+ 1504.6. Found: 1504.9. 
Enzymatic sialylation 
Tetrasaccharide 4.3 (1.0 mg, 1.3 µmol) was dissolved in 781 µL of H2O and 
combined with: 
− 12.6 µL of CIAP (calf-intestine alkaline phosphatase, Promega, 20 u/µL) 
− 25 µL of CIAP buffer (buffer supplied with the CIAP, when diluted 1:10, it has 
a composition of 50 mM Tris-HCl (pH 9.3 at 25°C), 1 mM MgCl2, 0.1 mM ZnCl2 
and 1 mM spermidine) 
− 12.6 µL of MgCl2 10 mM 
− 75.6 µL of CMP-NANA 3 mM (3 equiv) 
− 126 µL of α(2,3)-sialyltransferase from Pasteurella multocida (PmST1)64 
The resulting mixture was incubated at 37 °C for 18 h. Then the mixture was 
centrifuged, and the supernatant was filtered through a polyethersulfone Vivaspin 
500 membrane (MWCO 10 kDa). The resulting material was analysed and purified 
using preparative reverse-phase HPLC with a Hypercarb column (150 x 4.6 mm), 
flow 0.7 mL/min, starting with H2O (0.1% formic acid) isocratic for 5 min, then 
linear gradient of 0 to 30% ACN for 15 min, then linear gradient of 30 to 90% ACN 
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for 15 min. The purified fractions were lyophilized to give the pure compound 4.14 
(0.4 mg, 30%). 
Compound 4.14 
 
NMR in agreement with the literature67. 
1H NMR (400 MHz, Deuterium Oxide) δ 8.45 (s, 1H, formate), 4.69 (d, J = 8.2 
Hz, 1H, GlcNAc H-1), 4.56 (d, J = 7.9 Hz, 1H, Gals H-1), 4.49 (d, J = 8.0 Hz, 1H, Glc H-
1), 4.43 (d, J = 7.9 Hz, 1H, Gal H-1), 4.16 (d, J = 3.3 Hz, 1H, Gal H-4), 4.12 (dd, J = 9.9, 
3.1 Hz, 1H, Gals H-3), 4.00 – 3.54 (m, 30H), 3.30 (t, J = 8.4 Hz, 1H, Glc H-2), 3.00 (t, J = 
7.5 Hz, 2H, pentanylene chain, CH2NH2), 2.76 (dd, J = 12.5, 4.6 Hz, 1H, Neu5Ac H-3e), 
2.03 (s, 6H, 2x Ac), 1.80 (t, J = 12.2 Hz, 1H, Neu5Ac H-3a), 1.68 (m, 4H, pentanylene 
chain), 1.46 (p, J = 7.9 Hz, 2H, pentanylene chain). (Gals refers to the galactose 
residue linked to Neu5Ac.) 















Carbohydrate based vaccines are the most promising solutions to tackle the 
burden of GBS disease in the world. The availability of chemically defined GBS 
oligosaccharides can have an extraordinary impact in understanding the molecular 
mechanisms in the immunological events. In turn, this knowledge can be used to 
procure safer and more efficient vaccines.  
AGA is a powerful source of chemically defined glycans and despite the 
continuous advances in the field, it still requires great time and efforts to prepare 
libraries of oligosaccharides. The first bottle neck was identified as the availability 
of differentially protected “ready-to-use” building blocks. With the work in this 
thesis, a synthetic route to produce these BBs is standardized.  
With the building blocks in hand, the synthesis of GBS type IV repeating unit 
was attempted. The major bottle neck was identified as the Glc-α-1,4-Gal cis linkage. 
This linkage was obtained in poor yield. Further developments can be achieved by 
controlling the stereochemistry using dioxane, by repeating the coupling with the 
phosphate donor, or simply by synthesizing the Glc-α-1,4-Gal dimer in solution and 
using it as a building block in the Glyconeer. The work in this chapter can be used as 
a starting point that is one step ahead in achieving the repeating unit of GBS type IV. 
The synthesis of the monomer and dimer of GBS type IV repeating unit can lead to 
the elucidation of the minimal epitope crucial for the immunogenic response. 
In the fourth chapter, the synthesis of GBS type III glycans was achieved. Two 
different frameshifts of the repeating unit were synthesized as well as the 
corresponding dimers. The yield of the syntheses drops as the oligosaccharide 
chains grow, which reveals inefficient steps during the automated cycles. There is 
certainly room for improvement as the target oligosaccharides get longer. At the 
same time, the Glyconeer proved efficient in the synthesis of different molecules 
where the same linkages appeared in different positions. The combination of 
enzymatic sialylation with AGA proved to be an expeditious approach to the 
preparation of complex glycans for vaccine development. The glycans produced can 
be used in immunologic assays such as ELISA or conjugated to carrier proteins and 
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